

Draft

# Obstructive sleep apnoea/ hypopnoea syndrome and obesity hypoventilation syndrome in over 16s

Evidence review L: Monitoring

*NICE guideline*

*Intervention evidence review*

*March 2021*

*Draft for Consultation*

*Developed by the National Guideline Centre*



## **Disclaimer**

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

## **Copyright**

© NICE 2021. All rights reserved. Subject to Notice of rights.

# Contents

<b>1</b>	<b>Monitoring</b> .....	<b>5</b>
1.1	Review question: What is clinically and cost effective strategy for monitoring obstructive sleep apnoea/hypopnoea syndrome (OSAHS)/ obesity hypoventilation syndrome (OHS)/COPD-OSAHS overlap syndrome? .....	5
1.2	Introduction .....	5
1.3	PICO table.....	5
1.4	Clinical evidence .....	6
1.4.1	Included studies .....	6
1.4.2	Excluded studies.....	7
1.4.3	Summary of clinical studies included in the evidence review.....	8
1.4.4	Quality assessment of clinical studies included in the evidence review ....	24
1.5	Economic evidence .....	32
1.5.1	Included studies .....	32
1.5.2	Excluded studies.....	32
1.5.3	Summary of studies included in the economic evidence review .....	33
1.5.4	Health economic evidence statements.....	34
1.6	The committee’s discussion of the evidence.....	35
1.6.1	Interpreting the evidence.....	35
1.6.2	Cost effectiveness and resource use .....	42
1.6.3	Other factors the committee took into account .....	44
	<b>Appendices</b> .....	<b>49</b>
	Appendix A: Review protocols .....	49
	Appendix B: Literature search strategies .....	58
	Appendix C: Clinical evidence selection.....	70
	Appendix D: Clinical evidence tables .....	71
	Appendix E: Forest plots.....	96
	Appendix F: GRADE tables .....	101
	Appendix G: Health economic evidence selection.....	108
	Appendix H: Health economic evidence tables .....	109
	Appendix I: Excluded studies.....	113

# 1 <sup>1</sup> Monitoring

## 1.1 <sup>2</sup> Review question: What is clinically and cost effective <sup>3</sup> strategy for monitoring obstructive sleep <sup>4</sup> apnoea/hypopnoea syndrome (OSAHs)/ obesity <sup>5</sup> hypoventilation syndrome (OHS)/COPD-OSAHs overlap <sup>6</sup> syndrome?

### 1.2 <sup>7</sup> Introduction

<sup>8</sup> Patients who have been diagnosed with OSAHS/OHS/COPD-OSAHs overlap syndrome can  
<sup>9</sup> have a significant health burden. The provision of treatment by the health care provider to  
<sup>10</sup> manage these conditions requires some form of follow-up and monitoring, similar to most  
<sup>11</sup> conditions. Traditionally patients attend outpatient clinics after first treatment to discuss the  
<sup>12</sup> care they are receiving, issues that are occurring, titration of the therapy as well as to allow  
<sup>13</sup> for any further testing or answering clinical questionnaires. The timeliness of a patient's  
<sup>14</sup> review may impact on a number of factors including compliance and success of treatment.  
<sup>15</sup> Yet the time to follow-up can vary between various health care providers. Services may see  
<sup>16</sup> patients within the first two weeks after being set up on therapy, whilst others may not have  
<sup>17</sup> the ability to review for 3 months. On-going reviews may also be varied from 2 weeks to 6, 12  
<sup>18</sup> months or 2 years and longer in some cases.

<sup>19</sup> When a patient is reviewed, the type of monitoring of a patient's treatment is also an area  
<sup>20</sup> which is not uniform across the health service. There are differences in whether services  
<sup>21</sup> repeat a sleep study, download patient's device data, take a blood gas or overnight CO<sub>2</sub>  
<sup>22</sup> level. The advent of modems and the capability to use tele-monitoring allows review patient  
<sup>23</sup> data and even titration of therapy without actually having the patient present. This has  
<sup>24</sup> opened up further options, to examine what is clinically as well as cost effective in the  
<sup>25</sup> monitoring of patients' treatment.

<sup>26</sup>

### 1.3 <sup>27</sup> PICO table

<sup>28</sup> For full details see the review protocol in appendix A.

<sup>29</sup> **Table 1: PICO characteristics of review question**

<b>Population</b>	People with OSAHS/OHS/COPD-OSAHs overlap syndrome  Stratified by: <ul style="list-style-type: none"><li>• OSAHS vs OHS vs COPD-OSAHs overlap syndrome</li><li>• stage of treatment (&lt;1 year vs ≥ 1 year)</li><li>• severity (mild vs moderate vs severe, based on AHI)</li></ul>
<b>Interventions</b>	In person outpatient visits Download of data from devices Telephone follow-up Telemonitoring  Any of the above at any of the following frequencies: <ul style="list-style-type: none"><li>• no routine monitoring</li><li>• 3 yearly</li></ul>

	<ul style="list-style-type: none"> <li>yearly</li> <li>6 monthly</li> <li>3 monthly</li> <li>1 monthly</li> <li>&lt;1 monthly</li> </ul>
<b>Comparisons</b>	Any of the above methods at any frequency vs the same or any other method at any frequency
<b>Outcomes</b>	<p><b>Critical</b></p> <ul style="list-style-type: none"> <li>generic or disease specific quality of life measures (continuous)</li> <li>mortality (dichotomous)</li> </ul> <p><b>Important</b></p> <ul style="list-style-type: none"> <li>sleepiness scores (continuous, e.g. Epworth)</li> <li>apnoea-hypopnoea index (continuous)</li> <li>oxygen desaturation index (continuous)</li> <li>CO<sub>2</sub> control (continuous)</li> <li>hours of use (adherence measure, continuous)</li> <li>minor adverse effects of treatment (rates or dichotomous)</li> <li>driving outcomes (continuous)</li> <li>neurocognitive outcomes (continuous)</li> <li>healthcare contacts (rates/dichotomous)</li> <li>impact on co-existing conditions: <ul style="list-style-type: none"> <li>HbA1c for diabetes (continuous)</li> <li>cardiovascular events for cardiovascular disease (dichotomous)</li> <li>systolic blood pressure for hypertension (continuous)</li> </ul> </li> </ul>
<b>Study design</b>	<ul style="list-style-type: none"> <li>RCTs will be prioritised, if insufficient RCTs are found for guideline decision making, non-randomised studies will be considered if they adjust for key confounders (age, sex, BMI, co-existing conditions)</li> <li>minimum duration of follow-up 1 month</li> <li>parallel or crossover studies to be included</li> </ul>

## 1.4 1 Clinical evidence

### 1.4.1 2 Included studies

#### 3 OSAHS

#### 4 CPAP

5 Ten studies were included in this review,<sup>3, 10, 14, 19, 23, 25, 26, 36, 40, 42</sup> these are summarised in Table  
6 2 below. Evidence from these studies is summarised in the clinical evidence table below  
7 (Table 3).

8 Six studies compared telemonitoring and in person follow-up with in-person follow-up. One  
9 study compared telemonitoring and phone follow-up with phone follow-up. One study  
10 compared multimodal telemonitoring with usual care. Two studies compared telemonitoring  
11 and tele visits with in person follow-up. The duration of all included studies was of one year  
12 or less.

13 All studies were in people using fixed level CPAP, except for one study in people using auto  
14 CPAP.

- 1 All studies included a severe OSAHS population determined by their baseline mean AHI.
- 2 Studies were stratified based on the AHI/ODI severity of the population. When a mixed
- 3 severity population was included the severity of the majority of the population was used by
- 4 taking the mean AHI of the patients included and the study was downgraded for indirectness.
  
- 5 Follow-up of studies ranged from 2 to 12 months. Studies varied in size with the number of
- 6 participants ranging from 45 in the smallest study to 306 in the largest. Oral devices
  
- 7 No evidence was identified for monitoring of people using oral devices.
  
- 8 Positional modifiers
  
- 9 No evidence was identified for monitoring of people using positional modifiers.
  
- 10 Surgery
  
- 11 No evidence was identified for monitoring of people who have undergone surgery.
  
- 12 **OHS**
  
- 13 There was no evidence available for people with OHS.
  
- 14 **COPD-OSAHS overlap syndrome**
  
- 15 There was no evidence available for people with COPD-OSAHS overlap syndrome.
  
- 16 See also the study selection flow chart in appendix C, study evidence tables in appendix D,
- 17 forest plots in appendix E and GRADE tables in appendix H.

#### **1.4.28 Excluded studies**

- 19 See the excluded studies list in appendix I.
- 20
- 21

1.4.3 1 Summary of clinical studies included in the evidence review

2 Table 2: Summary of studies included in the evidence review

Study	Intervention and comparison	Population	Outcomes	Comments
Anttalainen 2016 <sup>3</sup>  RCT  Finland	<p><b>Telemonitoring and in person follow up:</b> Wireless telemonitoring system ( ResTaxx Online, ResMed Sydney, Australia). The module was attached to the S9 Elite (ResMed, Sydney Australia) CPAP device, which transmitted compliance data every day automatically to ResTaxx Online. The treatment was considered successful when CPAP use was &gt;4h/day, mask &lt;0.4 L/s and AHI &lt;5/h during the last 6 days. Study nurses made the data checkups daily during weekdays and if the criteria for successful CPAP therapy were not achieved during two consecutive nights the nurses adjusted the CPAP remotely and called the patient to give further advice. The patients were encouraged to contact the nurse in case they had any problems. TM group answered the questionnaire at 3 months by email.</p> <p>N=50</p>	<p>OSAHs patients who were commencing CPAP treatment at the department of pulmonary diseases of Turku university hospital. All patients were over 18 years of age.</p> <p>Mean age (SD): Telemonitoring and in person follow up group – 53.9(12.2).  In person follow up group – 56.4(11.8)  Finland</p> <p>Baseline AHI Telemonitoring group = 34.4 (20.6) Usual care = 34.8 (23.4)</p>	<p>Follow up - 12 months</p> <ul style="list-style-type: none"> <li>• Quality of life - GHQ12 score</li> <li>• Sleepiness - Epworth scale</li> <li>• AHI</li> <li>• Adherence – CPAP usage h/day</li> </ul>	<p>Mixed analysis of mostly randomised and some non-randomised patients in the study</p> <p>Severe OSAHS strata population (strata based on mean AHI)</p>



Study	Intervention and comparison	Population	Outcomes	Comments
	<p><b>In person follow up:</b> In Person follow up. Usual care group visited the pulmonologist after 3 months leading in a 3 month habituation phase in the UC group. UC group answered the questionnaire at the 3 month visit. CPAP device was used without wireless telemonitoring</p> <p>N=61</p>			
<p>Fox 2012<sup>10</sup></p> <p>RCT</p> <p>Canada</p>	<p><b>Telemonitoring and in person follow up:</b> Auto-titrating PAP machine that transmitted physiologic information (i.e. adherence, air leak, residual AHI) daily to a website that could be reviewed.</p> <p>N=39</p> <p><b>In person follow up:</b> Standard care with auto-titrating CPAP. In Person follow up</p> <p>N=36</p>	<p>Patients were recruited from adult (<math>\geq 19</math> yr. of age) patients with moderate to severe OSAHS (AHI <math>\geq 15</math> events/hr by polysomnography (PSG) using the Chicago scoring criteria for the determination of apnoeas and hypopnoeas, according to the American Academy of Sleep Medicine)<sup>10</sup> diagnosed at the Sleep Disorders Program who were seen by one of three respirologists (JF, CFR, NTA) at the University of British Columbia (UBC) between April 8, 2008 to June 1, 2010. Patients with OSAHS who were prescribed PAP therapy by their regular sleep physician and who were willing to accept a trial of therapy were</p>	<p>Follow up 3 months</p> <ul style="list-style-type: none"> <li>• Epworth sleeping scale</li> <li>• Apnoea-Hypopnea index (AHI)</li> <li>• Adherence</li> <li>• Mean percentage days CPAP used</li> </ul>	<p>Severe OSAHS strata population (strata based on mean AHI)</p>

Study	Intervention and comparison	Population	Outcomes	Comments
		<p>potentially eligible for the trial.</p> <p>Mean age (SD):</p> <p>Telemonitoring and in person follow up – 52(10.8)</p> <p>In person follow up – 55.2 (11.5)</p> <p>Canada</p> <p>Baseline AHI</p> <p>Telemedicine group = 44.3 (24.8)</p> <p>Standard = 39.5 (19.6)</p>		
<p>Hoet 2017<sup>14</sup></p> <p>RCT</p> <p>Belgium</p>	<p><b>Telemonitoring and in person follow up:</b></p> <p>T4P TM unit was added to the CPAP device of the patient at home. Sleep laboratory technical staff were instructed to connect to the web portal and to analyse individual patient's data each Tuesday and Friday. In case of air leaks &gt;50 L/min, residual AHI &gt;10/h, or CPAP use &lt;3h on 3 consecutive days, they were required to call the patient and to set up a visit with the staff of the sleep laboratory.</p>	<p>Eligible patients were ≥18 years old. They were recently diagnosed with OSAHS with an apnoea-hypopnea index (AHI) ≥20/h according to AASM 2012 scoring rules and sent to our sleep laboratory for initiation of treatment with CPAP therapy.</p> <p>Mean age (SD):</p>	<p>Follow up – 3 months</p> <ul style="list-style-type: none"> <li>Adherence – hours of use</li> <li>Mean percentage nights CPAP use &gt;4 hours</li> </ul>	<p>Severe OSAHS strata population (strata based on mean AHI)</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>N=23</p> <p><b>In person follow up:</b></p> <p>After CPAP titration night, patients were instructed to use the device each night for the whole night. They received written instructions and were able to contact the sleep unit (with telephone call or visit) as often as needed, during weekdays, in order to resolve any current problem interfering with their CPAP use. a group educational session for CPAP-treated patients was scheduled 1 month after CPAP initiation, and a visit to the pneumologist was scheduled 1.5 and 3 months after CPAP initiation.</p> <p>N=23</p>	<p>Telemonitoring and in person follow up – 59(13)</p> <p>In person follow up – 54(14)</p> <p>Baseline AHI = Telemonitoring and in person follow up – 50(26)</p> <p>In person follow up – 49(24)</p>		
<p>Isetta 2015<sup>19</sup></p> <p>RCT</p> <p>Spain</p>	<p><b>Telemonitoring and televisits:</b></p> <p>Patients randomised to the telemedicine group received their follow-up at home supported by a website developed for this study, where they could find information about OSA and CPAP therapy, and a biweekly six-item questionnaire about their status, physical activity, sleep time, CPAP use and treatment side effects. Each centre's staff monitored</p>	<p>All enrolled patients were classified as requiring CPAP treatment after an overnight study</p> <p>Mean age (SD)</p> <p>Telemonitoring and televisits group – 51 (8.9)</p> <p>In person follow up group – 47 (10.9)</p> <p>Spain</p>	<p>Follow up 6 months</p> <ul style="list-style-type: none"> <li>• Quality of life (E5QD, FOSQ)</li> <li>• Sleepiness Epworth scale</li> <li>• Mean percentage nights CPAP use &gt;4 hours</li> <li>• Adherence</li> </ul>	<p>Severe OSAHS strata population (strata based on mean AHI)</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>questionnaire answers and communicated with patients through the website messaging tool to solve treatment-related problems. To participate, patients only required an internet-connected device with a microphone and webcam. Televisits via video conference were undertaken at months 1 and 3. We used Skype due to its availability, ease of use and good performance. Patients automatically received a confirmation email indicating the date and time of their appointment. Extra televisits or hospital visits were scheduled as necessary.</p> <p>N=69</p> <p><b>In person follow up:</b></p> <p>Patients randomised to the control group had the same follow-up schedule as the telemedicine group but attended the hospital. Specifically, they received standard face-to-face follow-up with visits at months 1, 3 and 6, and extra visits if needed.</p> <p>N=70</p>	<p>Baseline AHI - median (IQR) = 49 (35-46)</p>		

Study	Intervention and comparison	Population	Outcomes	Comments
Lugo 2019 <sup>23</sup>  RCT  Spain	<p><b>Telemonitoring patients and virtual follow up:</b></p> <p>Patients treated with a Virtual sleep unit (VSU) were managed exclusively outside of the hospital setting. The diagnostic sleep test consisted of home-based respiratory polygraphy for three consecutive nights, and recorded data were downloaded to a secure server and analysed by a specialised technician. If OSA was diagnosed and CPAP was indicated, patients received CPAP education and along with an automatic CPAP device (Dreamstation, Respironics) at the provider's pick-up point. A technician could remotely adjust CPAP pressure through a website based on data sent by the device. Follow-up visits at 3, 6 and 12 weeks were performed through a custom web application and follow up interviews lasted no more than 15 minutes. Patients could access general information about OSA, CPAP, healthy sleep, and lifestyle, as well as their medical agenda, FAQs, and online clinical questionnaires. An email address to contact professionals and a</p>	<p>Patients with suspected OSA and/or refractory hypertension, age 18–75 years with a basic knowledge of ICTs use (e.g., tablet, smartphone, or computer), and Internet access were considered for inclusion.</p> <p>Consecutive patients with suspected OSA referred to the sleep unit in Barcelona between 2016 and Feb 2017 were randomised if they signed the consent form.</p> <p>Mean age (SD)</p> <p>Telemonitoring group – 50.39 (11.31)</p> <p>In person hospital follow up group – 50.82 (12.15)</p> <p>AHI = 29.12 (25.6)</p>	<p>Follow up at 3 and 6 months</p> <p>EQ5D EQ-VAS ESS</p> <p>Adherence – hours of use Number of healthcare contacts – GP and specialists OSA related</p>	<p>Severe OSAHS strata population for analysis as mean AHI was borderline between both moderate and severe populations (strata based on mean AHI)</p> <p>This study included people with suspected OSHAS and after sleep testing 80.4% of the population had a diagnosis of OSAHS with a mean baseline AHI of 29.12. 19.6% of patients did not have an OSAHS diagnosis, therefore the study was included but downgraded for very serious indirectness.</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>teleconference service to perform the interviews were also available.</p> <p>N=94</p> <p><b>In person hospital follow up:</b></p> <p>Sleep tests, medical assessments, and follow-up visits were performed in the Sleep Unit. Based on the patient characteristics, physicians not involved in the trial requested sleep studies (e.g. PSG, or hospital- or home-based respiratory polygraphy). After sleep testing, a sleep physician interviewed patients. If CPAP was indicated, patients received education and training in CPAP use from a specialized nurse or technician in the hospital. CPAP was then titrated in the hospital with manual adjustment by the technician during a sleep study. Once the optimal pressure was determined, patients were provided with a fixed pressure CPAP device to use at home (DreamStation, Respirationics). All visits were performed face-to-face in the consultation at 3, 6 and 12 weeks.</p>			

Study	Intervention and comparison	Population	Outcomes	Comments
	N=92			
Mendelson 2014 <sup>25</sup>  RCT  France	<p><b>Telemonitoring and in person follow up:</b></p> <p>Patients assigned to telemedicine were oriented to CPAP, fitted with a nasal mask, and given an auto titrating machine. Patients received a smartphone with an application designed to transmit clinical information. The patients transmitted self-measured morning and evening BP (3-day measurements), CPAP adherence, and subjective sleepiness weekly through a questionnaire-based application. Quality of life questionnaires were transmitted monthly. Patients received daily pictograms with diet and physical-activity related messages on their smartphones. Patients were contacted after 2 days to ask about adherence, side effects, and any problems encountered with the machine. After 4 weeks of treatment, patients met with their sleep specialist and information was reviewed. After 4 months of treatment, patients consulted their sleep specialist and were re-evaluated. Both groups were asked to continue on their</p>	<p>Patients were eligible for the study if they were between 18 and 85 years old, diagnosed OSA on the diagnostic sleep study with AHI &gt; 15 events/h, BMI of less than 40 kg/m<sup>2</sup>, cardiovascular risk SCORE &gt; 5%,20 or being in secondary prevention with a past history of cardiovascular disease (transient ischemic attack, stroke, cerebral haemorrhage, myocardial infarction, angina, coronary revascularization, arteriopathy, aortic aneurism).</p> <p>Mean age (SD):</p> <p>Telemonitoring and in person follow up – 62(9)</p> <p>In person follow up – 63(9)</p> <p>France</p> <p>Baseline AHI = 39.0 (16.7)</p>	<p>Length of follow up – 4 months</p> <ul style="list-style-type: none"> <li>• Quality of life – Physical composite score and mental composite score</li> <li>• Sleepiness - Epworth score</li> <li>• Adherence</li> </ul>	Severe OSAHS strata population (strata based on mean AHI)

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>normal medication regimen.</p> <p>N=54</p> <p><b>In person follow up:</b></p> <p>Patients assigned to standard care were evaluated at baseline, fitted with a nasal mask and given an auto titrating machine. Patients were contacted after 2 days to ask about adherence, side effects, and any problems encountered with the machine. After 4 weeks of treatment, patients met with their sleep specialist and information was transferred from their machines (adherence, mask leak, residual respiratory events). After 4 months of treatment, data were downloaded from the machine, and patients saw their sleep specialist and were re-evaluated.</p> <p>N=53</p>			
<p>Munafò 2016<sup>26</sup></p> <p>RCT</p> <p>USA</p>	<p><b>Telemonitoring and phone follow up:</b></p> <p>Patients in the telemonitoring group were dispensed a CPAP device on Day 0, along with a pamphlet about U-Sleep, which</p>	<p>Study was conducted by Sleep Data Holdings, LLC, a Joint Commission on Accreditation of Healthcare Organizations-accredited CPAP durable</p>	<p>Length of follow up – 3 months</p> <p>Adherence</p>	<p>Severe OSAHS strata population (strata based on mean AHI)</p>



Study	Intervention and comparison	Population	Outcomes	Comments
	<p>was used to monitor adherence. U-Sleep is a secure, HIPAA-compliant, web-based application that is designed to receive CPAP device data and message patients and providers via text and/or e-mail based on a customisable set of rules. At the time of set up, patients were encouraged to log-in to the U-Sleep website from home so that they could follow their therapy. Sleep Data study staff were trained to set up and use the software, which was provided to patients at no charge. Initial patient contacts were triggered by <math>\geq 1</math> of five intervention points based on metrics (AHI, leak, therapy hours) After initial contact, subsequent contacts were in response to an automated message or based on clinical judgment. All TH patients received a final phone call on day 90. All patients were contacted at day 90 and asked to rate how well the follow-up program had met their expectations (on a scale from 1 to 5)</p> <p>N=70</p>	<p>medical equipment provider in Southern California, USA.</p> <p>Mean age (SD):</p> <p>Telemonitoring group – 52.3(10.6)</p> <p>Phone follow up group – 50 (11.7)</p> <p>USA</p> <p>Baseline AHI=</p> <p>Telemonitoring group = 33.4(24.5)</p> <p>Phone follow up group = 27.4 (18.0)</p>		

Study	Intervention and comparison	Population	Outcomes	Comments
	<p><b>Phone follow up:</b> Telephone follow up: Patients randomised to telephone follow-up were dispensed a CPAP device on Day 0, then contacted via phone on Days 1, 7, 14, 30, and 90 . CPAP usage and efficacy data were tracked via the wireless modem attached to the CPAP machine. Modem data were accessed via ResMed’s EasyCare Online (ECO) platform. Sleep Data SOC procedures include frequent phone calls and return clinic visits as necessary</p> <p>N=70</p>			
<p>Pepin 2019<sup>36</sup></p> <p>RCT</p> <p>France</p>	<p><b>Multimodal telemonitoring:</b> Multimodal telemonitoring included systolic and diastolic HBP and physical activity recorded by connected devices. This assessment of individual risk was associated with CPAP telemonitoring providing adherence, leaks and residual events. Symptoms and quality of life were recorded via electronic questionnaires to be filled by patients. Patients benefited from a demonstration of how to use the remote home telemonitoring equipment and</p>	<p>Eligible patients were aged from 18-75, with severe OSA (apnoea-hypopnea index (AHI)&gt;30events/h) on the basis of respiratory polygraphy or poly somnography. Patients should suffer from at least one cardiovascular disease or exhibit an elevated cardiovascular risk assessed by the 10 year risk of fatal cardiovascular event Systematic Coronary Risk evaluation calculation established specifically for</p>	<p>Length of follow up – 6 months</p> <ul style="list-style-type: none"> <li>• Quality of life: SF12-physical and SF12 mental</li> <li>• Systolic blood pressure</li> <li>• Sleepiness – Epworth scale</li> <li>• Adherence</li> <li>• Systolic blood pressure</li> </ul>	<p>Severe OSAHS strata population (strata based on mean AHI)</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>an explanation of why monitoring psychological variables is relevant for their care. Concerning HBP recommendations, patients had to perform three measurements in the morning and the evening for 3 consecutive days in both groups. one minute was required between each measurement and the patient had to stay sedentary before and during the measurements.</p> <p>N=157</p> <p><b>Usual care:</b></p> <p>Not much detail</p> <p>N=149</p>	<p>European countries. Patients with a Systematic Coronary Risk evaluation risk&gt;5% or in secondary prevention were included.</p> <p>Mean age(range):</p> <p>Multimodal telemonitoring group - 60.8(53.8; 66)</p> <p>Usual care group - 61.8 (54.7; 66.1)</p> <p>Baseline AHI - median (IQR)= 46 (35-61)</p>		
<p>Stepnowsky 2007<sup>40</sup></p> <p>RCT</p> <p>USA</p>	<p><b>Telemonitoring and in person follow up:</b></p> <p>Telemonitored clinical care group. (Telemonitoring and in person follow up) The essence of the TCC intervention is the ability to telemonitor compliance and efficacy data for each patient on a daily basis from the first day of treatment and to act on those data collaboratively, and in partnership, with the patient. Collaborative management</p>	<p>Diagnosis of moderate-to-severe OSA, defined as an Apnoea-Hypopnea Index (AHI) <math>\geq 15</math> events per hour; naive to CPAP therapy; stable sleep environment (operationally defined as a permanent address, requisite for wireless monitoring); and at least 18 years of age. An AHI of <math>\geq 15</math> was chosen in an effort to be consistent with current OSA guidelines and practice parameters.</p>	<p>Length of follow up – 2 months</p> <ul style="list-style-type: none"> <li>• Functional outcomes of sleep</li> <li>• Sleepiness – Epworth</li> <li>• Apnoea-hypopnea index</li> <li>• Adherence</li> <li>• Mean percentage nights CPAP use &gt;4 hours</li> </ul>	<p>Severe OSAHS strata population (strata based on mean AHI)</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>refers to the joint decision making and partnership between provider and patient and is characterized by communication, negotiation, and consideration of important patient factors and preferences. Patients in this group had their objective flow generator data monitored as frequently as needed per specified clinical pathways throughout the active 2-month treatment period. The frequency and nature of the clinical interactions depended on both the objectively measured nightly data values and subjective patient reports.</p> <p>N=24</p> <p><b>In person follow up:</b></p> <p>Usual clinical care group. In person follow up. Patients randomised to UCC were treated according to the prevailing standard of care for OSA patients at the VASDHS CPAP Clinic. Usual care consisted of a 1-week telephone call after CPAP initiation and a 1-month in-office follow-up visit by CPAP clinic staff. Patients were encouraged to call the clinic any time they had a problem or</p>	<p>Mean age (SD)</p> <p>Telemonitoring and in person follow up group: 60(10.8)</p> <p>In person follow up group – 58 (13.7)</p> <p>USA</p> <p>Baseline AHI= 39 (16.8)</p>		

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>concern. CPAP compliance and efficacy data were downloaded at the 1-month time point to help direct clinical management.</p> <p>N=21</p>			
<p>Turino 2017<sup>42</sup></p> <p>RCT</p> <p>Spain</p>	<p><b>Telemonitoring and in person follow up:</b></p> <p>In the telemonitoring group, patients were also fitted with a mask and given a CPAP device (AirSense 10) and a leaflet explaining how to use it and received the same training sessions from the same personnel as in the standard care arm. Each CPAP device given to patients in this group was equipped with mobile 2G (GSM/GPRS) technology capable of sending daily information on CPAP adherence, CPAP pressures, mask leak and residual respiratory events to the MyOSA–Oxigen Salud web database (www.oxigenosalud.com) Automatic alarms for the provider were generated in case of mask leak &gt;30 L·min<sup>-1</sup> for &gt;30% of the night or usage of &lt;4 h·night<sup>-1</sup> on two consecutive nights. In case of alarm, the pulmonary specialist</p>	<p>Included adult patients (&gt;18 years) with newly diagnosed OSA requiring treatment with CPAP (AHI &gt;15 events·h<sup>-1</sup>). Assuming an <math>\alpha</math> risk of 0.05 and a <math>\beta</math> risk of 0.2 in a two-sided test, a sample size of 49 subjects in each group was needed to detect differences <math>\geq 1</math> h in CPAP treatment compliance. A common standard deviation of 1.75 was assumed. Given the high motivation of both professionals and patients to be involved, no dropouts were anticipated and thus a total of 100 patients were planned to be recruited</p> <p>Mean age (SD):</p> <p>Telemonitoring and in person follow up – 56(13)</p> <p>In person follow up group – 54 (12)</p>	<p>Length of follow up – 3 months</p> <ul style="list-style-type: none"> <li>• Quality of life – EQ5D</li> <li>• Adherence</li> <li>• Systolic blood pressure</li> </ul>	<p>Severe OSAHS strata population (strata based on mean AHI)</p>

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>medical officer of the CPAP provider contacted the patient, providing case-by-case problem solving. This included suggestions about how to minimise symptoms (dry mouth, mask issues, discomfort with the device), specific interventions to improve compliance (mask changing, chin strap, pressure or humidifier settings, saline nasal sprays) and support for the patient in the use of CPAP.</p> <p>N=52</p> <p><b>In person follow up:</b></p> <p>Patients randomised to standard care were fitted with a mask and given a CPAP device (AirSense 10; ResMed, Martinsried, Germany) and a leaflet explaining how to use it. A short instruction session on how to use a CPAP device was also given to patients and partners in the sleep unit by a trained nurse with experience in the follow-up of CPAP-treated patients. This included a practical demonstration of how to put on the mask, and the correct management and cleaning of the tubes, masks</p>	<p>Telemonitoring and in person follow up – 52 (25)</p> <p>In person follow up group – 53 (26)</p>		

Study	Intervention and comparison	Population	Outcomes	Comments
	<p>and humidifier. Information on how to turn the CPAP device on and off was provided by the homecare provider at the time of machine delivery. All patients were visited after 1 month of treatment by the specialist nurse at the sleep unit. Information about CPAP pressure, compliance and adherence (use of CPAP for <math>\geq 4</math> h·day<sup>-1</sup>), residual respiratory events and leaks were downloaded from the device. CPAP-related side-effects, CPAP machine care and maintenance (changes of mask, tubes and humidifier), and the number of additional visits and calls were recorded by the nurse.</p> <p>N=48</p>			

1 See appendix D for full evidence tables.

2

**1.4.4 1 Quality assessment of clinical studies included in the evidence review**

**2 Table 3: Clinical evidence summary: Telemonitoring and in person follow up versus in person follow up – severe OSAHS  
3 population**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with In person follow up	Risk difference with Telemonitoring + in person follow up (95% CI)
Systolic blood pressure – morning	406 (2 studies) 3-6 months	⊕⊕⊕⊖ LOW1 due to risk of bias,		The mean systolic blood pressure - morning in the control groups was 63.48	The mean systolic blood pressure - morning in the intervention groups was 0.33 higher (3.1 lower to 3.75 higher)
Adherence- h per day Scale from: 0 to 8.	405 (6 studies) 3 - 12 months	⊕⊖⊖⊖ VERY LOW1,2,3,4 due to risk of bias, inconsistency, imprecision, indirectness		The mean adherence- h per day in the control groups was 3.9861	The mean adherence- h per day in the intervention groups was 0.6 higher (0.12 lower to 1.31 higher)
Adherence-on nights PAP used (h per day) Scale from: 0 to 8.	94 (2 studies) 2-3 months	⊕⊖⊖⊖ VERY LOW1,2,4 due to risk of bias, imprecision, indirectness		The mean adherence-on nights pap used (h per day) in the control groups was 3.65	The mean adherence-on nights pap used (h per day) in the intervention groups was 1.22 higher (0.03 lower to 2.48 higher)
Mean % nights CPAP use >4 hours Scale from: 0 to 100 Higher is better	40 (1 study) 2 months	⊕⊖⊖⊖ VERY LOW1,2,4 due to risk of bias, imprecision, indirectness		The mean % nights CPAP use >4 hours in the control groups was 37 %	The mean % nights CPAP use >4 hours in the intervention groups was 15 higher (4.03 lower to 34.03 higher)
Mean % days used Scale from: 0 to 100. Higher is better	54 (1 study) 3 months	⊕⊖⊖⊖ VERY LOW1,2,4 due to risk of bias,		The mean % days used in the control groups was 45.9 %	The mean % days used in the intervention groups was



Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with In person follow up	Risk difference with Telemonitoring + in person follow up (95% CI)
		imprecision, indirectness			10 higher (10.81 lower to 30.81 higher)
Quality of life (Physical composite) difference Scale from: 0 to 100. Higher is better	82 (1 study) 4 months	⊕⊕⊕⊕ VERY LOW <sup>1,2,4</sup> due to risk of bias, indirectness, imprecision		The mean quality of life (physical composite) difference in the control groups was 2.9	The mean quality of life (physical composite) difference in the intervention groups was 0.3 higher (3.1 lower to 3.7 higher)
Quality of life (mental) difference Scale from: 0 to 100. Higher is better	82 (1 study) 4 months	⊕⊕⊕⊕ VERY LOW <sup>1,2,4</sup> due to risk of bias, imprecision, indirectness		The mean quality of life (mental) difference in the control groups was 1.6	The mean quality of life (mental) difference in the intervention groups was 0 higher (4.15 lower to 4.15 higher)
Quality of life EQ5D Scale from: 0 to 1. Higher is better	100 (1 study) 3 months	⊕⊕⊕⊕ VERY LOW <sup>1,2,4</sup> due to risk of bias, indirectness, imprecision		The mean quality of life eq5d in the control groups was 1.6	The mean quality of life eq5d in the intervention groups was 0 higher (0.07 lower to 0.07 higher)
Quality of Life-GHQ12 Scale from: 0 to 12. Higher is better	88 (1 study) 12 months	⊕⊕⊕⊕ VERY LOW <sup>1,2,4</sup> due to risk of bias, imprecision, indirectness		The mean quality of life-ghq12 in the control groups was 4.9	The mean quality of life-ghq12 in the intervention groups was 0.2 higher (2.31 lower to 2.71 higher)
Sleepiness Epworth (ESS) Scale from: 0 to 24. Lower is better	264 (4 studies) 2-12 months	⊕⊕⊕⊕ VERY LOW <sup>1,4</sup> due to risk of bias, indirectness		The mean sleepiness Epworth (ESS) in the control groups was 3.475	The mean sleepiness Epworth (ESS) in the intervention groups was 0 higher (1 lower to 1 higher)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with In person follow up	Risk difference with Telemonitoring + in person follow up (95% CI)
Apnoea-Hypopnea index (AHI) events/hour Lower is better	182 (3 studies) 3-12 months	⊕⊖⊖⊖ VERY LOW <sup>1,2,3,4</sup> due to risk of bias, inconsistency, imprecision, indirectness		The mean apnoea-hypopnea index (ahi) events/hour in the control groups was 4.9333	The mean apnoea-hypopnea index (ahi) events/hour in the intervention groups was 0.44 lower (3.21 lower to 2.33 higher)
Functional outcome of A. sleep questionnaire Higher is better	40 (1 study) 2 months	⊕⊖⊖⊖ VERY LOW <sup>1,2,4</sup> due to risk of bias, imprecision, indirectness		The mean functional outcome of sleep a. questionnaire in the control groups was 14.4	The mean functional outcome of sleep a. questionnaire in the intervention groups was 0.8 higher (2.06 lower to 3.66 higher)
Mortality	Outcome not reported				
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs, MID for machine usage (adherence)-1 hour; MID for Systolic and Diastolic BP – 5 mm hg. For mean % of nights that the CPAP was used &gt;4 hours outcome, clinically important difference was considered to be 10 % or 1 hour. Established MIDs for SF-36 physical/mental- 2/3; ESS- 2.5; EQ5D- 0.03; FOSQ- 2. GRADE default MID (0.5XSD) used for all other continuous outcomes.</p> <p>3 Downgraded by 1 or 2 increments because: The point estimate varies widely across studies, unexplained by subgroup analysis. The confidence intervals across studies show minimal or no overlap, I<sup>2</sup> =50%, unexplained by subgroup analysis. Subgroup analyses were tested for BMI &lt; or &gt;30 kg/m<sup>2</sup>, ESS &lt; or &gt;9, coexisting conditions, high risk occupation and type of treatment. Random effects analysis used.</p> <p>4 Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect population respectively. The study included a mixed OSASHS severity population based on mean baseline AHI.</p>					

1

**2 Table 4: Clinical evidence summary: Telemonitoring and phone follow-up versus phone follow up – severe OSASHS population**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Phone follow up	Risk difference with Telemonitoring (95% CI)
Adherence hours per day Scale from: 0 to 8.	122 (1 study) 3 months	⊕⊖⊖⊖ VERY LOW <sup>1,2,3</sup> due to risk of bias, imprecision, indirectness		The mean adherence hours per day in the control groups was 4.7	The mean adherence hours per day in the intervention groups was 0.4 higher (0.31 lower to 1.11 higher)
Days CPAP used >4 hours, % patients Scale from: 0 to 100. Higher is better	122 (1 study) 3 months	⊕⊖⊖⊖ VERY LOW <sup>1,2,3</sup> due to risk of bias, imprecision, indirectness		The mean days CPAP used >4 hours in the control groups was 63.3	The mean days CPAP used >4 hours in the intervention groups was 6.9 higher (2.9 lower to 16.70 higher)
Mortality	No outcome reported				
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs. MID for machine usage (adherence)-1 hour. For mean % of nights that the CPAP was used &gt;4 hours outcome, clinically important difference was considered to be 10 % or 1 hour. GRADE default MID(0.5XSD) used for all other continuous outcomes.</p> <p>3 Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect population respectively. The study included a mixed OSASHS severity population based on mean baseline AHI.</p>					

**1 Table 5: Clinical evidence summary: Multimodal telemonitoring versus usual care – severe OSAHS population**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Usual care	Risk difference with Multimodal telemonitoring (95% CI)
Adherence Scale from: 0 to 8. Higher is better	239 (1 study) 6 months	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision		The mean adherence in the control groups was <b>4.75</b>	The mean adherence in the intervention groups was <b>0.53 higher</b> (0.07 lower to 1.13 higher)
Sleepiness ESS Scale from: 0 to 24. Lower is better	239 (1 study) 6 months	⊕⊕⊕⊕ LOW <sup>1</sup> due to risk of bias		The mean sleepiness (ESS) in the control groups was 6.05	The mean sleepiness (ESS) in the intervention groups was 1.47 lower (2.48 to 0.46 lower)
Quality of life-SF12-Physical Scale from: 0 to 100. Higher is better	239 (1 study) 6 months	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision		The mean quality of life-sf12-physical in the control groups was 44.1	The mean quality of life-sf12-physical in the intervention groups was 1.5 higher (0.14 to 2.86 higher)
Quality of life-SF12 -Mental Scale from: 0 to 100. Higher is better	239 (1 study) 6 months	⊕⊕⊕⊕ LOW <sup>1</sup>  due to risk of bias		The mean quality of life-sf12 - mental in the control groups was 43.6	The mean quality of life-sf12 - mental in the intervention groups was 0.3 higher (0.88 lower to 1.48 higher)
Systolic blood pressure	239 (1 study) 6 months	⊕⊕⊕⊕ VERY LOW <sup>1,2</sup> due to risk of bias, imprecision		The mean systolic blood pressure in the control group was 130.06	The mean systolic blood pressure in the intervention group was 0.92 higher (3.65 lower to 5.49 higher)
Mortality	No outcome reported				

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs. MID for machine usage (adherence)-1 hour; MID for Systolic and Diastolic BP – 5 mm hg. Established MIDs for SF-36 physical/mental- 2/3; ESS- 2.5. GRADE default MID (0.5XSD)used for all other continuous outcomes.

**1 Table 6: Clinical evidence summary: Telemonitoring and tele-visits versus in person follow up – severe OSAHS population**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with in person follow-up	Risk difference with Telemonitoring+televisits (95% CI)
Adherence h/day	183 (2 studies) 3-6 months	⊕⊖⊖⊖ VERY LOW <sup>1,2</sup> due to risk of bias, and indirectness		The mean adherence h/day in the control groups was 4.92	The mean adherence h/day in the intervention groups was 0.14 higher (0.39 lower to 0.66 higher)
EQ5D <sup>4</sup> Scale from: 0 to 1. Higher is better	282 (2 studies) 3-6 months	⊕⊖⊖⊖ VERY LOW <sup>1,2,3,4</sup> due to risk of bias, indirectness and imprecision		The mean EQ5D in the control groups was 0.87	The mean EQ5D in the intervention groups was 0.03 lower (0.07 lower to 0.01 higher)
FOSQ Scale from: 5 to 20. Higher is better	128 (1 study) 6 months	⊕⊕⊖⊖ LOW <sup>1,2</sup> due to risk of bias and imprecision		The mean FoSQ in the control groups was 18.01	The mean FoSQ in the intervention groups was 1.11 lower (2.32 lower to 0.1 higher)
Sleepiness ESS Scale from: 0 to 24. Lower is better	314 (2 studies) 3-6 months	⊕⊖⊖⊖ VERY LOW <sup>1,2</sup> due to risk of bias, and indirectness		The mean sleepiness (ESS) in the control groups was 6.47	The mean sleepiness (ESS) in the intervention groups was 1.02 higher ( 0.07 lower to 1.98 higher)
EQ5D- VAS Higher is better	154 (1 study) 3 months	⊕⊖⊖⊖ VERY LOW <sup>1,3</sup> due to risk of bias, indirectness		The mean EQ5D-VAS in the control groups was 75.09	The mean EQ5D-VAS in the intervention groups was 0.57 higher (4.39 lower to 5.53 higher)
Number of OSA related GP visits	186 (1 study) 6 months	⊕⊖⊖⊖ VERY LOW <sup>1,2,3</sup> due to risk of bias, indirectness and imprecision	RR 0.65 (0.19 to 2.24)	65 per 1000	23 fewer per 1000 (from 53 fewer to 81 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with in person follow-up	Risk difference with Telemonitoring+televisits (95% CI)
Number of OSA related specialist visits	186 (1 study) 6 months	⊕⊖⊖⊖ VERY LOW <sup>1,2,3</sup> due to risk of bias, indirectness and imprecision	RR 1.20 (0.52 to 2.75)	99 per 1000	20 fewer per 1000 (from 47 fewer to 173 more)
Mortality	No outcome reported				
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs. MID for machine usage (adherence)-1 hour; MID for Systolic and Diastolic BP – 5 mm hg. Established MIDs for ESS- 2.5; EQ5D- 0.03; EQ5D VAS- 3.GRADE default MID(0.5XSD) used for all other continuous outcomes.</p> <p>3 Downgraded by 1 or 2 increments because: The majority of the evidence included an indirect population of moderate to severe severity patients based on the AHI of included population (downgrade by one increment) or a very indirect population (downgrade by two increments)</p> <p>4 Baseline values differed in the Lugo study for this outcome. Therefore, while the in person follow up group has a higher (better) end score the telemonitoring group had a better change score of 0.04 compared to 0.01 in the in person follow up group.</p>					

- 1
- 2 **Narrative results:**
- 3 Data on machine usage outcomes were measured and reported inconsistently across the studies. Data have been presented narratively for
- 4 studies where could not be analysed (data were presented as a percentage only). Narrative data was considered alongside the GRADE
- 5 evidence by the committee when making recommendations. The overall study quality was taken into account as GRADE analysis for each
- 6 outcome could not be performed.
- 7     1. Telemonitoring and in person follow up compared to in person follow up
- 8 Hoet 2017 (n=46) (very low quality):
- 9 CPAP use of over 4 hours per night %
- 10 The study reported a lower rate of CPAP use of over 4 hours per night in the in person follow up group compared to the telemonitoring group
- 11 (64% versus 82%).

- 1 2. Telemonitoring and tele visits compared to in person follow up
- 2 Isetta 2015 (n=138) (very low quality): Mean % of nights CPAP used >4 hours
- 3 The study reported the mean percentage of nights where CPAP was used for > 4 hours. Results showed this was slightly higher in the
- 4 telemonitoring plus in person follow up group compared to the in person follow up only group (65% versus 57%, p=0.329).
- 5
- 6 See appendix F for full GRADE tables.
- 7

## **1.5 1 Economic evidence**

### **1.5.1 2 Included studies**

3 Two health economic studies were identified with the relevant comparison and have been  
4 included in this review.<sup>19, 42</sup> These are summarised in the health economic evidence profile  
5 below (Table 7) and the health economic evidence tables in appendix H.

### **1.5.2 6 Excluded studies**

7 One economic study relating to this review question was identified but was excluded due to  
8 the availability of more applicable evidence.<sup>2</sup> Reasons for exclusion are given in Appendix I:.

9 See also the health economic study selection flow chart in appendix G.

10

11



1

**1.5.3.2 Summary of studies included in the economic evidence review**

**3 Table 7: Health economic evidence profile: Telemonitoring versus hospital follow-up**

Study	Applicability <sup>(a)</sup>	Limitations	Other comments	Incremental cost <sup>(d)</sup>	Incremental effects <sup>(f)</sup>	Cost effectiveness	Uncertainty
Isetta 2015 <sup>19</sup> Spain	Partially applicable	Potentially serious limitations <sup>(b)</sup>	Within trial (RCT) cost-utility analysis, with a 6 month follow up	+£10 Excluding GP visits, outpatient visits and medicines: +£2 <sup>(e)</sup>	- 0.0012 QALYs (95% CI: -0.0500 to 0.0474)	Hospital follow-up dominates telemonitoring in both costing scenarios	Uncertainty reported in study not relevant <sup>(h)</sup>
Turino 2017 <sup>42</sup> Spain	Partially applicable	Potentially serious limitations <sup>(c)</sup>	Within trial (RCT) cost-utility analysis, with a 3 month follow up	Saves £45	Scenario 1: -0.003 QALYs  Scenario 2: -0.001 QALYs <sup>(g)</sup>	Scenario 1: Standard care cost £15,000 per extra QALY gained  Scenario 2: Standard care cost £60,000 per extra QALY gained	Deterministic sensitivity analysis when there are 25% - 50% cost increases in the CPAP provider costs <sup>(i)</sup> ICERs in scenario 1: £12,333/£10,000 ICERs in scenario 2: £49,000/£40,000

4 Abbreviations: ICER= incremental cost-effectiveness ratio; QALY= quality-adjusted life years; RCT= randomised controlled trial

5 (a) Both these studies have been judged as partially applicable as they are from a Spanish perspective.

6 (b) There is lack of clarity in the components that have been summed to calculate mean cost per patient (see appendix G).

7 (c) There is a lack of clarity around the methods used to calculate QALYs (see appendix G).

8 (d) 2015 and 2013 euros have been converted to UK pounds using the purchasing power parities<sup>30</sup>

9 (e) There is lack of clarity in the components that have been summed to calculate mean cost per patient (see appendix G).

10 (f) Both studies used the Euroqol 5 dimensions (EQ-5D) to derive utilities (scale: 0.0 [death] to 1.0 [full health])

11 (g) There is a lack of clarity around the methods used to calculate QALYs (see appendix G).

12 (h) The authors have conducted a probabilistic sensitivity analysis (PSA) around the ICER which includes costs from a societal perspective. As the costs have been recalculated to report provider perspective only (thereby conforming to the NICE reference case), this PSA is no longer relevant for the purpose of the guideline.

14 (i) Scenario 1 reports the QALYs reported in the study which implicitly extrapolates the difference from 3 months to 12 months. Scenario 2 assumes quality of life difference is only for 3 months (see appendix G for more details).

15

#### 1.5.4 1 Health economic evidence statements

- 2 • One cost-utility analysis found that hospital follow-up dominated telemonitoring for  
3 people with OSAHS. This study was assessed as being partially applicable with  
4 potentially serious limitations.
- 5 • One cost-utility analysis found that hospital follow-up was cost-effective compared  
6 with telemonitoring for people with OSAHS, depending on the duration of the quality  
7 of life effect (£15,000-£60,000 per QALY gained). This study was assessed as being  
8 partially applicable with potentially serious limitations.  
9

1

## 1.6 2 The committee's discussion of the evidence

### 1.6.1 3 Interpreting the evidence

#### 1.6.1.1 4 The outcomes that matter most

5 The committee considered the outcomes of quality of life and mortality as critical outcomes  
6 for decision making. Other important outcomes included sleepiness scores (e.g. Epworth),  
7 Apnoea –Hypopnea index (AHI), oxygen desaturation index (ODI), CO<sub>2</sub> control, hours of use  
8 (adherence), minor adverse effects of treatment, driving outcomes, neurocognitive outcomes,  
9 healthcare contacts, impact on co-existing conditions (HbA1c for diabetes, cardiovascular  
10 events for cardiovascular disease, systolic blood pressure for hypertension).

11 No evidence was identified for the critical outcome mortality in all ten studies.

#### 1.6.1.2 2 The quality of the evidence

##### 13 OSAHS (all severities)

##### 14 CPAP

15 There was evidence from 10 studies - 6 studies compared telemonitoring (telemonitoring unit  
16 added to CPAP device which allows sleep laboratory staff and to connect to web portal to  
17 analyse patients data and arrange a visit or phone consultation when necessary) and in  
18 person follow-up, 1 study compared telemonitoring and phone follow-up with phone follow-  
19 up, 1 study compared multimodal telemonitoring (which included systolic and diastolic blood  
20 pressure and physical activity recorded by connected devices) with usual care, 2 studies  
21 compared telemonitoring and tele visits (tele visits via video conference (Skype)) with in  
22 person follow up.

23 The duration of all included studies was of one year or less. Studies varied in size with the  
24 number of participants ranging from 45 in the smallest study to 306 in the largest.

25 All studies were in people using fixed level CPAP except for one study in people using auto  
26 CPAP.

27 Studies were stratified based on the AHI/ODI severity of the population. When a mixed  
28 severity population was included the severity of the majority of the population was used by  
29 taking the mean AHI of the patients included and the study was downgraded for indirectness.  
30 The majority of studies included in this review were downgraded for indirectness.

31 All evidence was in people with severe sleep apnoea (AHI  $\geq$ 30 severe) determined by their  
32 baseline AHI.

33 The quality of the evidence varied from very low to moderate quality; majority of evidence  
34 was downgraded due to risk of bias, imprecision, indirectness and inconsistency. Risk of bias  
35 was most commonly due to selection bias, performance bias and incomplete outcome data.  
36 Indirectness was present in many of the studies due to the inclusion of mixed severity  
37 OSAHS populations, combining people with mild, moderate or severe OSAHS. Imprecision  
38 was also present for many outcomes with confidence intervals crossing the MID thresholds.  
39 The low quality of evidence, small study sizes and uncertainty around the effect estimate was  
40 taken into consideration by the committee when assessing the evidence base for this review.

41 The committee considered the clinical importance for AHI on a case by case basis, taking  
42 into consideration the baseline AHI and the improvement in severity of sleep apnoea.

1

2 Oral devices

3 No evidence was identified for monitoring of people using oral devices.

4 Positional modifiers

5 No evidence was identified for monitoring of people using positional modifiers.

6 Surgery

7 No evidence was identified for monitoring of people who have undergone surgery.

8 **OHS**

9 There was no evidence identified for people with obesity hypoventilation syndrome

10 **COPD-OSAHS overlap syndrome**

11 There was no evidence identified for people with COPD-OSAHS overlap syndrome.

**1.6.1.312 Benefits and harms**

13 **OSAHS**

14 **CPAP**

15 ***Telemonitoring and in person follow-up vs in person follow-up - severe OSAHS.***

16 The evidence suggested that adherence measures (nights CPAP used (hours/day), mean %  
17 nights CPAP use >4 hours and mean % days used) showed a clinically important benefit of  
18 telemonitoring with in person follow-up compared to in person follow-up alone. The  
19 committee however were not confident of this outcome as there was some uncertainty  
20 around the effect estimate. Additionally, one small study in which results were reported  
21 narratively demonstrated a benefit for mean % CPAP used >4 hours in the telemonitoring  
22 group compared to in person follow-up alone. This study however was unsuitable for GRADE  
23 analysis so was deemed to be very low quality. One of the adherence outcomes – hours that  
24 CPAP was used per day showed no clinically important difference.

25 The evidence suggested that there was no clinically important difference between  
26 telemonitoring with in person follow-up and in person follow-up alone for the critical outcomes  
27 quality of life measures (SF12 questionnaire - physical and mental composite, quality of life-  
28 EQ5D scale, and quality of life – GHQ12 scale).

29 There was no clinically important difference between telemonitoring and in person follow-up  
30 for the outcomes of systolic blood pressure, sleepiness (Epworth), apnoea-hypopnea index,  
31 and functional outcome of sleep questionnaire.

32 Follow-up evidence from the studies was available for 2 – 12 months. The committee agreed  
33 that this range of the follow-up in the studies is very wide.

34 ***Telemonitoring and phone follow-up vs phone follow-up - severe OSAHS***

35 The evidence from one study suggested that that there was no clinically important difference  
36 between telemonitoring and phone follow-up for both adherence outcomes: hours per day  
37 used and days CPAP used >4 hours (% of patients). Follow-up evidence was available for 3  
38 months.

39 ***Multimodal telemonitoring vs usual care - severe OSAHS***

1 The evidence from one study suggested that there was no difference between multimodal  
2 telemonitoring and usual care for critical outcomes of quality of life SF12 physical composite  
3 and SF12 mental composite and important outcomes such as adherence (hours used) and  
4 systolic blood pressure. Follow-up evidence was available for 6 months.

#### 5 ***Telemonitoring and tele visits vs in person follow-up - severe OSAHS***

6 The evidence suggested that there was no difference between telemonitoring and tele visits  
7 and in person follow-up for the critical outcomes of quality of life (EQ5D VAS and FoSQ) and  
8 important outcomes of adherence (hours/day), sleepiness (Epworth), number of OSA related  
9 GP visits and number of OSA related specialist visits. One study in which results were  
10 reported narratively and of very low quality also showed no difference between the groups for  
11 % of nights CPAP used >4 hours.

12 There was a clinically important benefit of in person follow-up versus telemonitoring and tele  
13 visits for the critical outcome of EQ5D (quality of life measure) however this only just reached  
14 the threshold for clinical significance and there was uncertainty around the effect estimate  
15 with the confidence interval crossing the MID threshold. All follow-up evidence was available  
16 for 3-6 months.

#### 17 Follow-up for people with OSAHS-the committee's consideration of the evidence

18 The committee discussed that monitoring of patients on treatment for OSAHS should be  
19 used to assess control of symptoms, efficacy of therapy, impact on co-morbidities and  
20 adherence to treatment. They noted that follow-up should be tailored to the person's overall  
21 treatment plan. This may include lifestyle changes, such as weight management, modifying  
22 use of sedative drugs and alcohol, and stopping smoking, and treating underlying lung  
23 disease and other comorbidities.

#### 24 Follow-up for people using CPAP

25 The committee defined telemonitoring as the use of information and communication  
26 technologies to monitor patients remotely and transmit data related to their health. It provides  
27 data that can be downloaded including respiratory events, pressure requirements, mask leak  
28 and adherence and is used for follow-up with telephone or video consultations.

29 Overall, the evidence suggested that telemonitoring along with face-to-face or telephone  
30 consultations were equally effective as face to face or telephone consultations without  
31 telemonitoring. There was some evidence that adherence was improved by telemonitoring in  
32 people with severe OSAHS, and the committee discussed its advantages, such as early  
33 night-by-night access to data and remote adjustment of CPAP level. There was no evidence  
34 to suggest a difference between face-to-face, telephone and video consultations. None of  
35 the studies looked at telemonitoring for more than 12 months. The evidence was available for  
36 people with severe OSAHS; the committee agreed that the data could be extrapolated to  
37 people with mild and moderate OSAHS as well.

38 The committee discussed that although CPAP is considered the treatment of choice for  
39 OSAHS, CPAP adherence is a significant challenge. They agreed that CPAP follow-up  
40 through any means (face to face, telephone or video consultation, including review of  
41 telemonitoring data where available) would improve adherence and effectiveness of the  
42 treatment. The committee agreed that CPAP follow-up should be at least one month and  
43 the subsequent follow-up according to person's clinical needs, until optimal control of  
44 symptoms and AHI is achieved on CPAP. They discussed that the pattern of CPAP  
45 adherence is established within the first week of therapy; therefore, early assessment of  
46 progress is helpful for problem-solving and providing support. From their experience the  
47 committee believe that greater benefits of CPAP use are associated with longer duration of  
48 use; therefore, patients should be encouraged to wear CPAP throughout the whole night, but  
49 ideally at least 4 hours/ night. Data from the CPAP machine is important so that CPAP

1 settings can be adjusted to control residual respiratory events or to detect treatment  
2 emergent central sleep apnoea, and problems such as mask leak, rhinitis or poor tolerance  
3 to be identified. Some measures of adherence are improved by telemonitoring, and it allows  
4 early night-by-night access to data and remote adjustment of CPAP level without the need  
5 for patient visits.

6 The committee based on their experience discussed the advantages of telemonitoring.  
7 These include early night-by-night access to data which can lead to early detection of  
8 problems such as mask leaks or persistent respiratory events of sleep apnoea, and the  
9 ability to monitor that OSAHS so that it continues to be effectively controlled and the  
10 individual is adherent to therapy. Telemonitoring makes managing a person's OSAHS more  
11 efficient for clinicians as they have ready access to the data should they need it. For  
12 example, if contacted by a person with an issue they can use the data to help identify the  
13 problem (for example, mask leak or inadequate pressure) and take appropriate action  
14 without the need for a scheduled appointment.

15 The committee agreed that video and telephone consultations along with telemonitoring is  
16 also advantageous to people with OSAHS as it can reduce the number of in-person visits  
17 needed to the sleep service. This can be particularly beneficial to patients who have difficulty  
18 in getting to clinics, for example, people who live in remote places or people with poor  
19 mobility, there would be fewer clinic visits in such cases. The reduction in the number of  
20 face-to-face consultations will also help reduce the risk of infection during the COVID-19  
21 pandemic. The committee agreed that telemonitoring should be offered alongside CPAP for  
22 the first 12 months of treatment, and considered beyond 12 months where optimal control of  
23 symptoms and AHI has not been achieved, or to help with solving problems that people with  
24 OSAHS might experience.

25 The committee discussed how often long-term follow-up should happen. Annual and two-  
26 yearly follow-up were considered, they agreed that a two-yearly follow-up would probably be  
27 too long and interval and decided to make a recommendation to consider annual follow-up.  
28 The committee agreed that after CPAP treatment is established, annual follow-up allows  
29 continued efficacy of therapy and adherence to be assessed, along with co-morbidities and  
30 continuing need of therapy.

31 In between follow-up appointments the committee agreed that people with OSAHS using  
32 CPAP should be offered access to a sleep service for clinical support in case of problems, for  
33 provision of advice, and for replacement consumable equipment such as masks, circuitry and  
34 filters as needed.

35 Current practice includes a mixture of face-to-face, telephone, video consultations and  
36 telemonitoring. The increasing number of people being offered CPAP means that provision of  
37 regular outpatient follow-up is becoming increasingly difficult. Increasing website and app-  
38 based access to telemonitoring data will allow patients to access their own results and  
39 encourage self-management.

40 The committee stressed that telemonitoring crucially involves feedback to patients and time  
41 should be available for sleep centre staff to review data, act on this and share with the  
42 person using CPAP. Current practice already includes ready access to advice and CPAP  
43 equipment from sleep centres. Telemonitoring has facilitated remote assessment of patients  
44 during the coronavirus pandemic and has become a standard follow-up option in most sleep  
45 services. This use is likely to continue long term, because it is convenient for patients,  
46 enables them to assess progress themselves and allows access to efficacy and adherence  
47 data whenever needed, for example, for problem solving, routine follow-up and to complete  
48 DVLA reports. The committee noted that telemonitoring has changed practice for clinicians  
49 in terms of clinic staffing, and for patients in terms of saving time in attending the clinic. The  
50 committee also noted that in current practice follow-up is at 1-3 months and 1 year, hence  
51 implementation of these recommendations would not change practice.

1 Follow-up for people using mandibular advancement splints (MAS) and positional modifiers

2 As there was no evidence available for monitoring people using MAS or positional modifiers,  
3 the committee drew on their clinical experience and agreed that people using mandibular  
4 advancement splints or positional modifiers should have follow-up through face to face, video  
5 or telephone consultations (including review of downloads from oral device or positional  
6 modifiers if available), with early (3 months for both mandibular advancement splints  
7 positional modifiers) and subsequent follow-up according to person's clinical needs, until  
8 optimal control of symptoms and AHI is achieved. Adherence to oral devices is less easy to  
9 measure objectively. Early face to face follow-up is advisable as further gradual  
10 advancement of the mandible by the device may be required. However, the committee  
11 agreed that in light of COVID-19 video or telephone consultations may be preferable.  
12 Subsequent follow-up should be personalised, with assessment of side effects including  
13 impact on dentition and bite.

14 Objective adherence data can be obtained from positional devices for people with positional  
15 OSHAS, but early review allows assessment of symptom control and determination of  
16 whether respiratory events are minimised.

17 Recommendations on monitoring for positional modifiers and mandibular advancement  
18 splints are considered to be current practice in many areas and are not expected to lead to  
19 major changes in practice.

20 Follow-up for people who have had surgery

21 For people who have undergone surgery, initial follow-up consultation within 3 months of the  
22 operation should be to assess wound healing, side effects, control of symptoms and include  
23 respiratory polygraphy. Any subsequent follow-up is according to the person's clinical needs.  
24 There was no evidence available for this population, so recommendations were based on the  
25 committee's consensus opinion and clinical experience.

26 The recommendation on monitoring for surgery is considered to be current practice in many  
27 areas and are not expected to lead to major changes in practice.

28 Follow-up for drivers with excessive sleepiness

29 The committee agreed that people must not drive if they have excessive sleepiness, having  
30 or likely to have an adverse effect on driving, in keeping with DVLA guidance.<sup>8</sup> Driving may  
31 resume after satisfactory symptom control, which needs medical confirmation if moderate or  
32 severe OSAHS. This is the patient's responsibility, but sleep team professionals will help  
33 them assess the likely impact of their symptoms on their safety to drive, by taking a detailed  
34 driving history, including distances driven, episodes of drowsy driving, use of alerting  
35 mechanisms when driving to avoid falling asleep, or a history of a sleep related accident or  
36 near miss. Using a high Epworth Sleepiness Score alone for driving advice is unlikely to be  
37 adequate, as it is subjective. Many people can doze off in relaxed situations but retain  
38 concentration during specific tasks such as driving. Patients with excessive sleepiness  
39 having or likely to have an adverse impact on driving with confirmed moderate or severe  
40 obstructive sleep apnoea syndrome must inform the DVLA and their car insurance company  
41 of their diagnosis. If patients have excessive sleepiness having or likely to have an adverse  
42 impact on driving and a diagnosis of mild OSAHS, they must inform the DVLA of their  
43 diagnosis if they have not achieved symptom control in 3 months.<sup>8</sup>

44 For subsequent licensing, annual review is required by the DVLA for Group 2 licence holders  
45 (lorry and bus drivers) and a minimum of 3 yearly review for Group 1 licence holders (cars  
46 and motorcycles), to confirm control of OSAHS, improved sleepiness and treatment  
47 adherence.<sup>7</sup> The committee noted that people with OSAHS who do not have symptoms of  
48 excessive sleepiness during waking hours will continue to have an annual review which  
49 includes assessment of any changes in symptoms.

1 Even though there was limited evidence on monitoring strategies for CPAP and lack of  
2 evidence on monitoring strategies for oral devices, positional modifiers and surgery for  
3 people with OSAHS, based on their experience the committee made strong  
4 recommendations hence they did not make any research recommendation for monitoring  
5 strategies for these treatments.

6

## 7 **OHS**

8 The committee noted the lack of evidence for monitoring strategies in OHS and decided to  
9 make consensus recommendations based on evidence reviewed for OSAHS, their  
10 experience and current practice.

11 The committee noted that CPAP and non-invasive ventilation are just part of treatment for  
12 OHS, and that follow-up should be tailored to the person's overall treatment plan. This should  
13 also include lifestyle changes, such as weight management, modifying use of sedative drugs  
14 and alcohol, and stopping smoking, and treating underlying lung disease and other  
15 comorbidities.

16 For people with OHS using CPAP or non-invasive ventilation, early follow-up at 1 month is  
17 advised to ensure control of symptoms, sleep disordered breathing and adherence. Problem-  
18 solving can be achieved by face to face, telephone or video consultations, including review of  
19 telemonitoring data where available. The committee agreed that once optimised on CPAP or  
20 non-invasive ventilation (with or without oxygen supplementation), 6-monthly to one year  
21 follow-up should be considered according to person's clinical needs. The committee agreed  
22 that video and telephone consultations with telemonitoring will help reduce the risk of  
23 infection during the COVID-19 pandemic.

24 The committee also agreed that although most studies of telemonitoring are in patients with  
25 OSAHS, and that there is not yet the ability to assess hypercapnia through telemonitoring, it  
26 is still of value to use for people with OHS.

27 The committee noted that in current practice follow-up is at is 4 weeks and 1 year, hence  
28 implementation of these recommendations would not change practice.

29 In addition to annual review, people with OSAHS and OHS on CPAP or non-invasive  
30 ventilation therapy need to be able to access the sleep service for advice and provision of  
31 consumables such as masks, circuitry and filters.

32 Current practice includes a mixture of face-to-face /telephone/video consultations and  
33 telemonitoring. The increasing number of people being offered CPAP means that provision of  
34 regular outpatient follow-up has become increasingly difficult. In addition, a more  
35 personalised approach enables attention to be focussed on people with problems adapting to  
36 therapy. Telemonitoring is included in the overall cost of CPAP devices by some  
37 manufacturers for variable periods and is increasingly available for non-invasive ventilators.

38 The committee discussed that routine use of telemonitoring should reduce the need for face-  
39 to-face consultations, and reduce pressure on outpatient clinics, but feedback and discussion  
40 with patients is still needed. Increasing website and app-based access to telemonitoring data  
41 will allow patients to access their own results to aid self-care.

42 The committee noted that there has been a significant move to video and telephone  
43 consultations to reduce the risk of infection during the COVID-19 pandemic.

### 44 Follow-up for drivers with excessive sleepiness

45 The committee agreed that people must not drive if they have excessive sleepiness, having  
46 or likely to have an adverse effect on driving, in keeping with DVLA guidance.<sup>8</sup> Driving may  
47 resume after satisfactory symptom control, which needs medical confirmation if moderate or



1 severe OSAHS. This is the patient's responsibility, but sleep team professionals will help  
2 them assess the likely impact of their symptoms on their safety to drive, by taking a detailed  
3 driving history, including distances driven, episodes of drowsy driving, use of alerting  
4 mechanisms when driving to avoid falling asleep, or a history of a sleep related accident or  
5 near miss. Using a high Epworth Sleepiness Score alone for driving advice is unlikely to be  
6 adequate, as it is subjective. Many people can doze off in relaxed situations but retain  
7 concentration during specific tasks such as driving. Patients with excessive sleepiness  
8 having or likely to have an adverse impact on driving with confirmed moderate or severe  
9 OSAHS with their OHS must inform the DVLA and their car insurance company of their  
10 diagnosis. If patients have excessive sleepiness having or likely to have an adverse impact  
11 on driving and a diagnosis of mild OSAHS with their OHS, they must inform the DVLA of their  
12 diagnosis if they have not achieved symptom control in 3 months.<sup>8</sup>

13 For subsequent licensing, annual review is required by the DVLA for Group 2 licence holders  
14 (lorry and bus drivers) and a minimum of 3 yearly review for Group 1 licence holders (cars  
15 and motorcycles), to confirm control of OSAHS, improved sleepiness and treatment  
16 adherence.<sup>7</sup> The committee noted that people with OHS who do not have symptoms of  
17 excessive sleepiness during waking hours will continue to have an annual review which  
18 includes assessment of any changes in symptoms.

19 Even though there was a lack of evidence on monitoring strategies for people with OHS,  
20 based on their experience the committee made strong recommendations hence they did not  
21 make any research recommendation for this topic.

22

### 23 **COPD-OSAHS overlap syndrome**

24 The committee noted the lack of evidence for monitoring strategies in COPD-OSAHS overlap  
25 syndrome and decided to make consensus recommendations based on evidence reviewed  
26 for OSAHS, their experience and current practice.

27 The committee noted that CPAP and non-invasive ventilation are just part of treatment for  
28 COPD-OSAHS overlap syndrome, and that follow-up should be tailored to the person's  
29 overall treatment plan. This should also include lifestyle changes, such as weight  
30 management, modifying use of sedative drugs and alcohol, and stopping smoking, and  
31 treating underlying lung disease and other comorbidities. For people with severe COPD, it  
32 may also include discussions about care planning (for example COPD exacerbation action  
33 plan and advance care planning for those with severe COPD).

34 The committee agreed that for people with COPD-OSAHS overlap syndrome started on  
35 CPAP or non-invasive ventilation early follow-up is advised to ensure control of symptoms,  
36 sleep disordered breathing and adherence. Problem-solving can be achieved by face to face  
37 consultations, video or telephone consultations, including review of telemonitoring data  
38 where available. The committee also agreed that although most studies of telemonitoring are  
39 in patients with OSAHS, and that there is not yet the ability to assess hypercapnia through  
40 telemonitoring, it is still of value to use for people with COPD-OSAHS overlap syndrome for  
41 monitoring OSAHS. The committee agreed that video and telephone consultations with  
42 telemonitoring will help reduce the risk of infection during the COVID-19 pandemic.

43 In addition to their 6-monthly or annual review people with OSAHS and COPD-OSAHS  
44 overlap syndrome on therapy need open access to a sleep service for advice, and provision  
45 of consumables such as masks, circuitry and filters.

46 The committee noted that in current practice follow-up is at 2 weeks and 1 year, hence  
47 implementation of these recommendations would not change practice.

48 Current practice includes a mixture of face-to-face, telephone, video consultations and  
49 telemonitoring. The increasing number of people being offered CPAP and non-invasive

1 ventilation means that regular outpatient follow-up becomes increasingly difficult for sleep  
2 centres to provide. In addition, a more personalised approach enables attention to be  
3 focussed on people with problems adapting to therapy. Telemonitoring is included in the  
4 overall cost of CPAP devices by some manufacturers for variable periods. Increasing website  
5 and app-based access to telemonitoring data will allow patients to access their own results to  
6 aid self-care.

7 The committee noted that there has been a significant move to video and telephone  
8 consultations to reduce the risk of infection during the COVID-19 pandemic.

#### 9 Follow-up for drivers with excessive sleepiness

10 The committee agreed that people must not drive if they have excessive sleepiness, having  
11 or likely to have an adverse effect on driving, in keeping with DVLA guidance.<sup>8</sup> Driving may  
12 resume after satisfactory symptom control, which needs medical confirmation if moderate or  
13 severe OSAHS. This is the patient's responsibility, but sleep team professionals will help  
14 them assess the likely impact of their symptoms on their safety to drive, by taking a detailed  
15 driving history, including distances driven, episodes of drowsy driving, use of alerting  
16 mechanisms when driving to avoid falling asleep, or a history of a sleep related accident or  
17 near miss. Using a high Epworth Sleepiness Score alone for driving advice is unlikely to be  
18 adequate, as it is subjective. Many people can doze off in relaxed situations but retain  
19 concentration during specific tasks such as driving. Patients with excessive sleepiness  
20 having or likely to have an adverse impact on driving with confirmed moderate or severe  
21 obstructive sleep apnoea syndrome must inform the DVLA and their car insurance company  
22 of their diagnosis. If patients have excessive sleepiness having or likely to have an adverse  
23 impact on driving and a diagnosis of mild OSAHS, they must inform the DVLA of their  
24 diagnosis if they have not achieved symptom control in 3 months.<sup>8</sup>

25 For subsequent licensing, annual review is required by the DVLA for Group 2 licence holders  
26 (lorry and bus drivers) and a minimum of 3 yearly review for Group 1 licence holders (cars  
27 and motorcycles), to confirm control of OSAHS, improved sleepiness and treatment  
28 adherence.<sup>7</sup> The committee noted that people with COPD-OSAHS overlap syndrome who do  
29 not have symptoms of excessive sleepiness during waking hours will continue to have an  
30 annual review which includes assessment of any changes in symptoms.

31 Even though there was a lack of evidence on monitoring strategies for people with COPD-  
32 OSAHS overlap syndrome, based on their experience the committee made strong  
33 recommendations hence they did not make any research recommendation for this topic.

34

### 1.6.25 **Cost effectiveness and resource use**

36 Since treatments in these conditions are potentially for life it is important for cost  
37 effectiveness as well as for patient welfare to monitor whether a treatment is working and  
38 then, if necessary, to modify, switch or discontinue treatment.

39 The clinical evidence was mainly for telemonitoring compared with outpatient follow up for  
40 people with OSAHS. There was little difference in the clinical outcomes and so the question  
41 of which is less costly is important.

42 Different manufacturers seem to have different pricing models for telemonitoring.

- 43 • Mostly telemonitoring for one year is included in the price of the CPAP machine and a  
44 fee is charged for subsequent years
- 45 • Sometimes a small fee (e.g. £20) is charged for the modem that will cover the  
46 lifespan of the machine when purchased at the same time as the machine.

1 It might also be possible to turn on and off the modem and transfer it to other patients, thus  
2 reducing the price of telemonitoring. This might facilitate the use of telemonitoring to sample  
3 one month's data ahead of a follow-up consultation.

4 Intuitively, there could be cost savings with telemonitoring if it reduces the need for face-to-  
5 face consultations (e.g. reduced need for fully equipped outpatient room and reduced staff  
6 time as well as reduced risk of transmission of infectious disease) but there are also costs.

7 Two cost-utility analyses were included, each comparing telemonitoring with hospital clinic  
8 follow-up for people with OSAHS. Both were randomised trials in a Spanish setting.

9 In one study the authors concluded that the telemonitoring strategy was dominated (less  
10 effective and more costly) by the hospital follow-up. In this within-trial study, people with  
11 OSAHS completed a biweekly six-item questionnaire about the status of their physical  
12 activity, sleep time, CPAP use and treatment side effects. Clinicians monitored responses  
13 and communicated with patients via the website messaging tool. In this scenario, the  
14 committee were of the view that one reason that telemonitoring may not be cost-effective  
15 was because clinicians may have been over-using the data, that is respond to all aspects of  
16 the remote data. The committee reasoned that the responses to the questionnaire may not  
17 be a reliable proxy to identify people with OSAHS who need further follow-up from a clinician  
18 because they are still symptomatic or have poor adherence with their CPAP device.  
19 Therefore, monitoring responses to this questionnaire may result in clinicians over engaging  
20 with participants who may not need this extra attention.

21 In contrast, the second study found that using an alarm-based system where clinicians only  
22 respond if certain events occur (e.g. mask leakage or poor adherence) resulted in standard  
23 care being more effective than telemonitoring but not being cost-effective at the £20,000  
24 threshold. However, it should be noted the authors have equated improvements in quality of  
25 life measured by the EQ-5D to improvements in QALYs. However, a 0.003 higher EQ-5D at  
26 3 months is not the same as a 0.003 gain in QALYs. Instead, to calculate the correct QALY  
27 gains over the three-month period the EQ-5D gains must be multiplied by 0.25 or else an  
28 assumption must be stated about how long the difference would be sustained. The results  
29 were very sensitive to this assumption.

30 An original comparative cost analysis was conducted (See Evidence Report F). It found that  
31 CPAP with re-titration using auto-CPAP was slightly less costly than CPAP with re-titration  
32 using telemonitoring, but this was largely based on assumption rather than evidence. In  
33 particular, it only assumed that telemonitoring would reduce the need for follow-up in those  
34 patients who needed re-titration.

35 The committee concluded that there is uncertainty about whether remote follow-up with  
36 telemonitoring is less costly than traditional outpatient follow-up and could be affected by  
37 local factors including the charges by manufacturers for telemonitoring. However, where  
38 telemonitoring for the first year is included in the price of the machine, this is likely to be cost  
39 effective. Longer term monitoring could also be cost effective if the price is relatively low.  
40 Furthermore, the evidence has not accounted for the need to avoid face-to-face  
41 consultations to reduce transmission of infectious disease

42 All the clinical evidence in the guideline review was for CPAP in the OSAHS population,  
43 however the committee used the evidence and their experience to establish principles that  
44 cover all interventions and all three guideline populations. The committee recommended that  
45 all patients provided with an intervention (CPAP, non-invasive ventilation, oral device or  
46 positional modifier), be offered follow-up through face to face, telephone or video  
47 consultations within 1 month and telemonitoring then follow-up as required. The provision of  
48 face to face appointments was usual practice but recently there has been a big shift to  
49 remote consultations. The committee do not expect there to be an additional resource impact  
50 as a result of this recommendation. Also, the number of appointments that people with  
51 OSAHS, OHS or OS would be expected to attend is not expected to increase.

### **1.6.3 1 Other factors the committee took into account**

2 The committee noted that telemonitoring can be seen as beneficial to patients if it reduces  
3 the need for them to attend hospital. They also noted that there has been a significant move  
4 to video and telephone consultations to reduce the risk of infection during the COVID-19  
5 pandemic. This change in practice along with telemonitoring has allowed less face to face to  
6 appointments while still enabling review of a patient's CPAP data and changing their  
7 prescriptions. The committee were of the view that if the cost of modems comes down, then  
8 leaving a modem on a device would allow year on year CPAP review without seeing the  
9 patient. This can be augmented with telephone consultations where required. Potentially  
10 using IT Epworth sleepiness scores could be gained. There could be a lot of options gained  
11 from using IT monitoring.

12

## 1 References

- 2 1. Abreu T, Silva AM, Canhão C, Paula P, Cristina B. Evaluation of wireless  
3 telemonitoring of CPAP therapy in obstructive sleep apnea - TELEPAP study.  
4 European Respiratory Journal. 2013; 42(Suppl 57):P2043
- 5 2. Andreu AL, Chiner E, Sancho-Chust JN, Pastor E, Llombart M, Gomez-Merino E et  
6 al. Effect of an ambulatory diagnostic and treatment programme in patients with sleep  
7 apnoea. European Respiratory Journal. 2012; 39(2):305-312
- 8 3. Anttalainen U, Melkko S, Hakko S, Laitinen T, Saaresranta T. Telemonitoring of  
9 CPAP therapy may save nursing time. Sleep & Breathing. 2016; 20(4):1209-1215
- 10 4. Chen C, Wang J, Pang L, Wang Y, Ma G, Liao W. Telemonitor care helps CPAP  
11 compliance in patients with obstructive sleep apnea: a systemic review and meta-  
12 analysis of randomized controlled trials. Therapeutic Advances in Chronic Disease.  
13 2020; <https://dx.doi.org/10.1177/2040622320901625>
- 14 5. Delanote I, Borzee P, Belge C, Buyse B, Testelmans D. Adherence to CPAP therapy:  
15 comparing the effect of three educational approaches in patients with obstructive  
16 sleep apnoea. Clinical Respiratory Journal. 2018; 12(1):91-96
- 17 6. DeMolles DA, Sparrow D, Gottlieb DJ, Friedman R. A pilot trial of a  
18 telecommunications system in sleep apnea management. Medical Care. 2004;  
19 42(8):764-769
- 20 7. Driving and Vehicle Licensing Agency (DVLA). Assessing fitness to drive: a guide for  
21 medical professionals [DVLA guidance]. Available from:  
22 [https://www.gov.uk/government/publications/assessing-fitness-to-drive-a-guide-for-](https://www.gov.uk/government/publications/assessing-fitness-to-drive-a-guide-for-medical-professionals)  
23 [medical-professionals](https://www.gov.uk/government/publications/assessing-fitness-to-drive-a-guide-for-medical-professionals) Last accessed: 10/03/2020.
- 24 8. Driving and Vehicle Licensing Agency (DVLA). Excessive sleepiness and driving  
25 [DVLA guidance]. Available from: [https://www.gov.uk/excessive-sleepiness-and-](https://www.gov.uk/excessive-sleepiness-and-driving)  
26 [driving](https://www.gov.uk/excessive-sleepiness-and-driving) Last accessed: 10/03/2020.
- 27 9. Fields BG, Behari PP, McCloskey S, True G, Richardson D, Thomasson A et al.  
28 Remote ambulatory management of veterans with obstructive sleep apnea. Sleep.  
29 2016; 39(3):501-509
- 30 10. Fox N, Hirsch-Allen AJ, Goodfellow E, Wenner J, Fleetham J, Ryan CF et al. The  
31 impact of a telemedicine monitoring system on positive airway pressure adherence in  
32 patients with obstructive sleep apnea: A randomized controlled trial. Sleep. 2012;  
33 35(4):477-481
- 34 11. Frasnelli M, Baty F, Niedermann J, Brutsche MH, Schoch OD. Effect of telemetric  
35 monitoring in the first 30 days of continuous positive airway pressure adaptation for  
36 obstructive sleep apnoea syndrome - a controlled pilot study. Journal of Telemedicine  
37 and Telecare. 2016; 22(4):209-214
- 38 12. Gong F, Chen X, Wu Y, Yao D, Xie L, Ouyang Q et al. Nurse vs. physician-led care  
39 for obstructive sleep apnoea: A systematic review and meta-analysis of randomized  
40 trials. Journal of Advanced Nursing. 2018; 74(3):501-506
- 41 13. Hanger KL. Use of telemedicine to improve CPAP non-adherence in patients with  
42 obstructive sleep apnea, a pilot study. 2018; Doctor of Nursing Practice (DNP) Final  
43 Clinical Projects. 22
- 44 14. Hoet F, Libert W, Sanida C, Van den Broecke S, Bruyneel AV, Bruyneel M.  
45 Telemonitoring in continuous positive airway pressure-treated patients improves

- 1 delay to first intervention and early compliance: A randomized trial. *Sleep Medicine*.  
2 2017; 39:77-83
- 3 15. Hood MM, Corsica J, Cvengros J, Wyatt J. Impact of a brief dietary self-monitoring  
4 intervention on weight change and CPAP adherence in patients with obstructive sleep  
5 apnea. *Journal of Psychosomatic Research*. 2013; 74(2):170-174
- 6 16. Hwang D, Chang JW, Benjafield AV, Crocker ME, Kelly C, Becker KA et al. Effect of  
7 telemedicine education and telemonitoring on continuous positive airway pressure  
8 adherence. The Tele-OSA randomized trial. *American Journal of Respiratory and  
9 Critical Care Medicine*. 2018; 197(1):117-126
- 10 17. Isetta V, León C, Embid C, de la Peña M, Cambrodí R, Puertas FJ. Telemedicine-  
11 based strategy for sleep apnea management: a multicenter randomized controlled  
12 trial. *European Respiratory Journal*. 2014; 44(Suppl 58):P2020
- 13 18. Isetta V, Leon C, Torres M, Embid C, Roca J, Navajas D et al. Telemedicine-based  
14 approach for obstructive sleep apnea management: building evidence. *Interactive  
15 Journal of Medical Research*. 2014; 3(1):e6
- 16 19. Isetta V, Negrin MA, Monasterio C, Masa JF, Feu N, Alvarez A et al. A bayesian cost-  
17 effectiveness analysis of a telemedicine-based strategy for the management of sleep  
18 apnoea: A multicentre randomised controlled trial. *Thorax*. 2015; 70(11):1054-1061
- 19 20. Isetta V, Torres M, Gonzalez K, Ruiz C, Dalmases M, Embid C et al. A New mHealth  
20 application to support treatment of sleep apnoea patients. *Journal of Telemedicine  
21 and Telecare*. 2017; 23(1):14-18
- 22 21. Kotzian ST, Saletu MT, Schwarzingler A, Haider S, Spatt J, Kranz G et al. Proactive  
23 telemedicine monitoring of sleep apnea treatment improves adherence in people with  
24 stroke- a randomized controlled trial (HOPES study). *Sleep Medicine*. 2019; 64:48-55
- 25 22. Kotzian ST, Schwarzingler A, Haider S, Saletu B, Spatt J, Saletu MT. Home  
26 polygraphic recording with telemedicine monitoring for diagnosis and treatment of  
27 sleep apnoea in stroke (HOPES Study): study protocol for a single-blind, randomised  
28 controlled trial. *BMJ Open*. 2018; 8(1):e018847
- 29 23. Lugo VM, Garmendia O, Suarez-Giron M, Torres M, Vazquez-Polo FJ, Negrin MA et  
30 al. Comprehensive management of obstructive sleep apnea by telemedicine: Clinical  
31 improvement and cost-effectiveness of a Virtual Sleep Unit. A randomized controlled  
32 trial. *PloS One*. 2019; 14(10):e0224069
- 33 24. Mendelson M, Vivodtzev I, Taminiser R, Laplaud D, Dias-Domingos S, Baguet JP.  
34 Continuous positive airway pressure (CPAP) supported by telemedicine improves  
35 sleepiness and quality of life but not blood pressure in high cardiovascular risk  
36 obstructive sleep apnea (OSA): a randomized, controlled trial. *European Respiratory  
37 Journal*. 2013; 42(Suppl 57):p2044
- 38 25. Mendelson M, Vivodtzev I, Tamisier R, Laplaud D, Dias-Domingos S, Baguet JP et al.  
39 CPAP treatment supported by telemedicine does not improve blood pressure in high  
40 cardiovascular risk OSA patients: A randomized, controlled trial. *Sleep*. 2014;  
41 37(11):1863-1870
- 42 26. Munafo D, Hevener W, Crocker M, Willes L, Sridasome S, Muhsin M. A telehealth  
43 program for CPAP adherence reduces labor and yields similar adherence and  
44 efficacy when compared to standard of care. *Sleep & Breathing*. 2016; 20(2):777-785
- 45 27. Murphie P, Little S, McKinstry B, Pinnock H. Remote consulting with telemonitoring of  
46 continuous positive airway pressure usage data for the routine review of people with

- 1 obstructive sleep apnoea hypopnoea syndrome: A systematic review *Journal of*  
2 *Telemedicine and Telecare*. 2019; 25(1):17-25
- 3 28. National Institute for Health and Care Excellence. Developing NICE guidelines: the  
4 manual [Updated 2018]. London. National Institute for Health and Care Excellence,  
5 2014. Available from:  
6 <http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview>
- 7 29. Nilius G, Cottin U, Domanski U, Van THT, Franke KJ, Burian S et al. Effects of  
8 intensive outpatient training on the adherence of CPAP therapy for patients with OSA:  
9 A randomised trial. *Somnologie*. 2012; 16(4):251-256
- 10 30. Organisation for Economic Co-operation and Development (OECD). Purchasing  
11 power parities (PPP). Available from: <https://doi.org/10.1787/1290ee5a-en> Last  
12 accessed: 06/07/2020.
- 13 31. Palmer S, Selvaraj S, Dunn C, Osman LM, Cairns J, Franklin D et al. Annual review  
14 of patients with sleep apnea/hypopnea syndrome: a pragmatic randomised trial of  
15 nurse home visit versus consultant clinic review. *Sleep Medicine*. 2004; 5(1):61-65
- 16 32. Parikh R, Touvelle MN, Wang H, Zallek SN. Sleep telemedicine: patient satisfaction  
17 and treatment adherence. *Telemedicine Journal and e-Health*. 2011; 17(8):609-614
- 18 33. Peach R, Basner R, Zimmerman B. Enhancing patients' self regulation of obstructive  
19 sleep apnea: the effect of self-monitoring and objective monitoring at 30-day follow-  
20 up. *Sleep Medicine*. 2006; 7(Suppl 2):S81
- 21 34. Peach RF, Jelic S, Zhong X, Basner RC, Zimmerman BJ. Effect of self-regulation and  
22 self-monitoring on CPAP adherence in obstructive sleep apnea (OSA). *Sleep*. 2003;  
23 26(Suppl):A263
- 24 35. Pengo MF, Czaban M, Berry MP, Nirmalan P, Brown R, Birdseye A et al. The effect  
25 of positive and negative message framing on short term continuous positive airway  
26 pressure compliance in patients with obstructive sleep apnea. *Journal of Thoracic*  
27 *Disease*. 2018; 10(Suppl 1):S160-S169
- 28 36. Pepin JL, Jullian-Desayes I, Sapene M, Treptow E, Joyeux-Faure M, Benmerad M et  
29 al. Multimodal remote monitoring of high cardiovascular risk patients with osa  
30 initiating CPAP: A randomized trial *Chest*. 2019; 155(4):730-739
- 31 37. Pepin JL, Mendelson M, Vivodtzev I, Tamisier R, Laplaud D, Dias Domingos S.  
32 Continuous positive airway pressure (CPAP) supported by telemedicine improves  
33 sleepiness and quality of life but not blood pressure in high cardiovascular risk  
34 obstructive sleep apnea (OSA): a randomized, controlled trial. *American Journal of*  
35 *Respiratory and Critical Care Medicine*. 2014; 189:A5626
- 36 38. Schoch OD, Baty F, Boesch M, Benz G, Niedermann J, Brutsche MH. Telemedicine  
37 for continuous positive airway pressure in sleep apnea: A randomized, controlled  
38 study. *Annals of the American Thoracic Society*. 2019; 16(12):1550-1557
- 39 39. Sparrow D, Aloia M, Demolles DA, Gottlieb DJ. A telemedicine intervention to  
40 improve adherence to continuous positive airway pressure: A randomised controlled  
41 trial. *Thorax*. 2010; 65(12):1061-1066
- 42 40. Stepnowsky CJ, Palau JJ, Marler MR, Gifford AL. Pilot randomized trial of the effect  
43 of wireless telemonitoring on compliance and treatment efficacy in obstructive sleep  
44 apnea. *Journal of Medical Internet Research*. 2007; 9(2):e14
- 45 41. Taylor YL. A comparison between a telemedicine and traditional management model  
46 of care with nasal continuous positive airway pressure use among individuals with

- 1 obstructive sleep apnea syndrome. Washington, D.C. George Washington University.  
2 2003
- 3 42. Turino C, de Batlle J, Woehrle H, Mayoral A, Castro-Grattoni AL, Gomez S et al.  
4 Management of continuous positive airway pressure treatment compliance using  
5 telemonitoring in obstructive sleep apnoea. *European Respiratory Journal*. 2017;  
6 49(2):1601128
- 7 43. Wozniak D, Lasserson T, Smith I. Educational, supportive and behavioural  
8 interventions to improve usage of continuous positive airway pressure machines in  
9 adults with obstructive sleep apnoea. *Cochrane Database of Systematic Reviews*  
10 2014, Issue 1. Art. No.: CD007736. DOI: 10.1002/14651858.CD007736.pub2.
- 11  
12  
13



# 1 Appendices

## 2 Appendix A: Review protocols

3 **Table 8: Review protocol: monitoring**

ID	Field	Content
0.	PROSPERO registration number	Not registered
1.	Review title	Monitoring
2.	Review question	<p>What is the most clinically and cost effective strategy for monitoring OSAHS/OHS/OS (for example based on outpatient visits, download of data from devices or telemonitoring)?</p> <p>What is the optimum frequency of monitoring of OSAHS/OHS/COPD-OSAHS overlap syndrome?</p>
3.	Objective	To determine the most clinically and cost effective strategy for monitoring OSAHS/OHS/OS, encompassing both modes of monitoring and their frequency
4.	Searches	<p>The following databases will be searched:</p> <ul style="list-style-type: none"> <li>• Cochrane Central Register of Controlled Trials (CENTRAL)</li> <li>• Cochrane Database of Systematic Reviews (CDSR)</li> <li>• Embase</li> <li>• MEDLINE</li> <li>• Epistemonikos</li> </ul> <p>Searches will be restricted by:</p> <ul style="list-style-type: none"> <li>• English language</li> <li>• Human studies</li> <li>• Letters and comments are excluded.</li> </ul> <p>Other searches:</p>

		<ul style="list-style-type: none"> <li>Inclusion lists of relevant systematic reviews will be checked by the reviewer.</li> </ul> <p>The searches may be re-run 6 weeks before the final committee meeting and further studies retrieved for inclusion if relevant.</p> <p>The full search strategies will be published in the final review.</p>
5.	Condition or domain being studied	<p>Obstructive sleep apnoea/hypopnoea syndrome is the most common form of sleep disordered breathing. The guideline will also cover obesity hypoventilation syndrome and COPD-OSAHS overlap syndrome (the coexistence of obstructive sleep apnoea/hypopnoea syndrome and chronic obstructive pulmonary disease).</p>
6.	Population	<p>People with OSAHS/OHS/COPD-OSAHS overlap syndrome</p> <p>Stratified by: OSAHS vs OHS vs COPD-OSAHS overlap syndrome Stage of treatment (&lt;1 year vs <math>\geq</math> 1 year)</p> <p>Severity (mild vs moderate vs severe, based on AHI)</p> <p>Mild OSAHS: AHI <math>&gt;5</math> but <math>&lt;15</math></p> <p>Moderate OSAHS: AHI <math>\geq 15</math> but <math>&lt;30</math></p> <p>Severe OSAHS: AHI <math>\geq 30</math></p>
7.	Intervention/Exposure/Test	<ul style="list-style-type: none"> <li>In person outpatient visits</li> <li>Download of data from devices</li> <li>Telephone follow-up</li> <li>Telemonitoring</li> </ul> <p>Any of the above at any of the following frequencies:</p> <ul style="list-style-type: none"> <li>No routine monitoring</li> <li>3 yearly</li> </ul>

		<ul style="list-style-type: none"> <li>• Yearly</li> <li>• 6 monthly</li> <li>• 3 monthly</li> <li>• 1 monthly</li> <li>• &lt;1 monthly</li> </ul>
8.	Comparator/Reference standard/Confounding factors	Any of the above methods at any frequency vs the same or any other method at any frequency
9.	Types of study to be included	<p>RCTs will be prioritised, if insufficient RCTs are found for guideline decision making, non-randomised studies will be considered if they adjust for key confounders (age, sex, BMI, co-existing conditions)</p> <p>Minimum duration of follow-up 1 month</p> <p>Parallel or crossover studies to be included</p>
10.	Other exclusion criteria	None
11.	Context	N/A
12.	Primary outcomes (critical outcomes)	<p>Generic or disease specific quality of life measures (continuous)</p> <p>Mortality (dichotomous)</p>
13.	Secondary outcomes (important outcomes)	<ul style="list-style-type: none"> <li>• Sleepiness scores (continuous, e.g. Epworth)</li> <li>• Apnoea-Hypopnoea index (continuous)</li> <li>• Oxygen desaturation index (continuous)</li> <li>• CO2 control (continuous)</li> <li>• Hours of use (adherence measure, continuous)</li> <li>• Minor adverse effects of treatment (rates or dichotomous)</li> <li>• Driving outcomes (continuous)</li> </ul>

		<ul style="list-style-type: none"> <li>• Neurocognitive outcomes (continuous)</li> <li>• Healthcare contacts (rates/dichotomous)</li> <li>• Impact on co-existing conditions: <ul style="list-style-type: none"> <li>o HbA1c for diabetes (continuous)</li> <li>o Cardiovascular events for cardiovascular disease (dichotomous)</li> <li>o Systolic blood pressure for hypertension (continuous)</li> </ul> </li> </ul>
14.	Data extraction (selection and coding)	<p>EndNote will be used for reference management, sifting, citations and bibliographies. All references identified by the searches and from other sources will be screened for inclusion. 10% of the abstracts will be reviewed by two reviewers, with any disagreements resolved by discussion or, if necessary, a third independent reviewer. The full text of potentially eligible studies will be retrieved and will be assessed in line with the criteria outlined above.</p> <p>EviBASE will be used for data extraction.</p>
15.	Risk of bias (quality) assessment	<p>Risk of bias will be assessed using the appropriate checklist as described in Developing NICE guidelines: the manual.</p> <ul style="list-style-type: none"> <li>• Systematic reviews: Risk of Bias in Systematic Reviews (ROBIS)</li> <li>• Randomised Controlled Trial: Cochrane RoB (2.0)</li> </ul> <p>10% of all evidence reviews are quality assured by a senior research fellow. This includes checking:</p> <ul style="list-style-type: none"> <li>• papers were included /excluded appropriately</li> <li>• a sample of the data extractions</li> <li>• correct methods are used to synthesise data</li> <li>• a sample of the risk of bias assessments</li> </ul> <p>Disagreements between the review authors over the risk of bias in particular studies will be resolved by discussion, with involvement of a third review author where necessary.</p>
16.	Strategy for data synthesis	<ul style="list-style-type: none"> <li>• Pairwise meta-analyses will be performed using Cochrane Review Manager (RevMan5).</li> <li>• GRADEpro will be used to assess the quality of evidence for each outcome, taking into account individual study quality and the meta-analysis results. The 4 main quality elements (risk of bias, indirectness, inconsistency and imprecision) will be appraised for each outcome.</li> </ul>

		<p>Publication bias is tested for when there are more than 5 studies for an outcome.</p> <p>The risk of bias across all available evidence was evaluated for each outcome using an adaptation of the 'Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox' developed by the international GRADE working group <a href="http://www.gradeworkinggroup.org/">http://www.gradeworkinggroup.org/</a></p> <ul style="list-style-type: none"> <li>• Where meta-analysis is not possible, data will be presented and quality assessed individually per outcome.</li> <li>• WinBUGS will be used for network meta-analysis, if possible given the data identified.</li> </ul> <p>Heterogeneity between the studies in effect measures will be assessed using the I<sup>2</sup> statistic and visually inspected. An I<sup>2</sup> value greater than 50% will be considered indicative of substantial heterogeneity. Sensitivity analyses will be conducted based on pre-specified subgroups using stratified meta-analysis to explore the heterogeneity in effect estimates. If this does not explain the heterogeneity, the results will be presented pooled using random-effects.</p>
17.	Analysis of sub-groups	<ul style="list-style-type: none"> <li>• High risk occupational groups (for example heavy goods vehicle drivers) vs general population</li> <li>• Sleepiness – Epworth &gt;9 vs Epworth 9 or less</li> <li>• Coexisting conditions – type 2 diabetes vs atrial fibrillation vs hypertension vs none</li> <li>• Type of treatment received – CPAP vs oral devices vs positional modifiers</li> </ul>
18.	Type and method of review	<ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> Intervention</li> <li><input type="checkbox"/> Diagnostic</li> <li><input type="checkbox"/> Prognostic</li> <li><input type="checkbox"/> Qualitative</li> <li><input type="checkbox"/> Epidemiologic</li> <li><input type="checkbox"/> Service Delivery</li> <li><input type="checkbox"/> Other (please specify)</li> </ul>
19.	Language	English
20.	Country	England
21.	Anticipated or actual start date	
22.	Anticipated completion date	
24.	Named contact	5a. Named contact National Guideline Centre

		<p>5b Named contact e-mail SleepApnoHypo@nice.org.uk</p> <p>5e Organisational affiliation of the review National Institute for Health and Care Excellence (NICE) and the National Guideline Centre</p>
25.	Review team members	<p>From the National Guideline Centre:</p> <p>Carlos Sharpin, Guideline lead</p> <p>Sharangini Rajesh, Senior systematic reviewer</p> <p>Audrius Stonkus, Systematic reviewer</p> <p>Emtiyaz Chowdhury (until January 2020), Health economist</p> <p>David Wonderling, Head of health economics</p> <p>Agnes Cuyas, Information specialist (till December 2019)</p> <p>Jill Cobb, Information Specialist</p>
26.	Funding sources/sponsor	This systematic review is being completed by the National Guideline Centre which receives funding from NICE.
27.	Conflicts of interest	<p>All guideline committee members and anyone who has direct input into NICE guidelines (including the evidence review team and expert witnesses) must declare any potential conflicts of interest in line with NICE's code of practice for declaring and dealing with conflicts of interest. Any relevant interests, or changes to interests, will also be declared publicly at the start of each guideline committee meeting. Before each meeting, any potential conflicts of interest will be considered by the guideline committee Chair and a senior member of the development team. Any decisions to exclude a person from all or part of a meeting will be documented. Any changes to a member's declaration of interests will be recorded in the minutes of the meeting. Declarations of interests will be published with the final guideline.</p>
28.	Collaborators	<p>Development of this systematic review will be overseen by an advisory committee who will use the review to inform the development of evidence-based recommendations in line with section 3 of Developing NICE guidelines: the manual. Members of the guideline committee are available on the NICE website:</p> <p><a href="https://www.nice.org.uk/guidance/indevelopment/gid-ng10098">https://www.nice.org.uk/guidance/indevelopment/gid-ng10098</a></p>
29.	Other registration details	NA – not registered
30.	Reference/URL for published protocol	NA – not registered

31.	Dissemination plans	<p>NICE may use a range of different methods to raise awareness of the guideline. These include standard approaches such as:</p> <ul style="list-style-type: none"> <li>• notifying registered stakeholders of publication</li> <li>• publicising the guideline through NICE's newsletter and alerts</li> <li>• issuing a press release or briefing as appropriate, posting news articles on the NICE website, using social media channels, and publicising the guideline within NICE.</li> </ul>
32.	Keywords	-
33.	Details of existing review of same topic by same authors	N/A
35..	Additional information	N/A
36.	Details of final publication	<a href="http://www.nice.org.uk">www.nice.org.uk</a>

1  
2

1 **Table 9: Health economic review protocol**

Review question	All questions – health economic evidence
<b>Objectives</b>	To identify health economic studies relevant to any of the review questions.
<b>Search criteria</b>	<ul style="list-style-type: none"> <li>• Populations, interventions and comparators must be as specified in the clinical review protocol above.</li> <li>• Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis).</li> <li>• Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.)</li> <li>• Unpublished reports will not be considered unless submitted as part of a call for evidence.</li> <li>• Studies must be in English.</li> </ul>
<b>Search strategy</b>	A health economic study search will be undertaken using population-specific terms and a health economic study filter – see appendix B below.
<b>Review strategy</b>	<p>Studies not meeting any of the search criteria above will be excluded. Studies published before 2003, abstract-only studies and studies from non-OECD countries or the USA will also be excluded.</p> <p>Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014).<sup>28</sup></p> <p><b>Inclusion and exclusion criteria</b></p> <ul style="list-style-type: none"> <li>• If a study is rated as both ‘Directly applicable’ and with ‘Minor limitations’ then it will be included in the guideline. A health economic evidence table will be completed and it will be included in the health economic evidence profile.</li> <li>• If a study is rated as either ‘Not applicable’ or with ‘Very serious limitations’ then it will usually be excluded from the guideline. If it is excluded then a health economic evidence table will not be completed and it will not be included in the health economic evidence profile.</li> <li>• If a study is rated as ‘Partially applicable’, with ‘Potentially serious limitations’ or both then there is discretion over whether it should be included.</li> </ul> <p><b>Where there is discretion</b></p> <p>The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded on the basis of applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.</p> <p>The health economist will be guided by the following hierarchies.</p> <p><i>Setting:</i></p> <ul style="list-style-type: none"> <li>• UK NHS (most applicable).</li> <li>• OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).</li> <li>• OECD countries with predominantly private health insurance systems (for example, Switzerland).</li> </ul>



- Studies set in non-OECD countries or in the USA will be excluded before being assessed for applicability and methodological limitations.

*Health economic study type:*

- Cost–utility analysis (most applicable).
- Other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequences analysis).
- Comparative cost analysis.
- Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations.

*Year of analysis:*

- The more recent the study, the more applicable it will be.
- Studies published in 2003 or later but that depend on unit costs and resource data entirely or predominantly from before 2003 will be rated as 'Not applicable'.
- Studies published before 2003 will be excluded before being assessed for applicability and methodological limitations.

*Quality and relevance of effectiveness data used in the health economic analysis:*

- The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline.

1  
2

## **1 Appendix B: Literature search strategies**

1 Sleep Apnoea search strategy 5 monitoring

2 This literature search strategy was used for the following reviews;

- 3 • What is the most clinically and cost effective strategy for monitoring OSAHS/OHS/OS  
4 (for example based on outpatient visits, download of data from devices or  
5 telemonitoring)?  
6 • What is the optimum frequency of monitoring of OSAHS/OHS/OS?

7 The literature searches for this review are detailed below and complied with the methodology  
8 outlined in Developing NICE guidelines: the manual.<sup>28</sup>

9 For more information, please see the Methods Report published as part of the accompanying  
10 documents for this guideline.

## B.1.1 Clinical search literature search strategy

12 Searches were constructed using a PICO framework where population (P) terms were  
13 combined with Intervention (I) and in some cases Comparison (C) terms. Outcomes (O) are  
14 rarely used in search strategies for interventions as these concepts may not be well  
15 described in title, abstract or indexes and therefore difficult to retrieve. Search filters were  
16 applied to the search where appropriate.

17 **Table 10: Database date parameters and filters used**

Database	Dates searched	Search filter used
Medline (OVID)	1946 – 6 July 2020	Exclusions Randomised controlled trials Systematic review studies Observational studies
Embase (OVID)	1974 – 6 July 2020	Exclusions Randomised controlled trials Systematic review studies Observational studies
The Cochrane Library (Wiley)	Cochrane Reviews to 2020 Issue 7 of 12 CENTRAL to 2020 Issue 7 of 12	None
Epistemonikos (Epistemonikos Foundation)	Inception – 29 November 2018	None

18 **Medline (Ovid) search terms**

1.	exp Sleep Apnea Syndromes/
2.	(sleep* adj4 (apn?ea* or hypopn?ea*)).ti,ab.
3.	(sleep* adj4 disorder* adj4 breath*).ti,ab.
4.	(OSAHs or OSA or OSAS).ti,ab.
5.	(obes* adj3 hypoventil*).ti,ab.
6.	pickwick*.ti,ab.
7.	or/1-6
8.	limit 7 to English language
9.	letter/
10.	editorial/
11.	news/
12.	exp historical article/

<Click this field on the first page and insert footer text if required>

© NICE 2021. All rights reserved. Subject to Notice of rights.

13.	Anecdotes as Topic/
14.	comment/
15.	case report/
16.	(letter or comment*).ti.
17.	or/9-16
18.	randomized controlled trial/ or random*.ti,ab.
19.	17 not 18
20.	animals/ not humans/
21.	exp Animals, Laboratory/
22.	exp Animal Experimentation/
23.	exp Models, Animal/
24.	exp Rodentia/
25.	(rat or rats or mouse or mice).ti.
26.	or/19-25
27.	8 not 26
28.	Monitoring, Physiologic/
29.	Patient Outcome Assessment/
30.	monitoring.ti,ab.
31.	((followup or follow-up or check* or evaluat* or appointment* or observation or observations) adj3 (timing* or interval* or year* or annual* or biannual* or month* or periodic* or frequen* or routine*)).ti,ab.
32.	((followup or follow-up or check* or evaluat* or appointment* or monitor*) adj3 (outpatient or out-patient or clinic or telephone or remote or virtual)).ti,ab.
33.	((monitor* or time point* or interval*) adj3 (year* or annual* or biannual* or month* or periodic* or frequen* or routine*)).ti,ab.
34.	(telemonitor* or telemedicine or telehealth or tele monitor* or tele medicine or tele health or download* or smartphone* or smart phone or ipad* or iphone*).ti,ab.
35.	((manage* or monitor*) adj3 (virtual or remote or web* or cloud* or wireless or Internet or wi fi or wifi)).ti,ab.
36.	(monitor* adj3 device*).ti,ab.
37.	Telemedicine/
38.	or/28-37
39.	27 and 38
40.	randomized controlled trial.pt.
41.	controlled clinical trial.pt.
42.	randomi#ed.ti,ab.
43.	placebo.ab.
44.	randomly.ti,ab.
45.	Clinical Trials as topic.sh.
46.	trial.ti.
47.	or/40-46
48.	Meta-Analysis/
49.	exp Meta-Analysis as Topic/
50.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.
51.	((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.
52.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.

53.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
54.	(search* adj4 literature).ab.
55.	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
56.	cochrane.jw.
57.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
58.	or/48-57
59.	Epidemiologic studies/
60.	Observational study/
61.	exp Cohort studies/
62.	(cohort adj (study or studies or analys* or data)).ti,ab.
63.	((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.
64.	((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort* or data)).ti,ab.
65.	Controlled Before-After Studies/
66.	Historically Controlled Study/
67.	Interrupted Time Series Analysis/
68.	(before adj2 after adj2 (study or studies or data)).ti,ab.
69.	exp case control studies/
70.	case control*.ti,ab.
71.	Cross-sectional studies/
72.	(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.
73.	or/59-72
74.	39 and (47 or 58 or 73)

### 1 Embase (Ovid) search terms

1.	exp Sleep Disordered Breathing/
2.	(sleep* adj4 (apn?ea* or hypopn?ea*)).ti,ab.
3.	(sleep* adj4 disorder* adj4 breath*).ti,ab.
4.	(OSAHs or OSA or OSAS).ti,ab.
5.	(obes* adj3 hypoventil*).ti,ab.
6.	pickwick*.ti,ab.
7.	or/1-6
8.	limit 7 to English language
9.	letter.pt. or letter/
10.	note.pt.
11.	editorial.pt.
12.	case report/ or case study/
13.	(letter or comment*).ti.
14.	or/9-13
15.	randomized controlled trial/ or random*.ti,ab.
16.	14 not 15
17.	animal/ not human/
18.	nonhuman/
19.	exp Animal Experiment/

20.	exp Experimental Animal/
21.	animal model/
22.	exp Rodent/
23.	(rat or rats or mouse or mice).ti.
24.	or/16-23
25.	8 not 24
26.	physiologic monitoring/
27.	outcome assessment/
28.	monitoring.ti,ab.
29.	((followup or follow-up or check* or evaluat* or appointment* or observation or observations) adj3 (timing* or interval* or year* or annual* or biannual* or month* or periodic* or frequen* or routine*)).ti,ab.
30.	((followup or follow-up or check* or evaluat* or appointment* or monitor*) adj3 (outpatient or out-patient or clinic or telephone or remote or virtual)).ti,ab.
31.	((monitor* or time point* or interval*) adj3 (year* or annual* or biannual* or month* or periodic* or frequen* or routine*)).ti,ab.
32.	(telemonitor* or telemedicine or telehealth or tele monitor* or tele medicine or tele health or download* or smartphone* or smart phone or ipad* or iphone*).ti,ab.
33.	((manage* or monitor*) adj3 (virtual or remote or web* or cloud* or wireless or Internet or wi fi or wifi)).ti,ab.
34.	(monitor* adj3 device*).ti,ab.
35.	exp telemedicine/
36.	or/26-35
37.	25 and 36
38.	random*.ti,ab.
39.	factorial*.ti,ab.
40.	(crossover* or cross over*).ti,ab.
41.	((doubl* or singl*) adj blind*).ti,ab.
42.	(assign* or allocat* or volunteer* or placebo*).ti,ab.
43.	crossover procedure/
44.	single blind procedure/
45.	randomized controlled trial/
46.	double blind procedure/
47.	or/38-46
48.	systematic review/
49.	meta-analysis/
50.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.
51.	((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.
52.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
53.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
54.	(search* adj4 literature).ab.
55.	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
56.	cochrane.jw.
57.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
58.	or/48-57

59.	Clinical study/
60.	Observational study/
61.	family study/
62.	longitudinal study/
63.	retrospective study/
64.	prospective study/
65.	cohort analysis/
66.	follow-up/
67.	cohort*.ti,ab.
68.	66 and 67
69.	(cohort adj (study or studies or analys* or data)).ti,ab.
70.	((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.
71.	((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort* or data)).ti,ab.
72.	(before adj2 after adj2 (study or studies or data)).ti,ab.
73.	or/59-65,68-72
74.	exp case control study/
75.	case control*.ti,ab.
76.	cross-sectional study/
77.	(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.
78.	or/73-77
79.	37 and (47 or 58 or 78)

### 1 Cochrane Library (Wiley) search terms

#1.	MeSH descriptor: [Sleep Apnea Syndromes] explode all trees
#2.	(sleep* near/4 (apnea* or apnoea* or hypopnea* or hypopnoea* )):ti,ab
#3.	(sleep* near/4 disorder* near/4 breath*):ti,ab
#4.	(OSAHs or OSA or OSAS):ti,ab
#5.	(obes* near/3 hypoventil*):ti,ab
#6.	pickwick*:ti,ab
#7.	(OR #1-#6)
#8.	MeSH descriptor: [Monitoring, Physiologic] this term only
#9.	MeSH descriptor: [Patient Outcome Assessment] this term only
#10.	monitoring:ti,ab
#11.	((followup or follow-up or check* or evaluat* or appointment* or observation or observations) near/3 (timing* or interval* or year* or annual* or biannual* or month* or periodic* or frequen* or routine*)):ti,ab
#12.	((followup or follow-up or check* or evaluat* or appointment* or monitor*) near/3 (outpatient or out-patient or clinic or telephone or remote or virtual)):ti,ab
#13.	((monitor* or time point* or interval*) near/3 (year* or annual* or biannual* or month* or periodic* or frequen* or routine*)):ti,ab
#14.	(telemonitor* or telemedicine or telehealth or download* or smartphone*):ti,ab
#15.	((manage* or monitor*) near/3 (virtual or remote or web* or cloud* or wireless or Internet)):ti,ab
#16.	(monitor* near/3 device*):ti,ab
#17.	MeSH descriptor: [Telemedicine] this term only
#18.	(or #8-#17)

#19.	#7 AND #18
------	------------

### 1 Epistemonikos search terms

1.	((title:((sleep apnea syndromes) OR (sleep* AND (apn?ea* OR hypopn?ea*)) OR (sleep* AND (apn?ea* OR hypopn?ea*)) OR (sleep* AND (disorder* OR breath*)) OR (OSAHs OR OSA OR OSAS) OR (obes* AND hypoventil*) OR pickwick*) OR abstract:((sleep apnea syndromes) OR (sleep* AND (apn?ea* OR hypopn?ea*)) OR (sleep* AND (apn?ea* OR hypopn?ea*)) OR (sleep* AND (disorder* OR breath*)) OR (OSAHs OR OSA OR OSAS) OR (obes* AND hypoventil*) OR pickwick*)))
----	---

## B.2.2 Health Economics literature search strategy

3 Health economic evidence was identified by conducting a broad search relating to sleep  
4 apnoea population in NHS Economic Evaluation Database (NHS EED – this ceased to be  
5 updated after March 2015) and the Health Technology Assessment database (HTA – this  
6 ceased to be updated after March 2018) with no date restrictions. NHS EED and HTA  
7 databases are hosted by the Centre for Research and Dissemination (CRD). Additional  
8 searches were run on Medline and Embase for health economics and quality of life studies.

### B.2.19 Health economic studies strategy

#### 10 Table 11: Database date parameters and filters used

Database	Dates searched	Search filter used
Medline	2014 – 6 July 2020	Exclusions Health economics studies
Embase	2014 – 6 July 2020	Exclusions Health economics studies
Centre for Research and Dissemination (CRD)	HTA - Inception – 31 March 2018 NHSEED - Inception to March 2015	None

#### 11 Medline (Ovid) search terms

	exp Sleep Apnea Syndromes/
1.	(sleep* adj4 (apn?ea* or hypopn?ea*)).ti,ab.
2.	(sleep* adj4 disorder* adj4 breath*).ti,ab.
3.	(OSAHs or OSA or OSAS).ti,ab.
4.	(obes* adj3 hypoventil*).ti,ab.
5.	pickwick*.ti,ab.
6.	or/1-6
7.	limit 7 to English language
8.	letter/
9.	editorial/
10.	news/
11.	exp historical article/
12.	Anecdotes as Topic/
13.	comment/
14.	case report/
15.	(letter or comment*).ti.
16.	or/9-16



17.	randomized controlled trial/ or random*.ti,ab.
18.	17 not 18
19.	animals/ not humans/
20.	exp Animals, Laboratory/
21.	exp Animal Experimentation/
22.	exp Models, Animal/
23.	exp Rodentia/
24.	(rat or rats or mouse or mice).ti.
25.	or/19-25
26.	8 not 26
27.	Economics/
28.	Value of life/
29.	exp "Costs and Cost Analysis"/
30.	exp Economics, Hospital/
31.	exp Economics, Medical/
32.	Economics, Nursing/
33.	Economics, Pharmaceutical/
34.	exp "Fees and Charges"/
35.	exp Budgets/
36.	budget*.ti,ab.
37.	cost*.ti.
38.	(economic* or pharmaco?economic*).ti.
39.	(price* or pricing*).ti,ab.
40.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
41.	(financ* or fee or fees).ti,ab.
42.	(value adj2 (money or monetary)).ti,ab.
43.	or/28-43
44.	27 and 44

### 1 Embase (Ovid) search terms

1.	exp Sleep Disordered Breathing/
2.	(sleep* adj4 (apn?ea* or hypopn?ea*)).ti,ab.
3.	(sleep* adj4 disorder* adj4 breath*).ti,ab.
4.	(OSAHs or OSA or OSAS).ti,ab.
5.	(obes* adj3 hypoventil*).ti,ab.
6.	pickwick*.ti,ab.
7.	or/1-6
8.	limit 7 to English language
9.	letter.pt. or letter/
10.	note.pt.
11.	editorial.pt.
12.	case report/ or case study/
13.	(letter or comment*).ti.

14.	or/9-13
15.	randomized controlled trial/ or random*.ti,ab.
16.	14 not 15
17.	animal/ not human/
18.	nonhuman/
19.	exp Animal Experiment/
20.	exp Experimental Animal/
21.	animal model/
22.	exp Rodent/
23.	(rat or rats or mouse or mice).ti.
24.	or/16-23
25.	8 not 24
26.	health economics/
27.	exp economic evaluation/
28.	exp health care cost/
29.	exp fee/
30.	budget/
31.	funding/
32.	budget*.ti,ab.
33.	cost*.ti.
34.	(economic* or pharmaco?economic*).ti.
35.	(price* or pricing*).ti,ab.
36.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)),ab.
37.	(financ* or fee or fees).ti,ab.
38.	(value adj2 (money or monetary)).ti,ab.
39.	or/26-38
40.	25 and 39

### 1 NHS EED and HTA (CRD) search terms

#1.	MeSH DESCRIPTOR Sleep Apnea Syndromes EXPLODE ALL TREES
#2.	(sleep* adj4 (apn?ea* or hypopn?ea*))
#3.	(sleep* adj4 disorder* adj4 breath*)
#4.	(OSAHs or OSA or OSAS)
#5.	(obes* adj3 hypoventil*)
#6.	(pickwick*)
#7.	#1 OR #2 OR #3 OR #4 OR #5 OR #6

## B.2.22 Quality of life studies strategy

### 3 Table 12: Database date parameters and filters used

Database	Dates searched	Search filter used
Medline	1946 – 26 November 2019	Exclusions Quality of life studies
Embase	1974 – 26 November 2019	Exclusions Quality of life studies

1 Medline (Ovid) search terms

1.	exp Sleep Apnea Syndromes/
2.	(sleep* adj4 (apn?ea* or hypopn?ea*)).ti,ab.
3.	(sleep* adj4 disorder* adj4 breath*).ti,ab.
4.	(OSAHs or OSA or OSAS).ti,ab.
5.	(obes* adj3 hypoventil*).ti,ab.
6.	pickwick*.ti,ab.
7.	or/1-6
8.	limit 7 to English language
9.	letter/
10.	editorial/
11.	news/
12.	exp historical article/
13.	Anecdotes as Topic/
14.	comment/
15.	case report/
16.	(letter or comment*).ti.
17.	or/9-16
18.	randomized controlled trial/ or random*.ti,ab.
19.	17 not 18
20.	animals/ not humans/
21.	exp Animals, Laboratory/
22.	exp Animal Experimentation/
23.	exp Models, Animal/
24.	exp Rodentia/
25.	(rat or rats or mouse or mice).ti.
26.	or/19-25
27.	8 not 26
28.	quality-adjusted life years/
29.	sickness impact profile/
30.	(quality adj2 (wellbeing or well being)).ti,ab.
31.	sickness impact profile.ti,ab.
32.	disability adjusted life.ti,ab.
33.	(qal* or qtime* or qwb* or daly*).ti,ab.
34.	(euroqol* or eq5d* or eq 5*).ti,ab.
35.	(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.
36.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.
37.	(hui or hui1 or hui2 or hui3).ti,ab.
38.	(health* year* equivalent* or hye or hyes).ti,ab.
39.	discrete choice*.ti,ab.
40.	rosser.ti,ab.

41.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
42.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.
43.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
44.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.
45.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.
46.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.
47.	or/28-46
48.	27 and 47

## 1 Embase (Ovid) search terms

1.	exp Sleep Disordered Breathing/
2.	(sleep* adj4 (apn?ea* or hypopn?ea*)).ti,ab.
3.	(sleep* adj4 disorder* adj4 breath*).ti,ab.
4.	(OSAHs or OSA or OSAS).ti,ab.
5.	(obes* adj3 hypoventil*).ti,ab.
6.	pickwick*.ti,ab.
7.	or/1-6
8.	limit 7 to English language
9.	letter.pt. or letter/
10.	note.pt.
11.	editorial.pt.
12.	case report/ or case study/
13.	(letter or comment*).ti.
14.	or/9-13
15.	randomized controlled trial/ or random*.ti,ab.
16.	14 not 15
17.	animal/ not human/
18.	nonhuman/
19.	exp Animal Experiment/
20.	exp Experimental Animal/
21.	animal model/
22.	exp Rodent/
23.	(rat or rats or mouse or mice).ti.
24.	or/16-23
25.	8 not 24
26.	quality adjusted life year/
27.	"quality of life index"/
28.	short form 12/ or short form 20/ or short form 36/ or short form 8/
29.	sickness impact profile/
30.	(quality adj2 (wellbeing or well being)).ti,ab.
31.	sickness impact profile.ti,ab.
32.	disability adjusted life.ti,ab.
33.	(qal* or qtime* or qwb* or daly*).ti,ab.
34.	(euroqol* or eq5d* or eq 5*).ti,ab.

35.	(qol* or hqi* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.
36.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.
37.	(hui or hui1 or hui2 or hui3).ti,ab.
38.	(health* year* equivalent* or hye or hyes).ti,ab.
39.	discrete choice*.ti,ab.
40.	rosser.ti,ab.
41.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
42.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.
43.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
44.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.
45.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.
46.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.
47.	or/26-46
48.	25 and 47


1

2

3

# 1 Appendix C: Clinical evidence selection

Figure 1: Flow chart of clinical study selection for the review of position modifiers



2  
3

## 1 Appendix D: Clinical evidence tables

Study	Anttalainen 2016 <sup>3</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=111)
Countries and setting	Conducted in Finland; Setting: Department of pulmonary diseases, Turku university hospital, Finland
Line of therapy	Not applicable
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Moderate-severe: n/a
Subgroup analysis within study	Not applicable: n/a
Inclusion criteria	OSAS patients who were commencing CPAP treatment at the department of pulmonary diseases of Turku university hospital. All patients were over 18 years of age.
Exclusion criteria	unclear/ not specified
Recruitment/selection of patients	Consecutive
Age, gender and ethnicity	Age - Mean (SD): Telemonitoring - 53.9(12.2); usual 56.4(11.8). Gender (M:F): Telemonitoring group 36/14; Usual care 43/18. Ethnicity: not stated
Further population details	1. BMI: BMI of 30 kg/m <sup>2</sup> or more (Telemonitoring 34.8(7.6); Usual care 32.9(6.9)). 2. Co-existing conditions: Not stated / Unclear 3. High risk occupation group: Not stated / Unclear 4. Sleepiness: ESS 9 or less (Telemonitoring - 8.2(4.9); Usual care 8.2 (4.2)).
Indirectness of population	No indirectness
Interventions	(n=50) Intervention 1: Telemonitoring. Wireless telemonitoring system ( ResTaxx Online, ResMed Sydney, Australia). The module was attached to the S9 Elite (ResMed, Sydney Australia) CPAP device, which transmitted compliance data every day automatically to ResTaxx Online. The treatment was considered successful when CPAP use was >4h/day, mask <0.4 L/s and AHI <5/h during the last 6 days. Study nurses made the data checkups daily during weekdays and if the criteria for successful CPAP therapy was not achieved during two consecutive nights the nurses adjusted the CPAP remotely and called the patient to give further advice. The patients were encouraged to contact the nurse in case they had any problems. TM group

	<p>answered the questionnaire at 3 months by email.. Duration 3 months. Concurrent medication/care: n/a. Indirectness: No indirectness Further details: 1. Intervention type: Electronic (telemonitoring).</p> <p>(n=61) Intervention 2: In person follow-up. In Person follow up. Usual care group visited the pulmonologist after 3 months leading in a 3 month habituation phase in the UC group. UC group answered the questionnaire at the 3 month visit. CPAP device was used without wireless telemonitoring. Duration 3 months. Concurrent medication/care: n/a. Indirectness: No indirectness Further details: 1. Intervention type:</p>
Funding	Equipment / drugs provided by industry (ResTaxx Online System was provided by ResMed)
<p><b>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TELEMONITORING versus IN PERSON FOLLOW-UP</b></p> <p>Protocol outcome 1: Quality of life at &gt;1 month - Actual outcome for Moderate-severe: GHQ-12 score at 12 months; Group 1: mean 5.1 (SD 6.1); n=39, Group 2: mean 4.9 (SD 5.8); n=49 Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Very high, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 11; Group 2 Number missing: 12</p> <p>Protocol outcome 2: Sleepiness score at &gt;1 month - Actual outcome for Moderate-severe: Sleepiness ESS at 12 months; Group 1: mean 5.4 (SD 3.5); n=39, Group 2: mean 5.4 (SD 3.4); n=49 Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Very high, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 11; Group 2 Number missing: 12</p> <p>Protocol outcome 3: AHI/RDI at &gt;1 month - Actual outcome for Moderate-severe: Residual AHI at 12 months; Group 1: mean 1.3 (SD 1); n=39, Group 2: mean 3.2 (SD 3.8); n=49 Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Very high, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 11; Group 2 Number missing: 12</p> <p>Protocol outcome 4: Patient preference at &gt;1 month - Actual outcome for Moderate-severe: Adherence - CPAP usage h/day at 12 months; Group 1: mean 6.4 h/day (SD 2.1); n=39, Group 2: mean 6.1 h/day (SD 1.7); n=49 Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Very high, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 11; Group 2 Number missing: 12</p>	



Protocol outcomes not reported by the study	Mortality at >1 month; ODI at >1 month; Minor adverse effects of Tx at >1 month; Driving outcomes at >1 month; Neurocognitive outcomes at >1 month; HbA1c at >1 month; CV events at >1 month; Systolic BP at >1 month; Healthcare contacts at >1 month
---	--

1

Study	Fox 2012 <sup>10</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=75)
Countries and setting	Conducted in Canada; Setting: University sleep disorders program in British Columbia, Canada
Line of therapy	Not applicable
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Moderate-severe: n/a
Subgroup analysis within study	Not applicable: n/a
Inclusion criteria	Patients were recruited from adult ( $\geq 19$ yr of age) patients with moderate to severe OSA (AHI $\geq 15$ events/hr by polysomnography (PSG) using the Chicago scoring criteria for the determination of apneas and hypopneas, according to the American Academy of Sleep Medicine) <sup>10</sup> diagnosed at the Sleep Disorders Program who were seen by one of three respirologists (JF, CFR, NTA) at the University of British Columbia (UBC) between April 8, 2008 to June 1, 2010. Patients with OSA who were prescribed PAP therapy by their regular sleep physician and who were willing to accept a trial of therapy were potentially eligible for the trial
Exclusion criteria	Patients were excluded from participating if they were unable or unwilling to provide informed consent, had active cardiopulmonary or psychiatric disease, had been previously treated for OSA, did not have a telephone line in their bedroom (necessary to transmit information by the modem), or could not return for follow-up visits
Recruitment/selection of patients	n/a
Age, gender and ethnicity	Age - Mean (SD): 52(10.8); 55.2(11.5). Gender (M:F): Telemedicine male - 82%; Standard care - 77.8. Ethnicity: not stated

Further population details	1. BMI: BMI of 30 kg/m <sup>2</sup> or more (Telemedicine - 31.9(5); Standard 32.6(6.2)). 2. Co-existing conditions: Not stated / Unclear 3. High risk occupation group: Not stated / Unclear 4. Sleepiness: ESS >9 (Telemedicine 9.9(5); standard care 9.7(4.7)).
Indirectness of population	No indirectness
Interventions	(n=39) Intervention 1: Combined strategies. Auto-titrating PAP machine that transmitted physiologic information (i.e. adherence, air leak, residual AHI) daily to a website that could be reviewed. Duration 3 months. Concurrent medication/care: all patients were oriented to CPAP, fitted with a mask, and given an auto-titrating machine. Indirectness: No indirectness Further details: 1. Intervention type: Not applicable  (n=36) Intervention 2: In person follow-up. Standard care with auto-titrating CPAP. In Person follow up. Duration 3 months. Concurrent medication/care: all patients were oriented to CPAP, fitted with a mask, and given an auto-titrating machine. Indirectness: No indirectness Further details: 1. Intervention type:
Funding	Study funded by industry (This study was partially supported by a research grant from Phillips Respironics Inc. The authors have indicated no financial conflicts of interest)

**RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: COMBINED STRATEGIES versus IN PERSON FOLLOW-UP**

**Protocol outcome 1: Sleepiness score at >1 month**

- Actual outcome for Moderate-severe: Epworth sleeping scale- mean decrease in ESS at 3 months; Group 1: mean 1.6 (SD 5.1); n=28, Group 2: mean 0.7 (SD 5.2); n=26; Comments: p=0.49

Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - Very high, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 11; Group 2 Number missing: 10

**Protocol outcome 2: AHI/RDI at >1 month**

- Actual outcome for Moderate-severe: Apnoea-Hypopnea index (AHI) at 3 months; Group 1: mean 4.7 (SD 3.8); n=28, Group 2: mean 6.6 (SD 4.8); n=26; Comments: p=0.12

Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - Very high, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 11; Group 2 Number missing: 10

**Protocol outcome 3: Patient preference at >1 month**

- Actual outcome for Moderate-severe: Mean adherence (min per day) at 3 months; Group 1: mean 191 minutes (SD 147); n=28, Group 2: mean 105 minutes (SD 118); n=26; Comments: p=0.006

<p>Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - Very high, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 11; Group 2 Number missing: 10                      - Actual outcome for Moderate-severe: Mean adherence on nights PAP used (min per day) at 3 months; Group 1: mean 321 minutes (SD 80); n=28, Group 2: mean 207 minutes (SD 106); n=26; Comments: &lt;0.0001                      Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - Very high, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 11; Group 2 Number missing: 10                      - Actual outcome for Moderate-severe: mean % days used at 3 months; Group 1: mean 55.9 % (SD 40); n=28, Group 2: mean 45.9 % (SD 38); n=26                      Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - Very high, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 11; Group 2 Number missing: 10</p>	
Protocol outcomes not reported by the study	Quality of life at >1 month; Mortality at >1 month; ODI at >1 month; Minor adverse effects of Tx at >1 month; Driving outcomes at >1 month; Neurocognitive outcomes at >1 month; HbA1c at >1 month; CV events at >1 month; Systolic BP at >1 month; Healthcare contacts at >1 month

1

Study	Hoet 2017 <sup>14</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=46)
Countries and setting	Conducted in Belgium; Setting: The study was performed in the sleep unit of the Saint-Pierre University Hospital in Brussels, Belgium.
Line of therapy	Not applicable
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Moderate-severe: n/a
Subgroup analysis within study	Not applicable: n/a
Inclusion criteria	Eligible patients were ≥18 years old. They were recently diagnosed with OSAS with an apnea-hypopnea index (AHI) ≥20/h according to AASM 2012 scoring rules and sent to our sleep laboratory for initiation of treatment with CPAP therapy.
Exclusion criteria	Previous exposure to CPAP therapy, mixed or predominantly central sleep apnea, a planned trip abroad for more than 3 weeks during the first 3 months of follow-up, language barriers, cognitive or psychiatric disorders

	making it difficult to comprehend information regarding CPAP therapy and provide informed consent, and significant comorbidities such as severe chronic obstructive pulmonary disease or hypoventilation syndromes.
Recruitment/selection of patients	n/a
Age, gender and ethnicity	Age - Mean (SD): Telemonitoring group -59(13; Usual care group - 54(14). Gender (M:F): Define. Ethnicity: not stated
Further population details	1. BMI: BMI of 30 kg/m <sup>2</sup> or more (Telemonitoring group - 31(4); usual care group - 32(6)). 2. Co-existing conditions: HTN (TM group - 52%; UC group-52%). 3. High risk occupation group: Not stated / Unclear 4. Sleepiness: ESS >9 (TM group - 10(4); UC group -15(5)).
Extra comments	All patients provided written informed consent to participate in the study
Indirectness of population	No indirectness
Interventions	<p>(n=23) Intervention 1: Telemonitoring. T4P TM unit was added to the CPAP device of the patient at home. Sleep laboratory technical staff were instructed to connect to the web portal and to analyze individual patient's data each Tuesday and Friday. In case of air leaks &gt;50 L/min, residual AHI &gt;10/h, or CPAP use &lt;3h on 3 consecutive days, they were required to call the patient and to set up a visit with the staff of the sleep laboratory. Duration 3 months. Concurrent medication/care: All eligible patients underwent on CPAP titration night with an automated CPAP(APAP) device under fully attended polysomnography (PSG) monitoring. Indirectness: No indirectness Further details: 1. Intervention type: Electronic (CPAP and T4P TM unit).</p> <p>(n=23) Intervention 2: In person follow-up. After CPAP titration night, patients were instructed to use the device each night for the whole night. They received written instructions and were able to contact the sleep unit (with telephone call or visit) as often as needed, during weekdays, in order to resolve any current problem interfering with their CPAP use. a group educational session for CPAP-treated patients was scheduled 1 month after CPAP initiation, and a visit to the pneumologist was scheduled 1.5 and 3 months after CPAP initiation. Duration 3 months. Concurrent medication/care: All eligible patients underwent on CPAP titration night with an automated CPAP(APAP) device under fully attended polysomnography (PSG) monitoring. Indirectness: No indirectness Further details: 1. Intervention type: Physical (CPAP).</p>
Funding	No funding

**RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TELEMONITORING versus IN PERSON FOLLOW-UP**

Protocol outcome 1: Patient preference at >1 month

<p>- Actual outcome for Severe: Adherence hours of use at 3 months; Group 1: mean 5.7 (SD 1.6); n=21, Group 2: mean 4.2 (SD 1.9); n=20                  Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 2; Group 2 Number missing: 3                  - Actual outcome for Severe: % nights CPAP use &gt;4 hours at 3 months; Mean; , Comments: Adherent patients (%) CPAP use &gt;4 hours                  Telemonitoring - 82 %; In person follow up - 64%                  Mean (range) - hours/night                  Telemonitoring + in p Follow-up group - 6.2(4-8.1); In person follow up group - 5.2 (4-7.5);                  Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 2; Group 2 Number missing: 3</p>	
Protocol outcomes not reported by the study	Quality of life at >1 month; Mortality at >1 month; Sleepiness score at >1 month; AHI/RDI at >1 month; ODI at >1 month; Minor adverse effects of Tx at >1 month; Driving outcomes at >1 month; Neurocognitive outcomes at >1 month; HbA1c at >1 month; CV events at >1 month; Systolic BP at >1 month; Healthcare contacts at >1 month

1

Study	Isetta 2015 <sup>19</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=139)
Countries and setting	Conducted in Spain; Setting: Multicentre randomised trial
Line of therapy	Not applicable
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Severe: n/a
Subgroup analysis within study	Not applicable: n/a
Inclusion criteria	All enrolled patients were classified as requiring CPAP treatment after an overnight study.
Exclusion criteria	Severe sleepiness, severe nasal obstruction, pregnancy, psychiatric disease, dangerous employment, clinical instability and current or previous treatment for OSA. We excluded patients who lacked sufficient internet skills or refused to participate in the study.
Recruitment/selection of patients	n/a

Age, gender and ethnicity	Age - Mean (SD): Telemedicine 51 (8.9); Control - 47(10.9). Gender (M: F): 120/19. Ethnicity: not stated
Further population details	1. BMI: BMI of 30 kg/m <sup>2</sup> or more (Telemedicine - 32.8(7.3); 33.6(8.3)). 2. Co-existing conditions: AF (cardiovascular disease: telemedicine-11; control-7). 3. High risk occupation group: Not applicable 4. Sleepiness: ESS >9 (Telemedicine 10.5(4.6); control 10.8(4.8)).
Indirectness of population	No indirectness
Interventions	<p>(n=69) Intervention 1: Telemonitoring. Telemonitoring +televisits Patients randomised to the telemedicine group received their follow-up at home supported by a website developed for this study, where they could find information about OSA and CPAP therapy, and a biweekly six-item questionnaire about their status, physical activity, sleep time, CPAP use and treatment side effects. Each centre's staff monitored questionnaire answers and communicated with patients through the website messaging tool to solve treatment-related problems. To participate, patients only required an internet-connected device with a microphone and webcam. Televisits via video conference were undertaken at months 1 and 3. We used Skype due to its availability, ease of use and good performance. 21 Patients automatically received a confirmation email indicating the date and time of their appointment. Extra televisits or hospital visits were scheduled as necessary.</p> <p>. Duration 6 months. Concurrent medication/care: n/a. Indirectness: No indirectness Further details: 1. Intervention type: Electronic (Telemedicine/Televisits).</p> <p>(n=70) Intervention 2: In person follow-up. Patients randomised to the control group had the same follow-up schedule as the telemedicine group but attended the hospital. Specifically, they received standard face-to-face follow-up with visits at months 1, 3 and 6, and extra visits if needed.</p> <p>. Duration 6 months. Concurrent medication/care: n/a. Indirectness: No indirectness Further details: 1. Intervention type: Physical (In person follow up).</p>
Funding	Equipment / drugs provided by industry (This project was supported by SEPAR/FIS PI14/00416 and ECO2013-47092 (MINECO, Spain).

**RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TELEMONITORING versus IN PERSON FOLLOW-UP**

Protocol outcome 1: Quality of life at >1 month

- Actual outcome for Severe: E5QD at 6 months; Group 1: mean 0.82 (SD 0.19); n=64, Group 2: mean 0.88 (SD 0.2); n=64

Risk of bias: All domain - High, Selection - Low, Blinding - Very high, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5; Group 2 Number missing: 6

- Actual outcome for Severe: FOSQ at 6 months; Group 1: mean 16.9 (SD 3.94); n=64, Group 2: mean 18.01 (SD 2.97); n=64

Risk of bias: All domain - High, Selection - Low, Blinding - Very high, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5; Group 2 Number missing: 6

Protocol outcome 2: Sleepiness score at >1 month

- Actual outcome for Severe: Sleepiness ESS at 6 months; Group 1: mean 6.52 (SD 4.14); n=64, Group 2: mean 5.89 (SD 3.51); n=64

Risk of bias: All domain - High, Selection - Low, Blinding - Very high, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5; Group 2 Number missing: 6

Protocol outcome 3: Patient preference at >1 month

- Actual outcome for Severe: Adherence h/day at 6 months; Group 1: mean 4.4 (SD 2); n=64, Group 2: mean 4.2 (SD 2); n=64

Risk of bias: All domain - High, Selection - Low, Blinding - Very high, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5; Group 2 Number missing: 6

- Actual outcome for Severe: % CPAP use >4 hours at 6 months; Percentage (%) >4 hours/night

Telemonitoring + televisits - 65 %; control group - 57%;

Risk of bias: All domain - High, Selection - Low, Blinding - Very high, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 5; Group 2 Number missing: 6

Protocol outcomes not reported by the study

Mortality at >1 month; AHI/RDI at >1 month; ODI at >1 month; Minor adverse effects of Tx at >1 month; Driving outcomes at >1 month; Neurocognitive outcomes at >1 month; HbA1c at >1 month; CV events at >1 month; Systolic BP at >1 month; Healthcare contacts at >1 month

1

<b>Study</b>	<b>Lugo 2019<sup>23</sup></b>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=186)
Countries and setting	Conducted in Spain; Setting: sleep unit in a hospital clinic Barcelona
Line of therapy	Unclear
Duration of study	Intervention + follow up: 12 weeks
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Moderate

Subgroup analysis within study	Not applicable
Inclusion criteria	suspected OSA and/or refractory hypertension, age 18–75 years, basic knowledge of ICTs use (e.g., tablet, smartphone, or computer), and Internet access.
Exclusion criteria	Patients with disabilities that prevented them from completing the questionnaires, invalidating somnolence (medical criteria), unstable disease, previous CPAP use, uvulopalatopharyngoplasty, risk profession or not signing the informed consent form.
Recruitment/selection of patients	Consecutive patients with suspected OSA referred to the sleep unit between 2016 and Feb 2017 were randomised if they signed the consent form
Age, gender and ethnicity	Age - Mean (SD): 50.6 (11.7). Gender (M:F): 127/59. Ethnicity: unclear AHI mean (SD): telemonitoring group 24.7, hospital group 33.6
Further population details	1. BMI: BMI of 30.2 kg/m <sup>2</sup> or more. Co-existing conditions: Not stated / Unclear 3. High risk occupation group: Not stated / Unclear 4. Sleepiness: ESS >9
Indirectness of population	Serious indirectness: patients with mild, moderate and severe OSA were included along with 19.6% of patients with no OSA diagnosis.
Interventions	(n=94) Intervention 1: Telemonitoring. Patients in the Virtual sleep unit (VSU) were managed exclusively outside of the hospital setting. The diagnostic sleep test consisted of home-based respiratory polygraphy for three consecutive nights, using ApneaLink air (ResMed, Spain). Recorded data were downloaded to a secure server and analyzed by a specialized technician. Subsequently, a sleep physician assessed all records and scheduled a video conference visit to inform the results and discuss the therapeutic decision. If OSA was diagnosed and CPAP was indicated, patients received CPAP education and along with an automatic CPAP device (Dreamstation, Resironics) at the providers pick-up point. A technician could remotely adjust CPAP pressure through a website (EncoreAnywhere, Resironics), based on data sent by the device (i.e., pressure, leaks, residual apnoea–hypopnea index, hours of use). Patients were managed remotely and treatment could accurately be controlled. The time of the interview with the physician was similar between the two arms (no more than 15 minute). Follow-up visits at 3, 6 and 12 weeks were performed through a custom web application ( <a href="https://plataforma.laboratori-virtual-son.com">https://plataforma.laboratori-virtual-son.com</a> ) developed for the study, with separated areas for patients and professionals or phone-calls. Patients could access general information about OSA, CPAP, healthy sleep, and lifestyle, as well as their medical agenda, FAQs, and online clinical questionnaires. An email address to contact professionals and a teleconference service to perform the interviews were also



	<p>available. Professionals could schedule and perform teleconference visits, send messages to patients, and analyze the questionnaire responses. Duration 12 weeks. Concurrent medication/care: Before the HR or VSU diagnostic procedures, patients underwent clinical evaluation of anthropometric data, medical history, OSA symptoms, and treatments received. Patients were or not diagnosed with OSA and, according to the medical opinions, received CPAP treatment and/or sleep hygiene measures and lifestyle recommendations (e.g., diet, exercise, regular sleep hours, sleeping on their side). Patients receiving CPAP treatment were monitored by a specialized nurse at 3, 6 and 12 weeks (face-to-face or videoconference, according to the study group) to assess their general symptoms, CPAP compliance, and side effects. At the final visit, all patients, including those who received sleep hygiene and lifestyle advice, were visited to assess the ESS, QSQ, EuroQol, and their overall satisfaction with the diagnostic and treatment procedure.</p> <p>Indirectness: Serious indirectness; Indirectness comment: patients with mild, moderate and severe OSA were included Further details: 1. Intervention type: Electronic</p> <p>(n=92) Intervention 2: In person follow-up. Sleep tests, medical assessments, and follow-up visits were performed in the Sleep Unit. Based on the patient characteristics, physicians not involved in the trial requested sleep studies (e.g. PSG, or hospital- or home-based respiratory polygraphy). After sleep testing, a sleep physician interviewed patients. If CPAP was indicated, patients received education and training in CPAP use from a specialized nurse or technician in the hospital. CPAP was then titrated in the hospital with manual adjustment by the technician during a sleep study. Once the optimal pressure was determined, patients were provided with a fixed pressure CPAP device to use at home (DreamStation, Respironics). All visits were performed face-to-face in the consultation at 3, 6 and 12 weeks.. Duration 12 weeks. Concurrent medication/care: Before the HR or VSU diagnostic procedures, patients underwent clinical evaluation of anthropometric data, medical history, OSA symptoms, and treatments received. Patients were or not diagnosed with OSA and, according to the medical opinions, received CPAP treatment and/or sleep hygiene measures and lifestyle recommendations (e.g., diet, exercise, regular sleep hours, sleeping on their side). Patients receiving CPAP treatment were monitored by a specialized nurse at 3, 6 and 12 weeks (face-to-face or videoconference, according to the study group) to assess their general symptoms, CPAP compliance, and side effects. At the final visit, all patients, including those who received sleep hygiene and lifestyle advice, were visited to assess the ESS, QSQ, EuroQol, and their overall satisfaction with the diagnostic and treatment procedure.. Indirectness: Serious indirectness; Indirectness comment: patients with mild, moderate and severe OSA were included. Further details: 1. Intervention type: Physical</p>
Funding	Academic or government funding

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TELEMONITORING versus IN PERSON FOLLOW-UP

Protocol outcome 1: Quality of life at >1 month

- Actual outcome for Moderate: EQ5D at 12 weeks ; Group 1: mean 0.84 (SD 0.18); n=80 (baseline value = 0.80, Group 2: mean 0.85 (SD 0.16); n=74 (baseline value = 0.84)

Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 14, Reason: none provided; Group 2 Number missing: 18, Reason: none provided

- Actual outcome for Moderate: EQ-VAS at 12 weeks ; Group 1: mean 75.66 (SD 13.68); n=80 (baseline value = 70.46), Group 2: mean 75.09 (SD 17.35); n=74 (baseline value = 73.70)

Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 14, Reason: none provided; Group 2 Number missing: 18, Reason: none provided

Protocol outcome 2: Sleepiness score at >1 month

- Actual outcome for Moderate: ESS at 12 weeks ; Group 1: mean 8.5 (SD 4.44); n=80, Group 2: mean 7.05 (SD 4.31); n=74

Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 14, Reason: none provided; Group 2 Number missing: 18, Reason: none provided

Protocol outcome 3: Healthcare contacts at >1 month

- Actual outcome for Moderate: number of OSA related GP visits at 6 months; Group 1: 4/94, Group 2: 6/92

Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 14, Reason: none provided; Group 2 Number missing: 18, Reason: none provided

- Actual outcome for Moderate: number of OSA related specialist visits at 6 months; Group 1: 11/94, Group 2: 9/92

Risk of bias: All domain - Very high, Selection - High, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 14, Reason: none provided; Group 2 Number missing: 18, Reason: none provided

Protocol outcomes not reported by the study

Mortality at >1 month; AHI/RDI at >1 month; ODI at >1 month; Minor adverse effects of Tx at >1 month; Driving outcomes at >1 month; Neurocognitive outcomes at >1 month; HbA1c at >1 month; CV events at >1 month; Systolic BP at >1 month; CO2 control at >1 month

Study	Mendelson 2014 <sup>25</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=107)
Countries and setting	Conducted in France; Setting: There were 14 recruiting centers in France, with Grenoble as the coordinating center
Line of therapy	Not applicable
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Moderate-severe: n/a
Subgroup analysis within study	Not applicable: n/a
Inclusion criteria	Patients were eligible for the study if they were between 18 and 85 years old, diagnosed OSA on the diagnostic sleep study with AHI > 15 events/h, BMI of less than 40 kg/m <sup>2</sup> , cardiovascular risk SCORE > 5%,20 or being in secondary prevention with a past history of cardiovascular disease (transient ischemic attack, stroke, cerebral emorrhage, myocardial infarction, angina, coronary revascularization, arteriopathy, aortic aneurism).
Exclusion criteria	Non-inclusion criteria were the following: central sleep apnea syndrome, cardiovascular score < 5%,20 cardiac failure, history of hypercapnic chronic respiratory failure, incapacitated patients, and pregnancy in accordance with article L 1121-6 of the French public health code, or patients taking part in another clinical trial. All patients provided written informed consent to participate in the study.
Recruitment/selection of patients	n/a
Age, gender and ethnicity	Age - Mean (SD): Total 63(9), Telemedicine - 62(9), Standard care - 63(9). Gender (M:F): Telemedicine male-90.7%; Standard care - 75.5. Ethnicity: not stated
Further population details	1. BMI: BMI of 30 kg/m <sup>2</sup> or more (Total 29.9(4.8), Telemedicine - 29.6 (3.9), Standard care - 30.2 (5.7)). 2. Co-existing conditions: T2DM (Total 36.4 %, Telemedicine - 38.9 %, Standard care - 34.0 %). 3. High risk occupation group: Not stated / Unclear 4. Sleepiness: ESS 9 or less (Total 7.9(4.4), Telemedicine - 8.7(4.5), Standard care - 7.2(4.3)).
Indirectness of population	No indirectness

Interventions	<p>(n=54) Intervention 1: Combined strategies. Patients assigned to telemedicine were oriented to CPAP, fitted with a nasal mask, and given an auto titrating machine. Patients received a smartphone with an application designed to transmit clinical information. The patients transmitted self-measured morning and evening BP (3-day measurements), CPAP adherence, and subjective sleepiness weekly through a questionnaire-based application. Quality of life questionnaires were transmitted monthly. Patients received daily pictograms with diet and physical-activity related messages on their smartphones. Patients were contacted after 2 days to ask about adherence, side effects, and any problems encountered with the machine. After 4 weeks of treatment, patients met with their sleep specialist and information was reviewed. After 4 months of treatment, patients consulted their sleep specialist and were re-evaluated. Both groups were asked to continue on their normal medication regimen Duration 4 months. Concurrent medication/care: n/a. Indirectness: No indirectness Further details: 1. Intervention type: Electronic (TM and In person follow up).</p> <p>(n=53) Intervention 2: In person follow-up. Patients assigned to standard care were evaluated at baseline, fitted with a nasal mask and given an auto titrating machine. Patients were contacted after 2 days to ask about adherence, side effects, and any problems encountered with the machine. After 4 weeks of treatment, patients met with their sleep specialist and information was transferred from their machines (adherence, mask leak, residual respiratory events). After 4 months of treatment, data were downloaded from the machine, and patients saw their sleep specialist and were re-evaluated. Duration 4 month. Concurrent medication/care: n/a. Indirectness: No indirectness Further details: 1. Intervention type: Physical (in person follow up).</p>
Funding	Academic or government funding (This study was supported by a grant from Initiatives pour la Santé Domicile

**RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: COMBINED STRATEGIES versus IN PERSON FOLLOW-UP**

Protocol outcome 1: Quality of life at >1 month

- Actual outcome for Moderate-severe: Quality of life (Physical composite score) difference (Visit 1 vs visit 2) at 4 months; Group 1: mean 3.2 (SD 8.6); n=40, Group 2: mean 2.9 (SD 7); n=42

Risk of bias: All domain - Very high, Selection - Low, Blinding - Very high, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 14; Group 2 Number missing: 11

- Actual outcome for Moderate-severe: Quality of life (mental composite score) difference (Visit 1 vs visit 2) at 4 months; Group 1: mean 1.6 (SD 10.9); n=40, Group 2: mean 1.6 (SD 8); n=42

Risk of bias: All domain - Very high, Selection - Low, Blinding - Very high, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 14; Group 2 Number missing: 11

<p>Protocol outcome 2: Sleepiness score at &gt;1 month                      - Actual outcome for Moderate-severe: Sleepiness score difference(ESS) at 4 months; Group 1: mean -2.3 (SD 4); n=40, Group 2: mean -2.1 (SD 4.1); n=42                      Risk of bias: All domain - Very high, Selection - Low, Blinding - Very high, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 14; Group 2 Number missing: 11</p>	
<p>Protocol outcome 3: Patient preference at &gt;1 month                      - Actual outcome for Moderate-severe: Adherence min per day at 4 months; Group 1: mean 187 (SD 178); n=40, Group 2: mean 250 (SD 166); n=42                      Risk of bias: All domain - Very high, Selection - Low, Blinding - Very high, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 14; Group 2 Number missing: 11</p>	
Protocol outcomes not reported by the study	Mortality at >1 month; AHI/RDI at >1 month; ODI at >1 month; Minor adverse effects of Tx at >1 month; Driving outcomes at >1 month; Neurocognitive outcomes at >1 month; HbA1c at >1 month; CV events at >1 month; Systolic BP at >1 month; Healthcare contacts at >1 month

1

Study	Munafa 2016 <sup>26</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=140)
Countries and setting	Conducted in USA; Setting: study was conducted by Sleep Data Holdings, LLC, a Joint Commission on Accreditation of Healthcare Organizations-accredited CPAP durable medical equipment provider in Southern California, USA.
Line of therapy	Not applicable
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Moderate-severe: n/a
Subgroup analysis within study	Not applicable: n/a
Inclusion criteria	Inclusion criteria were age 18–80 years, CPAP-naïve, confirmed OSA (AHI 5–70/h) diagnosis based on polysomnography (PSG) or home sleep test. In addition, patients were required to have access to and be able to utilize, communication technology (text messaging, e-mail)

Exclusion criteria	Exclusion criteria were prominent central apnea (>20 %), claustrophobia, current use of mandibular repositioning device, or other OSA therapy. A simple randomization scheme was used to allocate patients to CPAP treatment plus SOC or TH.
Recruitment/selection of patients	n/a
Age, gender and ethnicity	Age - Mean (SD): TH group - 52.3(10.6); SOC group 50(11.7). Gender (M:F): 45/43. Ethnicity: TH group (Caucasian 72.1%; Hispanic 16.2%; AfricanAmerican-4.4%; Asian 7.4% other-0%); SOC - (Caucasian 82%; Hispanic 6.6%; AfricanAmerican-3.3%; Asian 6.6% other-1.6%)
Further population details	1. BMI: BMI of 30 kg/m <sup>2</sup> or more (TH- 33.5(8.2); SOC-32.9(7.1)). 2. Co-existing conditions: Not stated / Unclear 3. High risk occupation group: Not stated / Unclear 4. Sleepiness: ESS >9 (TH- 10.9(4.7); SOC- 10.2(5.7)).
Indirectness of population	No indirectness
Interventions	<p>(n=70) Intervention 1: Telemonitoring. Patients in the TH group were dispensed a CPAP device on Day 0, along with a pamphlet about U-Sleep, which was used to monitor adherence. U-Sleep is a secure, HIPAA-compliant, web-based application that is designed to receive CPAP device data and message patients and providers via text and/or e-mail based on a customizable set of rules. At the time of set up, patients were encouraged to log-in to the U-Sleep website from home so that they could follow their therapy. Sleep Data study staff were trained to set up and use the software, which was provided to patients at no charge. Initial patient contacts were triggered by ≥1 of five intervention points based on metrics (AHI, leak, therapy hours) After initial contact, subsequent contacts were in response to an automated message or based on clinical judgment. All TH patients received a final phone call on day 90. All patients were contacted at day 90 and asked to rate how well the follow-up program had met their expectations (on a scale from 1 to 5)</p> <p>Duration 3 months. Concurrent medication/care: At baseline, all patients had a 1-h education session with a respiratory therapist (RRT) about OSA and its consequences, proper use and maintenance of the CPAP device and mask, and therapy expectations. All patients were provided with a fixed or auto CPAP device, heated humidifier, modems, and mask interface (S9 Elite, S9 AutoSet, H5i heated humidifier; ResMed Corp.). Patients saw an RRT at all clinic visits; telephone follow-up was performed by registered PSG technicians (RPSGT).</p> <p>Indirectness: No indirectness Further details: 1. Intervention type: Electronic (Telemonitoring).</p> <p>(n=70) Intervention 2: Telephone follow-up. Patients randomized to SOC were dispensed a CPAP device on Day 0, then contacted via phone on Days 1, 7, 14, 30, and 90 (Fig. 1). CPAP usage and efficacy data were tracked via the wireless modem attached to the CPAP machine. Modem data were accessed via ResMed's</p>

	<p>EasyCare Online (ECO) platform. Sleep Data SOC procedures include frequent phone calls and return clinic visits as necessary</p> <p>Duration 3 months. Concurrent medication/care: At baseline, all patients had a 1-h education session with a respiratory therapist (RRT) about OSA and its consequences, proper use and maintenance of the CPAP device and mask, and therapy expectations. All patients were provided with a fixed or auto CPAP device, heated humidifier, modems, and mask interface (S9 Elite, S9 AutoSet, H5i heated humidifier; ResMed Corp.). Patients saw an RRT at all clinic visits; telephone follow-up was performed by registered PSG technicians (RPSGT).</p> <p>Indirectness: No indirectness Further details: 1. Intervention type: Not applicable (Telephone follow up).</p>
Funding	Other author(s) funded by industry (Medical writing assistance from Nicola Ryan, independent medical writer, was funded by ResMed Corp)
<p><b>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TELEMONITORING versus TELEPHONE FOLLOW-UP</b></p> <p>Protocol outcome 1: Patient preference at &gt;1 month                      - Actual outcome for Moderate-severe: Adherence hours of use daily at 3 months; Group 1: mean 5.1 (SD 1.9); n=58, Group 2: mean 4.7 (SD 2.1); n=64                      Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 12; Group 2 Number missing: 6</p>	
Protocol outcomes not reported by the study	Quality of life at >1 month; Mortality at >1 month; Sleepiness score at >1 month; AHI/RDI at >1 month; ODI at >1 month; Minor adverse effects of Tx at >1 month; Driving outcomes at >1 month; Neurocognitive outcomes at >1 month; HbA1c at >1 month; CV events at >1 month; Systolic BP at >1 month; Healthcare contacts at >1 month

1

<b>Study</b>	<b>Pepin 2019<sup>36</sup></b>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=306)
Countries and setting	Conducted in France; Setting: Multicentre study. 23 centres were recruited. All centres were sleep units with facilities for diagnosis, treatment and follow up of OSA and had worked with professional home care

	providers trained in CPAP initiating and follow up.
Line of therapy	Not applicable
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Severe: n/a
Subgroup analysis within study	Not applicable: n/a
Inclusion criteria	Eligible patients were aged from 18-75, with severe OSA (apnoea-hypopnea index (AHI)>30events/h) on the basis of respiratory polygraphy or poly somnography. Patients should suffer from at least one cardiovascular disease or exhibit an elevated cardiovascular risk assessed by the 10 year risk of fatal cardiovascular event Systematic Coronary Risk evaluation calculation established specifically for European countries. Patients with a Systematic Coronary Risk evaluation risk>5% or in secondary prevention were included.
Exclusion criteria	Patients with central sleep apnea or heart failure with a left ventricular ejection fraction <40% were excluded
Recruitment/selection of patients	n/a
Age, gender and ethnicity	Age - Mean (range): 60.8(53.8; 66); Usual care - 61.8 (54.7; 66.1). Gender (M:F): 226/80. Ethnicity: not stated
Further population details	1. BMI: BMI of 30 kg/m <sup>2</sup> or more (Telemonitoring 32.4(29.6; 36.5); Usual care 31.4 (28.1; 35.2). 2. Co-existing conditions: T2DM (Telemonitoring 20(12.9); Usual care 18 (12.2)). 3. High risk occupation group: Not stated / Unclear 4. Sleepiness: ESS >9 (Telemonitoring 9(5;13); Usual care 9(5; 14)).
Indirectness of population	No indirectness
Interventions	(n=157) Intervention 1: Telemonitoring. Multimodal telemonitoring included systolic and diastolic HBP and physical activity recorded by connected devices. This assessment of individual risk was associated with CPAP telemonitoring providing adherence, leaks and residual events. Symptoms and quality of life were recorded via electronic questionnaires to be filled by patients. Patients benefited from a demonstration of how to use the remote home telemonitoring equipment and an explanation of why monitoring psychological variables is relevant for their care. Concerning HBP recommendations, patients had to perform three measurements in the morning and the evening for 3 consecutive days in both groups. One minute was required between each measurement and the patient had to stay sedentary before and during the measurements.  Duration 6 months. Concurrent medication/care: The patients were treated by auto-CPAP with a pressure



	<p>window between 6 and 14 cm H<sub>2</sub>O. Both usual care and remote multimodal telemonitoring arms received the same 1-h CPAP initiating educational program</p> <p>Indirectness: No indirectness Further details: 1. Intervention type: Electronic (multimodal telemonitoring).</p> <p>(n=149) Intervention 2: In person follow-up. In person follow up (not much detail)</p> <p>Duration 6 months. Concurrent medication/care: The patients were treated by auto-CPAP with a pressure window between 6 and 14 cm H<sub>2</sub>O. Both usual care and remote multimodal telemonitoring arms received the same 1-h CPAP initiating educational program</p> <p>Indirectness: No indirectness Further details: 1. Intervention type: Physical (in person follow up).</p>
Funding	<p>Equipment / drugs provided by industry (The authors have reported to CHEST the following: J.-L.P. and R.T. report grants from Philips, Resmed, Fisher and Paykel, Fondation de la recherche medicale, Direction dela recherche Clinique du CHU De Grenoble, Fond de donation "Agirpour les maladies chroniques"; and personal fees from Perimetre, Philips, Fisher and Paykel RESMED, Astra-Zeneka, SEFAM, Agiradom, ELIA, and Teva, outside the submitted work.</p>

**RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: TELEMONITORING versus IN PERSON FOLLOW-UP**

**Protocol outcome 1: Quality of life at >1 month**

- Actual outcome for Severe: SF12-Physical at 6 months; Group 1: mean 45.3 (SD 5.3); n=117, Group 2: mean 44.1 (SD 5.4); n=122  
 Risk of bias: All domain - Very high, Selection - Low, Blinding - Very high, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 40; Group 2 Number missing: 27  
 - Actual outcome for Severe: SF12-Mental at 6 months; Group 1: mean 43.9 (SD 4.4); n=117, Group 2: mean 43.6 (SD 4.9); n=122  
 Risk of bias: All domain - Very high, Selection - Low, Blinding - Very high, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 40; Group 2 Number missing: 27

**Protocol outcome 2: Patient preference at >1 month**

- Actual outcome for Severe: adherence at 6 months; Group 1: mean 5.28 (SD 2.23); n=117, Group 2: mean 4.75 (SD 2.5); n=122  
 Risk of bias: All domain - Very high, Selection - Low, Blinding - Very high, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 40; Group 2 Number missing: 27

<p>Protocol outcome 3: Systolic BP at &gt;1 month                  - Actual outcome for Severe:                  Sleepiness ESS (0-24) at 6 months; Group 1: mean 4.58 (SD 3.88); n=117, Group 2: mean 6.05 (SD 4.07); n=122                  Risk of bias: All domain - Very high, Selection - Low, Blinding - Very high, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 40; Group 2 Number missing: 27                  - Actual outcome for Severe: Systolic blood pressure difference - (6 months and baseline) morning at 6 months; Group 1: mean 130.98 (SD 18.47); n=117, Group 2: mean 130.06 (SD 17.53); n=122                  Risk of bias: All domain - Very high, Selection - Low, Blinding - Very high, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 40; Group 2 Number missing: 27</p>	
Protocol outcomes not reported by the study	Mortality at >1 month; Sleepiness score at >1 month; AHI/RDI at >1 month; ODI at >1 month; Minor adverse effects of Tx at >1 month; Driving outcomes at >1 month; Neurocognitive outcomes at >1 month; HbA1c at >1 month; CV events at >1 month; Healthcare contacts at >1 month

1

Study	Stepnowsky 2007 <sup>40</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=45)
Countries and setting	Conducted in USA; Setting: Participants were patients at the Veterans Affairs San Diego Healthcare System (VASDHS)
Line of therapy	Not applicable
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Moderate-severe: n/a
Subgroup analysis within study	Not applicable: n/a
Inclusion criteria	diagnosis of moderate-to-severe OSA, defined as an Apnea-Hypopnea Index (AHI) $\geq$ 15 events per hour; naive to CPAP therapy; stable sleep environment (operationally defined as a permanent address, requisite for wireless monitoring); and at least 18 years of age. An AHI of $\geq$ 15 was chosen in an effort to be consistent with current OSA guidelines and practice parameters
Exclusion criteria	Patients were excluded from the study if they met any one of the following criteria: allergies or sensitivity to the mask or mask material; previous use of any other PAP device (eg, bi-level PAP, auto-adjusting PAP);

	<p>current use of prescribed supplemental oxygen; or significant comorbid medical conditions that would prevent the patient from completing the protocol. Significant comorbidities were defined as any medical or mental health condition that could interfere with the daily use of CPAP. Additionally, patients were excluded if they lived in a geographically unsuitable region (ie, outside of the wireless network coverage area). A total of 91 patients at the VASDHS Sleep Clinic either signed or gave verbal consent to be contacted so they could learn more about the study. From these 91 patients, 46 were either were not interested in study participation or did not satisfy the inclusion and exclusion criteria</p>
Recruitment/selection of patients	n/a
Age, gender and ethnicity	Age - Mean (SD): TCC - 60(10.8); UCC - 58(13.7). Gender (M:F): overall 98 % male. Ethnicity: not stated
Further population details	1. BMI: BMI of 30 kg/m <sup>2</sup> or more (total- 32.8; TCC - 33.3(4.9); 30.5(5.1)). 2. Co-existing conditions: Not applicable 3. High risk occupation group: Not stated / Unclear 4. Sleepiness: Not stated / Unclear
Indirectness of population	No indirectness
Interventions	<p>(n=24) Intervention 1: Combined strategies. Telemonitored clinical care group. (Telemonitoring and in person follow up) The essence of the TCC intervention is the ability to tele monitor compliance and efficacy data for each patient on a daily basis from the first day of treatment and to act on those data collaboratively, and in partnership, with the patient. Collaborative management refers to the joint decision making and partnership between provider and patient and is characterized by communication, negotiation, and consideration of important patient factors and preferences. Patients in this group had their objective flow generator data monitored as frequently as needed per specified clinical pathways throughout the active 2-month treatment period. The frequency and nature of the clinical interactions depended on both the objectively measured nightly data values and subjective patient reports.</p> <p>Duration 2 months. Concurrent medication/care: Both groups of patients received the monitoring device and were followed for an intervention period of 2 months.</p> <p>Each participant was provided with an AutoSet Spirit flow generator unit (ResMed Corp, Poway, CA) set to fixed-mode pressure, which was equipped with the HumidAire 2i heated humidifier (ResMed Corp, Poway, CA). Each participant was provided a compatible nasal or full-face mask; nasal pillows were not used in this study.</p> <p>Indirectness: No indirectness Further details: 1. Intervention type: Not applicable (Combined - Telemonitoring and in person follow up).</p> <p>(n=21) Intervention 2: In person follow-up. Usual clinical care group. In person follow up. Patients randomized to UCC were treated according to the prevailing standard of care for OSA patients at the VASDHS CPAP</p>

	<p>Clinic. Usual care consisted of a 1-week telephone call after CPAP initiation and a 1-month in-office follow-up visit by CPAP clinic staff. Patients were encouraged to call the clinic any time they had a problem or concern. CPAP compliance and efficacy data were downloaded at the 1-month time point to help direct clinical management.</p> <p>Duration 2 months. Concurrent medication/care: Both groups of patients received the monitoring device and were followed for an intervention period of 2 months. Each participant was provided with an AutoSet Spirit flow generator unit (ResMed Corp, Poway, CA) set to fixed-mode pressure, which was equipped with the HumidAire 2i heated humidifier (ResMed Corp, Poway, CA). Each participant was provided a compatible nasal or full-face mask; nasal pillows were not used in this study.</p> <p>. Indirectness: No indirectness Further details: 1. Intervention type: Physical (In person follow up).</p>
Funding	Funding not stated

**RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: COMBINED STRATEGIES versus IN PERSON FOLLOW-UP**

Protocol outcome 1: Quality of life at >1 month

- Actual outcome for Moderate-severe: Functional outcomes of sleep at 2 months; Group 1: mean 15.2 (SD 5); n=20, Group 2: mean 14.4 (SD 4.2); n=20; Comments: 32 item self report measure. (1poor; 5 excellent)
- Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4; Group 2 Number missing: 1
- Actual outcome for Moderate-severe: Sleepiness- Epworth at 2 months; Group 1: mean 9.2 (SD 6.6); n=20, Group 2: mean 9.9 (SD 5.2); n=20
- Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4; Group 2 Number missing: 1
- Actual outcome for Moderate-severe: Adherence all days at 2 months; Group 1: mean 4.1 (SD 1.8); n=20, Group 2: mean 2.8 (SD 2.2); n=20
- Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4; Group 2 Number missing: 1
- Actual outcome for Moderate-severe: Adherence days used at 2 months; Group 1: mean 5 (SD 1.8); n=20, Group 2: mean 3.8 (SD 2.3); n=20
- Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4; Group 2 Number missing: 1
- Actual outcome for Moderate-severe: % nights with CPAP use >4 hours at 2 months; Group 1: mean 52 percentage (SD 27); n=20, Group 2: mean 37 percentage (SD 24); n=20
- Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4; Group 2 Number missing: 1

Protocol outcome 2: AHI/RDI at >1 month  
 - Actual outcome for Moderate-severe: AHI at 2 months; Group 1: mean 7.9 (SD 4.1); n=20, Group 2: mean 5 (SD 4); n=20  
 Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4; Group 2 Number missing: 1  
 - Actual outcome for Moderate-severe: AHI change at 2 months; Group 1: mean 38.1 (SD 18.4); n=20, Group 2: mean 32.2 (SD 14.8); n=20  
 Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 4; Group 2 Number missing: 1

Protocol outcomes not reported by the study Mortality at >1 month; Sleepiness score at >1 month; ODI at >1 month; Minor adverse effects of Tx at >1 month; Driving outcomes at >1 month; Neurocognitive outcomes at >1 month; Patient preference at >1 month; HbA1c at >1 month; CV events at >1 month; Systolic BP at >1 month; Healthcare contacts at >1 month

1

Study	Turino 2017 <sup>42</sup>
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=100)
Countries and setting	Conducted in Spain; Setting: St Maria Hospital (Lleida, Spain)
Line of therapy	Not applicable
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Moderate-severe: n/a
Subgroup analysis within study	Not applicable: n/a
Inclusion criteria	Included adult patients (>18 years) with newly diagnosed OSA requiring treatment with CPAP (AHI >15 events·h <sup>-1</sup> ). Assuming an $\alpha$ risk of 0.05 and a $\beta$ risk of 0.2 in a two-sided test, a sample size of 49 subjects in each group was needed to detect differences $\geq 1$ h in CPAP treatment compliance. A common standard deviation of 1.75 was assumed. Given the high motivation of both professionals and patients to be involved, no dropouts were anticipated and thus a total of 100 patients were planned to be recruited
Exclusion criteria	Patients with impaired lung function (COPD-OSAHs overlap syndrome, obesity hypoventilation and restrictive disorders), severe heart failure, psychiatric disorders, periodic leg movements, pregnancy, other dysomnias or parasomnias, and/or a history of previous CPAP treatment were excluded.

Recruitment/selection of patients	n/a
Age, gender and ethnicity	Age - Mean (SD): Telemedicine 56 (13); Standard care 54(12). Gender (M:F): 77/23. Ethnicity: stated
Further population details	1. BMI: BMI of 30 kg/m <sup>2</sup> or more (Telemedicine 35 (7); Standard care 35 (7)). 2. Co-existing conditions: Not stated / Unclear 3. High risk occupation group: Not stated / Unclear 4. Sleepiness: ESS >9 (Telemedicine 9(5); Standard care 10(4)).
Indirectness of population	No indirectness
Interventions	<p>(n=52) Intervention 1: Combined strategies. In the telemonitoring group, patients were also fitted with a mask and given a CPAP device (AirSense 10) and a leaflet explaining how to use it, and received the same training sessions from the same personnel as in the standard care arm. Each CPAP device given to patients in this group was equipped with mobile 2G (GSM/GPRS) technology capable of sending daily information on CPAP adherence, CPAP pressures, mask leak and residual respiratory events to the MyOSA–Oxigen Salud web database (www.oxigenasalud.com) Automatic alarms for the provider were generated in case of mask leak &gt;30 L·min<sup>-1</sup> for &gt;30% of the night or usage of &lt;4 h·night<sup>-1</sup> on two consecutive nights. In case of alarm, the pulmonary specialist medical officer of the CPAP provider contacted the patient, providing case-by-case problem solving. This included suggestions about how to minimise symptoms (dry mouth, mask issues, discomfort with the device), specific interventions to improve compliance (mask changing, chin strap, pressure or humidifier settings, saline nasal sprays) and support for the patient in the use of CPAP. Duration 3 months. Concurrent medication/care: n/a</p> <p>Indirectness: No indirectness Further details: 1. Intervention type: Electronic (Telemonitoring + in person follow up).</p> <p>(n=48) Intervention 2: In person follow-up. Patients randomised to standard care were fitted with a mask and given a CPAP device (AirSense 10; ResMed, Martinsried, Germany) and a leaflet explaining how to use it. A short instruction session on how to use a CPAP device was also given to patients and partners in the sleep unit by a trained nurse with experience in the follow-up of CPAP-treated patients. This included a practical demonstration of how to put on the mask, and the correct management and cleaning of the tubes, masks and humidifier. Information on how to turn the CPAP device on and off was provided by the homecare provider at the time of machine delivery. All patients were visited after 1 month of treatment by the specialist nurse at the sleep unit. Information about CPAP pressure, compliance and adherence (use of CPAP for ≥4 h·day<sup>-1</sup>), residual respiratory events and leaks were downloaded from the device. CPAP-related side-effects, CPAP machine care and maintenance (changes of mask, tubes and humidifier), and the number of additional visits and calls were recorded by the nurse</p> <p>Duration 3 months. Concurrent medication/care: n/a</p>

	. Indirectness: No indirectness Further details: 1. Intervention type:
Funding	Equipment / drugs provided by industry (This study was partially funded by ResMed Spain (Spain) and ALLER (Spain))
<p><b>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: COMBINED STRATEGIES versus IN PERSON FOLLOW-UP</b></p> <p>Protocol outcome 1: Quality of life at &gt;1 month                      - Actual outcome for Moderate-severe: EQ5D change at 3 months; Group 1: mean 0.057 (SD 0.19); n=52, Group 2: mean 0.06 (SD 0.17); n=48                      Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 2: Patient preference at &gt;1 month                      - Actual outcome for Moderate-severe: Adherence h/night at 3 months; Group 1: mean 5.1 (SD 2.1); n=52, Group 2: mean 4.9 (SD 2.2); n=48                      Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p> <p>Protocol outcome 3: Systolic BP at &gt;1 month                      - Actual outcome for Moderate-severe: Systolic blood pressure at 3 months; Group 1: mean -4.3 mmHg (SD 14.8); n=52, Group 2: mean -3.1 mmHg (SD 18); n=48                      Risk of bias: All domain - Very high, Selection - High, Blinding - Very high, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness ; Group 1 Number missing: 0; Group 2 Number missing: 0</p>	
Protocol outcomes not reported by the study	Mortality at >1 month; Sleepiness score at >1 month; AHI/RDI at >1 month; ODI at >1 month; Minor adverse effects of Tx at >1 month; Driving outcomes at >1 month; Neurocognitive outcomes at >1 month; HbA1c at >1 month; CV events at >1 month; Healthcare contacts at >1 month

1  
2  
3  
4  
5

# 1 Appendix E: Forest plots

## E.1.2 Telemonitoring and in person follow up vs in person follow up – severe OSAHS

Figure 2: Systolic blood pressure – morning




Figure 3: Adherence – hours per day





Figure 4: Adherence – on nights PAP used – hours per day




4

5

6 Figure 5: Mean % nights CPAP use >4 hours (adherence)


7




8



**Figure 6: Mean % days CPAP used (adherence)**




**Figure 7: Quality of life – physical composite (change score), 0-100, higher is better**




1

**Figure 8: Quality of life – mental composite (change score), 0-100, higher is better**




**Figure 9: Quality of life – EQ5D, 0-1, higher is better**




2


**Figure 10: Quality of life – GHQ12, 0-12, higher is worse**




**Figure 11: Sleepiness (ESS), 0-24, higher is worse**



**Figure 12: Apnoea-hypopnea index (AHI) events per hour (lower is better)**




**Figure 13: Functional outcome of sleep, 5-20, higher is better**




## E.2.1 Telemonitoring and phone follow up vs phone follow up – severe OSAHS

**Figure 14: Adherence – hours per day**




**Figure 15: Days CPAP used >4 hours, % patients**




## E.3.5 Multimodal telemonitoring vs usual care – severe OSAHS


**Figure 16: Adherence (range of scores), 0-8, higher is better**



**Figure 17: Sleepiness – Epworth scale (ESS), 0-24, higher is worse**




**Figure 18: Quality of life –SF 12 Physical, 0-100, higher is better**




1

**Figure 19: Quality of life – SF 12 mental, 0-100, higher is better**




**2 Figure 20: Systolic blood pressure**




3

## E.4.4 Telemonitoring and tele visits vs In person follow up – severe OSAHS

**Figure 21: Adherence Hours/day**




**Figure 22: Quality of life – EQ5D<sup>1</sup>, 0-1, lower is worse**



6


1. Lugo study reports SD in telemonitoring group as 18, however this appears to be a typo so 0.18 has been used for our analysis

**Figure 23: Quality of life – FoSQ 5-20, lower is worse**




1

**Figure 24: Sleepiness – Epworth scale (ESS), 0-24, higher is worse**




2

**Figure 25: EQ5D – VAS, 0-100, lower is worse**




3

**4 Figure 26: number of OSA related GP visits**



5

**6 Figure 27: number of OSA related specialist visits**



8

9

# 1 Appendix F: GRADE tables

2 Table 13: Telemonitoring and in person follow up versus in person follow up – Severe OSAHS

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Telemonitoring + in person follow up	Control	Relative (95% CI)	Absolute		
<b>Systolic blood pressure - morning (follow-up 3-6 months; Better indicated by lower values)</b>												
2	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	none	none	209	197	-	MD 0.33 higher (3.1 lower to 3.75 higher)	⊕⊕⊕⊕ LOW	IMPORTANT
<b>Adherence- h per day (follow-up 3 - 12 months; range of scores: 0-8; Better indicated by higher values)</b>												
6	randomised trials	very serious <sup>1</sup>	very serious <sup>3</sup>	serious indirectness <sup>4</sup>	serious <sup>2</sup>	none	200	205	-	MD 0.6 higher (0.12 lower to 1.31 higher)	⊕⊕⊕⊕ VERY LOW	IMPORTANT
<b>Adherence-on nights PAP used(h per day) (follow-up mean 2-3 months; range of scores: 0-8; Better indicated by higher values)</b>												
2	randomised trials	very serious <sup>1</sup>	no serious inconsistency	serious indirectness <sup>4</sup>	serious <sup>2</sup>	none	48	46	-	MD 1.22 higher (0.03 lower to 2.48 higher)	⊕⊕⊕⊕ VERY LOW	IMPORTANT
<b>Mean % nights CPAP use &gt;4 hours (follow-up mean 2 months; range of scores: 0-100; Better indicated by higher values)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	serious indirectness <sup>4</sup>	serious <sup>2</sup>	none	20	20	-	MD 15 higher (4.03 lower to 34.03 higher)	⊕⊕⊕⊕ VERY LOW	IMPORTANT

Mean % days used (range of scores: 0-100; Better indicated by higher values)												
1	randomised trials	very serious <sup>4</sup>	no serious inconsistency	serious indirectness <sup>4</sup>	serious <sup>2</sup>	none	28	26	-	MD 10 higher (10.81 lower to 30.81 higher)	⊕000 VERY LOW	IMPORTANT
Quality of life (Physical composite) difference (follow-up mean 4 months; range of scores: 0-100; Better indicated by higher values)												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	serious indirectness <sup>4</sup>	very serious <sup>2</sup>	none	40	42	-	MD 0.3 higher (3.1 lower to 3.7 higher)	⊕000 VERY LOW	CRITICAL
Quality of life (mental) difference (follow-up mean 4 months; range of scores: 0-100; Better indicated by higher values)												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	serious indirectness <sup>4</sup>	very serious <sup>2</sup>	none	40	42	-	MD 0 higher (4.15 lower to 4.15 higher)	⊕000 VERY LOW	CRITICAL
Quality of life EQ5D (follow-up mean 3 months; range of scores: 0-1; Better indicated by higher values)												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	serious indirectness <sup>4</sup>	very serious <sup>2</sup>	none	52	48	-	MD 0 higher (0.07 lower to 0.07 higher)	⊕000 VERY LOW	CRITICAL
Quality of Life-GHQ12 (follow-up mean 12 months; range of scores: 0-12; Better indicated by lower values)												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	serious indirectness <sup>4</sup>	very serious <sup>2</sup>	none	39	49	-	MD 0.2 higher (2.31 lower to 2.71 higher)	⊕000 VERY LOW	CRITICAL
Sleepiness Epworth (ESS) (follow-up mean 2-12; range of scores: 0-24; Better indicated by lower values)												
4	randomised trials	very serious <sup>1</sup>	no serious inconsistency	serious indirectness <sup>4</sup>	no serious imprecision	none	127	137	-	MD 0 higher (1 lower to 1 higher)	⊕000 VERY LOW	IMPORTANT
Apnoea Hypopnea index (AHI) events/hour (follow-up mean 3-12 months; Better indicated by lower values)												

3	randomised trials	very serious <sup>1</sup>	very serious <sup>3</sup>	serious indirectness <sup>4</sup>	very serious <sup>2</sup>	none	87	95	-	MD 0.44 lower (3.21 lower to 2.33 higher)	⊕○○○ VERY LOW	IMPORTANT
<b>Functional outcome of sleep A. questionnaire (follow-up mean 2 months; Better indicated by higher values)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	serious indirectness <sup>4</sup>	very serious <sup>2</sup>	none	20	20	-	MD 0.8 higher (2.06 lower to 3.66 higher)	⊕○○○ VERY LOW	CRITICAL
<b>Mortality</b>												
Not reported												CRITICAL

- 1 1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
- 2 2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs, MID for machine usage (adherence)-1 hour; MID for Systolic and Diastolic BP – 5 mm hg. For mean % of nights that the CPAP was used >4 hours outcome, clinically important difference was considered to be 10 % or 1 hour.. Established MIDs for
- 3 SF-36 physical/mental- 2/3; ESS- 2.5; EQ5D- 0.03; FOSQ- 2GRADE default MIDs (0.5XSD) used for all other continuous outcomes.
- 4 3 Downgraded by 1 or 2 increments because: The point estimate varies widely across studies, unexplained by subgroup analysis. The confidence intervals across studies show minimal or no overlap, I<sup>2</sup>=50% unexplained by subgroup analysis. Subgroup analyses were tested for BMI < or >30 kg/m<sup>2</sup>, ESS < or >9, coexisting conditions, high risk occupation and type of treatment.
- 5 Random effects analysis used.
- 6 4 Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect population respectively. The study included a mixed OSHAS severity population based on mean baseline AHI.

10

11 **Table 14: Telemonitoring versus phone follow up – Severe OSAHS**

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Telemonitoring	Phone follow up	Relative (95% CI)	Absolute		
<b>Adherence hours per day (follow-up mean 3 months; range of scores: 0-8; Better indicated by higher values)</b>												

1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	serious indirectness <sup>4</sup>	serious <sup>2</sup>	None	58	64	-	MD 0.4 higher (0.31 lower to 1.11 higher)	⊕000 VERY LOW	IMPORTANT
<b>Days CPAP used &gt;4 hours (follow-up mean 3 months; range of scores: 0-100; Better indicated by higher values)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	serious indirectness <sup>4</sup>	serious <sup>2</sup>	None	58	64	-	MD 6.9 higher (2.9 lower to 16.70 higher)	⊕000 VERY LOW	IMPORTANT
<b>Mortality</b>												
Not reported												CRITICAL

- 1 1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
- 2 2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs. MID for machine usage (adherence)-1 hour; MID, For mean % of nights that the CPAP was used >4 hours outcome, clinically important difference was considered to be 10 % or 1 hour GRADE default MID (0.5XSD) used for all other continuous outcomes.
- 3 3 Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect population respectively. The study included a mixed OSHAS severity population based on mean baseline AHI.
- 4 4 outcomes.
- 5 5
- 6 6

**7 Table 15: Multimodal telemonitoring versus usual care – severe OSAHS**

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Multimodal telemonitoring	Usual care	Relative (95% CI)	Absolute		
<b>Adherence (follow-up mean 6 months; range of scores: 0-8; Better indicated by higher values)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	None	117	122	-	MD 0.53 higher (0.07 lower to 1.13 higher)	⊕000 VERY LOW	IMPORTANT
<b>Sleepiness ESS (follow-up mean 6 months; range of scores: 0-24; Better indicated by lower values)</b>												



1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	None	117	122	-	MD 1.47 lower (2.48 to 0.46 lower)	⊕⊕⊕⊕ LOW	IMPORTANT
<b>Quality of life-SF12-Physical (follow-up mean 6 months; range of scores: 0-100; Better indicated by higher values)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	None	117	122	-	MD 1.5 higher (0.14 to 2.86 higher)	⊕⊕⊕⊕ VERY LOW	CRITICAL
<b>Quality of life-SF12 - Mental (follow-up mean 6 months; range of scores: 0-100; Better indicated by higher values)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	None	117	122	-	MD 0.3 higher (0.88 lower to 1.48 higher)	⊕⊕⊕⊕ LOW	CRITICAL
<b>Systolic blood pressure (follow-up mean 6 months; Better indicated by lower values)</b>												
	randomised trials	very serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	None	117	122	-	MD 0.92 higher (3.65 lower to 5.49 higher)	⊕⊕⊕⊕ VERY LOW	IMPORTANT
<b>Mortality</b>												
Not reported												CRITICAL

1 <sup>1</sup> Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

2 <sup>2</sup> Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs; MID for machine usage (adherence)-1 hour; MID for

3 Systolic and Diastolic BP – 5 mm hg. Established MIDs for SF-36 physical/mental- 2/3; ESS- 2.5; GRADE default MID (0.5XSD)used for all other continuous outcomes.

**4 Table 16: Telemonitoring and tele visits versus in person follow up – severe OSAHS**

Quality assessment	No of patients	Effect	Quality	Importance
--------------------	----------------	--------	---------	------------

No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Telemonitoring+televisits	In person follow-up	Relative (95% CI)	Absolute		
<b>Adherence h/day (follow-up range 3- 6 months; range of scores: 0-8; Better indicated by higher values)</b>												
2	randomised trials	serious <sup>1</sup>	no serious inconsistency	Very Serious <sup>3</sup>	no serious imprecision	none	91	92	-	MD 0.14 higher (0.39 lower to 0.66 higher)	⊕○○○ VERY LOW	IMPORTANT
<b>EQ5D (follow-up range 3- 6 months; range of scores: 0-1; Better indicated by higher values)</b>												
2	randomised trials	very serious <sup>1</sup>	no serious inconsistency	Very Serious <sup>3</sup>	serious <sup>2</sup>	none	144	138	-	MD 0.03 lower (0.7 lower to 0.01 higher)	⊕○○○ VERY LOW	CRITICAL
<b>FoSQ (follow-up mean 6 months; range of scores: 5-20; Better indicated by higher values)</b>												
1	randomised trials	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	64	64	-	MD 1.11 lower (2.32 lower to 0.1 higher)	⊕⊕○○ LOW	CRITICAL
<b>Sleepiness ESS (follow-up range 3- 6 months; range of scores: 0-24; Better indicated by lower values)</b>												
2	randomised trials	serious <sup>1</sup>	no serious inconsistency	Very Serious <sup>3</sup>	no serious imprecision	none	144	138	-	MD 1.02 higher (0.07 lower to 1.98 higher)	⊕○○○ VERY LOW	IMPORTANT
<b>EQ5D -VAS (follow-up mean 3 months; range of scores: 0-100; Better indicated by higher values)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	Very Serious <sup>3</sup>	no serious imprecision	none	80	74		MD 0.57 higher (4.39 lower to 5.53 higher)	⊕○○○ VERY LOW	CRITICAL
<b>Number of OSA related GP visits (follow-up mean 3 months; Better indicated by lower values)</b>												


1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	Very Serious <sup>3</sup>	Very serious <sup>2</sup>	none	4/94 (4.3%)	6.5%	RR 0.65 (0.19 to 2.24)	23 fewer per 1000 (from 53 fewer to 81 more)	⊕○○○ VERY LOW	IMPORTANT
<b>Number of OSA related specialist visits (follow-up mean 3 months; Better indicated by lower values)</b>												
1	randomised trials	very serious <sup>1</sup>	no serious inconsistency	Very Serious <sup>3</sup>	Very serious <sup>2</sup>	none	11/94 (11.7%)	9.86%	RR 1.20 (0.52 to 2.75)	20 more per 1000 (from 47 fewer to 173 more)	⊕○○○ VERY LOW	IMPORTANT
<b>Mortality</b>												
Not reported												CRITICAL

- 1 1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
- 2 2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs. MID for machine usage (adherence)-1 hour. Established
- 3 MIDs for ESS- 2.5; EQ5D- 0.03; FOSQ- 2. GRADE default MID (0.5XSD)used for all other continous outcomes.
- 4 3 Downgraded by 1 or 2 increments because: The majority of the evidence included an indirect population of moderate to severe severity patients based on the AHI of included population
- 5 (downgrade by one increment) or a very indirect population (downgrade by two increments)
- 6 4 Baseline values differed in the Lugo study for this outcome. While the in person follow up has a higher (better) end score the telemonitoring group had a better change score of 0.04 compared
- 7 to 0.01 in the control group.

# 1 Appendix G: Health economic evidence selection

3 Figure 28: Flow chart of health economic study selection for the guideline

4



\* Non-relevant population, intervention, comparison, design or setting; non-English language

\*\* Two studies (in three papers) were included for two different questions

\*\*\* One study was considered for two different questions

5

6

## Appendix H: Health economic evidence tables

1  
2  
3

Study	Isetta 2015 <sup>19</sup>			
Study details	Population & interventions	Costs	Health outcomes	Cost effectiveness
<p><b>Economic analysis:</b> Cost-utility analysis</p> <p><b>Study design:</b> <b>Approach to analysis:</b> Within trial analysis (RCT)</p> <p><b>Perspective:</b> Spanish provider perspective <sup>(a)</sup></p> <p><b>Follow-up:</b> 6 months</p> <p><b>Treatment effect duration:</b><sup>(b)</sup> 6 months</p> <p><b>Discounting:</b> Costs = NR Outcomes = NR</p>	<p><b>Population:</b> Patients requiring CPAP after an overnight sleep study.<sup>(c)</sup></p> <p><b>Cohort settings:</b> Mean: 49 N = 139 Drop out: 16 (11.5%)</p> <p><b>Intervention 1:</b> <u>Hospital-based follow-up</u> Received standard face-to-face follow-up with visits at months 1, 3 and 6, and extra visits if needed.</p> <p><b>Intervention 2:</b> <u>Telemedicine-based follow-up</u> Patients received their follow-up at home supported by website which included information about OSA and CPAP. Patients would also complete biweekly six-item questionnaire about their status, physical activity, sleep time, CPAP use and treatment side effects. Staff would monitor responses and</p>	<p><b>Scenario 1: Total costs (mean per patient) including GP visits, emergency visits and medication:</b> Intervention 1: £117 Intervention 2: £127 Incremental (2-1): £10 (95% CI: NR; p=NR)</p> <p><b>Scenario 2: Total costs (mean per patient) excluding GP visits, emergency visits and medication:</b> Intervention 1: £80 Intervention 2: £82 Incremental (2-1): £2 (95% CI: NR; p=NR)</p> <p><b>Currency &amp; cost year:</b> 2013 euros (presented here as 2013 UK pounds <sup>(d)</sup>)</p> <p><b>Cost components incorporated:</b> Scenario 1 includes follow-up visit time (month 1, 3 and 6), mask changes, extra visits by physician or nurse, plus <u>GP visits</u>,</p>	<p><b>QALYs (mean per patient):</b> Intervention 1: 0.0120 Intervention 2: 0.0108 Incremental (2-1): - 0.0012 (95% CI: -0.0500 to 0.0474 NR; p=NR)</p>	<p><b>ICER (Intervention 2 versus Intervention 1) <sup>(e)</sup>:</b> Intervention 2 is dominated by intervention 1 in both costing scenarios.</p>

	communicate with patients through the websites messaging tool. Skype calls were undertaken at months 1 and 3.	<u>emergency visits and medications.</u> Scenario 2 includes follow-up visit time, mask changes and extra visits only.		
--	---	---	--	--

**Data sources**

**Health outcomes:** Health-related quality of life (EQ-5D) reported directly from patients **Quality-of-life weights:** EQ-5D tariff used is not explicitly stated, though a reference to the Spanish version of the EQ-5D is made. **Cost sources:** Unit costs calculated by the administrative departments of one of the participating hospitals.

**Comments**

**Source of funding:** Spanish Society of Pneumology and Thoracic Surgery **Limitations:** Table 4 lists the costing inputs which should sum to the total mean costs (table 5). However, the sum of the costs in table 4 does not equate to the total mean costs reported in the study in table 5 and the difference is too large to be due to rounding. This indicates either a summing error or lack of transparency of other costs which were incurred that have not been reported. The authors have included patient and provider costs, therefore the patient costs were deducted by the NGC to conform to the NICE reference case. Furthermore, the authors have included costs for GP visits, emergency visits and medications without providing clarity as to whether these costs were related to the patient's OSA or another condition. To overcome this limitation two costing scenarios have been reported by the NGC: scenario 1 includes these additional costs, scenario 2 excludes these costs. Another limitation of the study is that the authors state that for hospital-based follow-up visits were arranged at months 1, 3 and 6. For the telemedicine-based follow-up only the appointments at month 1 and 3 are explicitly stated. It is unclear whether a skype meeting also took place at 6 months.

**Overall applicability:** Partially Applicable <sup>(f)</sup> **Overall quality:** Potentially serious limitations <sup>(g)</sup>

- 1 Abbreviations: 95% CI= 95% confidence interval; CUA= cost–utility analysis; EQ-5D= Euroqol 5 dimensions (scale: 0.0 [death] to 1.0 [full health], negative values mean worse
- 2 than death); ICER= incremental cost-effectiveness ratio; NGC=National Guideline Centre; NR= not reported; pa= probabilistic analysis; QALYs= quality-adjusted life years
- 3 (a) The study also presented patient costs therefore all costs and ICERs were recalculated to report a provider perspective only.
- 4 (b) It is unclear whether the telemedicine-based follow-up lasted for the whole 6 months – see limitations.
- 5 (c) It is unclear if the study included participants <18 years.
- 6 (d) Converted using 2013 purchasing power parities <sup>30</sup>. The within trial study lasted from 2011 to 2013, as the costs in individual years have not been reported, the UK costs
- 7 in 2013 has been calculated.
- 8 (e) A probabilistic sensitivity analysis (PSA) has been conducted; however the analysis was completed on input parameters which included patient perspective costs. For this
- 9 reason, the results of the PSA have not been reported here.
- 10 (f) Directly applicable / Partially applicable / Not applicable
- 11 (g) Minor limitations / Potentially serious limitations / Very serious limitations

12  
13

Study	Turino 2017 <sup>42</sup>																
Study details	Population & interventions	Costs	Health outcomes	Cost effectiveness													
<p><b>Economic analysis:</b> Cost-utility analysis</p> <p><b>Study design:</b> Within trial analysis (RCT)</p> <p><b>Approach to analysis:</b> Mean costs and mean QALYs compared over the duration of the study period (3 months).</p> <p><b>Perspective:</b> Spanish provider perspective</p> <p><b>Follow-up:</b> 3 months</p> <p><b>Treatment effect duration:</b> 3 months</p> <p><b>Discounting:</b> Costs = NR Outcomes = NR</p>	<p><b>Population:</b> Adult patients (18&gt;) with newly diagnosed OSA (AHI&gt;15events/hr) requiring treatment with CPAP.</p> <p><b>Cohort settings:</b> Mean age: 54 N = 100 Drop out: NR</p> <p><b>Intervention 1: <u>Standard Care</u></b> (1) Patients are fitted with a mask, given a CPAP device and provided a leaflet on how to use it. A short instruction session is also provided to patients and their partners in the sleep unit by a trained nurse to demonstrate how put on the mask, correct management and cleaning of device. When machine is delivered to patients, advice on how to turn the device on and was given by the homecare provider. (2) All patients visited after 1 month of treatment by the specialist nurse at the sleep unit. Data on: CPAP pressure, compliance and adherence (CPAP use ≥4hrs/day), residual respiratory events and leaks. (3)Additional visits and calls where appropriate.</p> <p><b>Intervention 2: <u>Telemonitoring</u></b></p>	<p><b>Total costs (mean per patient):</b> Intervention 1: £170 Intervention 2: £125 Incremental (2-1): saves £45 (95% CI: NR)</p> <p><b>Currency &amp; cost year:</b> 2015 euros (presented here as 2015 UK pounds <sup>(a)</sup>)</p> <p><b>Cost components incorporated:</b> Telemonitoring including 2G (GSM/GPRS) daily data transfer and alarm management, sleep unit visits and consultations, home visits and consultations and costs associated with changes in CPAP device components.</p>	<p><b>QALYs (mean per patient) reported in study:</b> Intervention 1: 0.060 Intervention 2: 0.057 Incremental (2-1): -0.003 (95% CI: NR; p=NR)</p> <p><b>QALYs (mean per patient) recalculated<sup>(b)</sup>:</b> Intervention 1: 0.015 Intervention 2: 0.014 Incremental (2-1): -0.001 (95% CI: NR; p=NR)</p>	<p><b>ICER (Intervention 1 versus Intervention 2) using <i>study</i> reported QALYs:</b> £15,000 per QALY gained</p> <p><b>ICER (Intervention 1 versus Intervention 2) using <i>recalculated</i> QALYs:</b> £45,000 per QALY gained</p> <p><b>Analysis of uncertainty:</b> A deterministic sensitivity analysis was conducted which explored 25% and 50% increases in the CPAP provider costs.</p> <table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th style="width: 25%;">New costs</th> <th style="width: 25%;">25%</th> <th style="width: 25%;">50%</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>£174</td> <td>£178</td> </tr> <tr> <td>2</td> <td>£137</td> <td>£148</td> </tr> </tbody> </table> <p>ICER (intervention 1 versus intervention 2) when provider costs are increased and <i>study</i> QALYs are used:</p> <table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <tbody> <tr> <td style="width: 25%;">25%</td> <td>£12,333 per QALY gained</td> </tr> <tr> <td>50%</td> <td>£10,000 per QALY gained</td> </tr> </tbody> </table> <p>ICER (intervention 1 versus intervention 2) when provider</p>	New costs	25%	50%	1	£174	£178	2	£137	£148	25%	£12,333 per QALY gained	50%	£10,000 per QALY gained
New costs	25%	50%															
1	£174	£178															
2	£137	£148															
25%	£12,333 per QALY gained																
50%	£10,000 per QALY gained																

	<p>(1) Same as (1) in intervention 1. However in this instance, each CPAP device provided to patients was equipped with mobile 2G (GSM/GPRS) technology capable of sending daily information on: CPAP adherence, CPAP pressures, mask leak and residual respiratory events.</p> <p>(2) Data uploaded to a web database. Automatic alarms were generated in case of mask leak (&gt;30L/min for more than 30% of night) or poor compliance (&lt;4hr/night). In cases of alarm, specialist contacted patient to provide case-by-case problem solving.</p>			<p>costs are increased and <i>recalculated</i> QALYs are used:</p> <table border="1" style="width: 100%;"> <tr> <td style="width: 15%;">25%</td> <td>£37,000 per QALY gained</td> </tr> <tr> <td>50%</td> <td>£30,000 per QALY gained</td> </tr> </table>	25%	£37,000 per QALY gained	50%	£30,000 per QALY gained
25%	£37,000 per QALY gained							
50%	£30,000 per QALY gained							

**Data sources**

**Health outcomes:** Health-related quality of life (EQ-5D) reported directly from patients. **Quality-of-life weights:** EQ-5D tariff used not stated. **Cost sources:** Resource use from within RCT; costs reported as the mean costs incurred per patient for the trial duration (January and July 2015) by Catalan Institute of Health.

**Comments**

**Source of funding:** Partially funded by ResMed Spain and Associacio Lleidatana de Respiratori (ALLER). **Limitations:** A key limitation of this study is that it has not reported its method for deriving QALYs. Based on the explanations provided, it appears the authors have equated improvements in quality of life measured by the EQ-5D to improvements in QALYs which is methodologically incorrect i.e. a 0.003 higher EQ-5D at 3 months is not the same as a 0.003 gain in QALYs. Instead, to calculate the correct QALY gains over the three month period the EQ-5D gains must be multiplied by 0.25 or else an assumption must be stated about how long the difference would be sustained. Another limitation of the study is the short follow-up and it is unclear whether a longer time horizon would have indicated that the telemonitoring group have greater compliance and therefore improved health outcomes. **Other:** If the QALYs reported in the study are accepted as the true QALYs, standard care would be cost-effective when compared to telemonitoring at the £20,000 threshold. However, if the recalculated QALYs are used, then the new ICER would indicate that standard care is not cost-effective at that threshold.

**Overall applicability:**<sup>(c)</sup> Partially Applicable      **Overall quality:**<sup>(d)</sup> Potentially Serious Limitations

1 Abbreviations: CPAP=Continuous positive airway pressure; EQ-5D= Euroqol 5 dimensions (scale: 0.0 [death] to 1.0 [full health], negative values mean worse than death);  
 2 ICER= incremental cost-effectiveness ratio; NR= not reported; pa= probabilistic analysis; QALYs= quality-adjusted life years; RCT = Randomised control trial  
 3 (a) Converted using 2014 purchasing power parities<sup>30</sup>  
 4 (b) The authors have not clearly described their method of calculating QALYs, and based on their current explanation the authors may have overestimated the QALY gained.  
 5 Further explanation is provided in the limitation section of the above table.  
 6 (c) Directly applicable / Partially applicable / Not applicable  
 7 (d) Minor limitations / Potentially serious limitations / Very serious limitations



1

## 2 Appendix I: Excluded studies

### I.1.3 Excluded clinical studies

4 Table 17: Studies excluded from the clinical review

Study	Exclusion reason
Abreu 2013 <sup>1</sup>	Abstract only
Chen 2020 <sup>4</sup>	Systematic review- screened for relevant references.
Delanote 2018 <sup>5</sup>	Inappropriate intervention
DeMolles 2004 <sup>6</sup>	Inappropriate intervention
Fields 2016 <sup>9</sup>	Inappropriate intervention
Frasnelli 2016 <sup>11</sup>	Inappropriate study design – non randomised study without adequate adjustment for confounders.
Gong 2018 <sup>12</sup>	Systematic review references checked
Hanger 2018 <sup>13</sup>	Included in adherence review
Hood 2013 <sup>15</sup>	Inappropriate intervention -self monitoring or an attention-control (AC) condition.
Hwang 2018 <sup>16</sup>	Inappropriate intervention. Study included in the adherence evidence review.
Isetta 2014 <sup>18</sup>	Inappropriate intervention
Isetta 2014 <sup>17</sup>	Abstract only
Isetta 2017 <sup>20</sup>	Inappropriate study design – non comparative study.
Kotzian 2018 <sup>22</sup>	Protocol only
Kotzian 2019 <sup>21</sup>	Inappropriate intervention- included in adherence review
Mendelson 2013 <sup>24</sup>	Abstract only
Murphie 2019 <sup>27</sup>	Systematic review references checked
Nilius 2012 <sup>29</sup>	Inappropriate intervention – included in adherence review
Palmer 2004 <sup>31</sup>	Inappropriate intervention
Parikh 2011 <sup>32</sup>	Inappropriate study design – non randomised study without adequate adjustment for confounders.
Peach 2003 <sup>34</sup>	Abstract only
Peach 2006 <sup>33</sup>	Abstract only
Pengo 2018 <sup>35</sup>	Inappropriate intervention.
Pepin 2014 <sup>37</sup>	Abstract only
Schoch 2019 <sup>38</sup>	Inappropriate intervention- included in adherence review
Sparrow 2010 <sup>39</sup>	Inappropriate intervention

Study	Exclusion reason
Taylor 2003 <sup>41</sup>	Thesis unavailable
Wozniak 2014 <sup>43</sup>	Systematic review references checked

1

## I.2.2 Excluded health economic studies

3 Published health economic studies that met the inclusion criteria (relevant population,  
4 comparators, economic study design, published 2003 or later and not from non-OECD  
5 country or USA) but that were excluded following appraisal of applicability and  
6 methodological quality are listed below. See the health economic evaluation protocol for  
7 more details.

8 **Table 18: Studies excluded from the health economic review**

Reference	Reason for exclusion
Andreu 2012 <sup>2</sup>	This study was assessed as partially applicable (cost analysis from Spanish perspective – no health outcomes); however, given that two studies were included, which evaluated both costs and QALYs, this study was selectively excluded.

9

10

11